Note: Descriptions are shown in the official language in which they were submitted.
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
VOLATILE ORGANIC COMPOUND FORMULATIONS HAVING ANTIMICROBIAL
ACTIVITY
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a Continuation-in-Part Application of: U.S. Patent Application No.
16/179,370, filed on
November 2, 2018, as a continuation application of U.S. Patent Application No.
14/322,757, filed on
July 2, 2014 (and which issued as U.S. Patent 10,117,841 on November 6, 2018),
as an application
claiming the benefit from U.S. Provisional Application No. 61/842,362, filed
July 2, 2013, and from
U.S. Provisional Application No. 61/948,902, filed March 6,2014; and claiming
the benefit from U.S.
Provisional Application No. 62/738,541, filed September 28, 2018; each of
which applications are
incorporated by reference herein in their entireties.
BACKGROUND OF THE INVENTION
The importance of safely disposing billions of pounds of human and animal
excrement
each day so as to avoid the myriad of health problems associated with such
wastes cannot be
overstated. In reality, only a fraction of this massive amount of material is
safely treated, while
the remainder is untreated and poses a threat to human and animal health. For
instance, it is well
known that the complex of bacterial and other agents causing gastrointestinal
diseases is the
world's largest single cause of mortality. It is also well known that these
types of diseases impact
primarily infants and children, as well as livestock. It is estimated that
over the next ten
years, at least twenty million people will die as a result of poor or
inadequate sanitation facilities.
One of the reasons for this is that approximately 2.4 billion people live in
areas without
adequate sanitation facilities. Nearly 4000 children die each day from
conditions such as
diarrhea. In addition, people suffering from water-borne diseases occupy about
half of the
world's hospital beds. In several Asiatic countries, twice as many people are
dying from
diarrhea-related diseases as from AIDS. Essentially, the poor sanitation
conditions are resulting
from or related to the inability of homes, communities and in some instances,
entire countries, to
adequately treat and dispose of human and animal wastes, which bear and
promote the growth
and development of disease-causing microorganisms.
Without question, the unwanted effects of microorganisms in industrial
settings are
numerous. For example, safer and more effective means for treating microbe-
laden surfaces in
medical or hospital environments are needed. Safer and more effective means
for treating
agricultural crops for unwanted microbial growth are needed. Further, a means
for reducing the
1
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
unwanted odors produced in the breakdown of fecal matter in industrial farming
operations is
desperately needed.
There is an urgent need for the replacement of antibiotics with other types of
compounds
that also exhibit antimicrobial activity. Continued use of most of the
commonly used antibiotics
for animals and agriculture has resulted in acquired resistance in microbial
populations,
especially microbes that are capable of being pathogenic. Every year, at least
23,000 people in
the United States die due to infections caused by drug resistant bacteria, and
the number is
increasing.
Thus, there is a need in the art for antimicrobial compositions suitable for
reducing
microorganisms and the effects of microbial outgrowth in a wide range of
industrial settings, as
well as for formulas and methods of human and animal waste treatment. The
present invention
satisfies this need.
BRIEF SUMMARY OF THE INVENTION
In one embodiment, the present invention relates to a chemical formulation
having
antimicrobial activity comprising propanoic acid, isobutyric acid, and at
least one ester. In
another embodiment, the at least one ester is isoamyl hexanoates. In another
embodiment, the
formulation further includes at least one carrier selected from the group
consisting of bentonite,
zeolite and perlite. In another embodiment, the ratio of propanoic acid:
isobutyric acid: isoamyl
hexanoates is about 3.5:3.5:2 v/v/v. In another embodiment, the ratio of
propanoic acid,
isobutyric acid and isoamyl hexanoates is about 7 parts of the two acids and 2
parts of isoamyl
butyrate. In another embodiment, the formulation further includes at least one
endophyte. In
another embodiment, the endophyte is of the genus Fusarium.
In another embodiment, the present invention relates to a chemical formulation
consisting essentially of propanoic acid, isobutyric acid, isoamyl hexanoates
and a carrier
selected from the group consisting of bentonite, zeolite and perlite.
In another embodiment, the present invention relates to a chemical formulation
comprising propanoic acid and at least one 6-12 carbon (acid) component ester,
wherein the
chemical formulation has a ratio of propanoic acid to ester component of about
7:2 v/v. In
another embodiment, the at least one ester is isoamyl hexanoates. In another
embodiment, the
formulation further includes at least one nutritional supplement and at least
one salt. In another
embodiment, formulation comprises glucose, whey protein, potassium chloride,
magnesium
2
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
sulfate, and sodium chloride. In another embodiment, the formulation comprises
glucose,
glycine, potassium chloride, sodium chloride, and magnesium acetate. In
another embodiment,
the formulation comprises glucose, glycine, potassium chloride, sodium
chloride, magnesium
acetate, and monopotassium phosphate. In another embodiment, the formulation
further includes
at least one carrier. In another embodiment, the formulation consists
essentially of propanoic
acid and isoamyl hexanoates at a ratio of propanoic acid to isoamyl hexanoates
of about 7:2 v/v.
In another embodiment, the formulation includes at least one endophyte. In
another embodiment,
the endophyte is of the genus Fusarium.
In another embodiment, the present invention relates to a method of treating
an
animal having a disease or disorder associated with a microbial infection,
comprising
administering to the animal an effective amount of a composition comprising at
least one organic
acid and at least one ester. In another embodiment, the present invention
relates to a composition
comprising propanoic acid and at least one 6-12 carbon (acid) component ester,
wherein the
chemical formulation has a ratio of propanoic acid to ester component of about
7:2 v/v.
BRIEF DESCRIPTION OF THE DRAWINGS
The following detailed description of embodiments of the invention will be
better
understood when read in conjunction with the appended drawings. For the
purpose of illustrating
the invention, there are shown in the drawings embodiments which are presently
preferred. It
should be understood, however, that the invention is not limited to the
precise arrangements and
instrumentalities of the embodiments shown in the drawings.
Figures 1 illustrates a plate bioassay to determine the bioactivity of various
esters when
combined with a 1:1 mix of the two organic acids as per Table 2. The test
organisms were as
follows- Cercospora (dark-lower left bottom) then clockwise- Phytophthora,
Verticillium,
Sclerotinia, Pythium. Fusarium, Trichoderma, Rhizoctonia, and Aspergillus. The
streaks were
Saccharomyces (far right bottom) then Candida, E coli and Bacillus (left
bottom). A = control
plate, and B = plate with System 1 after incubation for 30 hr.
Figure 2 illustrates the effects of System 1 on the growth of bacteria from
human wastes.
About 5 mg of fresh human waste was spread over the surface of a Petri plate
with potato
dextrose agar. Then plugs were removed from the center and bentonite was
placed in the well ca.
0.5 g. The bentonite in the center well did not have the ingredients in System
1 on it (center) but
the well on the far right had System 1 at the rate of 1 ml System 1 per 10 g
of bentonite. The
3
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
plates were incubated for 48 hr at 22 C and then photographed. There was no
detectable
bacterial growth in the System 1 treated plate, but the control plates had
ample bacterial colonies.
Figure 3 illustrates the effects of System 2 on the growth of bacteria from
human wastes.
About 5 mg of fresh human waste was spread over the surface of a Petri plate
with potato
dextrose agar. Plugs were removed from the center and bentonite was placed in
the well ca. 0.5
g. The bentonite in the center well did not have the ingredients in System 1
on it (center) but the
well on the far right had system 1 at the rate of 1 ml System 1 per 10 g of
bentonite. The plates
were incubated for 48 hr at 22 C and then photographed. There was no
detectable bacterial
growth in the System 2 treated plate.
Figure 4 illustrates two cat litter boxes with cat fecal matter each from 5
different cats ca.
140 g. The box on the right had been treated with System 1 on bentonite with
(0.5 ml / 100 g
bentonite). After 5 days the ammonia readings were 14 ppm on the control
(left) and 0 ppm on
the treated right. The overall odor was significantly reduced in the treated
box.
Figure 5 illustrates treatment of ca. 140 g of human waste in the presence of
urine with
Fusarium subglutinans 06-1 in the presence of System 2 (1 ml on 10 g of
zeolite). After 3 weeks
there was substantial growth of the F. subglutinans (white mycelium in the
right container). The
ammonia level was 71.4 in the control on the left and 12.1 in the treated
container on the right.
No fungal growth and no degradation of the wastes occurred in the control
(left).
Figure 6 illustrates the progressive growth of Fusarium spp (species) on small
dollops of
human waste ca. 100 mg (fresh weight) over the course of many days. The growth
of newly
isolated and characterized Fusarium spp. are each compared to P2-24 (Fusarium
culmorum). The
new Fusarium spp. especially E06-1 and E06-5 do grow faster on the waste.
Growth was
measured from the extent of the mycelium moving out from the agar plug placed
on the dollop of
waste.
Figure 7 illustrates a six day old culture of Fusarium subglutinans E06-1
(top) the
preferred fungus to be used to treat human and animal wastes in combination
with System 2. A
light microscopic view of spores and hyphae of F. subglutinans is also shown
(bottom). The
spores are slightly curved and are 9.8 - 12 x 2.5 .
Figure 8 illustrates Fusarium subglutinans (E06-8) growing profusely on human
waste
(center) in the presence of System 2 with bentonite as the carrier. Please
note the inhibition of
bacterial growth to the left and center of the culture plate which is
influenced by the vapors of
System 2 emanating from the bentonite particles on the left side of the plate
allowing for fungal
4
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
growth. There were 0.5 g of treated bentonite added, ca 100 mg of human waste
and the plate
had incubated for 12 days. See Figure 6 for comparative growth measurements.
Figure 9 depicts the biological activities of various test mixtures against a
panel of test
microbes. A small plug of each organism was placed in the periphery of the PDA
plate. In the
center well was placed the test solution in the plastic cup holder. A control
plate (A) was also set
up. After 30 hr the growth of the test organisms was compared to that of the
control and the%
inhibition was calculated. The (B) plate contained the test mixture.
Measurements were made 30
hr after plate set up.
Figure 10 depicts the reduction of microbial contamination of cracked corn via
a 1 hr
treatment with various concentrations of the S-3 solution. Concentrations
above 0.5% totally
reduced bacterial contamination as seen by the lack of bacterial colonies in
the 0.5% and 1.0%
treatments (above). Some minimal fungal contamination was observed in the
latter- notice two
fungal colonies in each of the plates on the right. Incubation was for two
days at room temp and
then photographed.
Figure 11 depicts the use of bentonite with various (S) formulae treatments
over the
course of 3 days to kill E. coli in human wastes (mid plate streak) while
allowing for the growth
of fusarium (top of plate) that would otherwise breakdown and consume the
solid matter in
human waste.
Figure 12 depicts the effectiveness of the S-3 formula in treating the fecal
matter of
chickens made up by first spreading a suspension on plates of PDA and then
adding 0.5 g of
zeolite treated with 3m1 per lb of S-3. The photo was taken after 3 days of
incubation at room
temp. It can be seen that the plate containing the S-3 zeolite was virtually
free of bacterial
contamination.
Figure 13 depicts 1 ft.2 plastic snap-seal-top containers filled with litter
treatment plus
untreated bentonite in the proportions indicated by the packaging instructions
to compare
efficacy of the (S) formulae.
Figure 14 depicts ammonia levels taken over 5-minute intervals every 24 hours.
Figure
14A depicts the average ammonia levels taken over 5-minute intervals every 24
hours. Figure
14B depicts the peak ammonia levels displayed a similar trend, with 5-1
treated litter showing
significantly reduced ammonia production levels. Figure 14B also depicts peak
ammonia levels
taken from 5-minute interval tests every 24 hours.
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Figure 15 depicts the microbiological activity of S-1 verses a control sample.
Figures
15A and 15B indicate that the bentonite control (Figure 15A) had massive
amounts of bacterial
colonies growing all over the plate, including in those areas close to the
well containing the litter.
In contrast, the S-1 treatment (4 ml S3 per pound of carrier, Figure 15B) was
virtually free of
bacterial colonies around the well of the plate.
Figure 16 depicts 1 ft.2 plastic snap-seal-top containers filled with pine
shavings and the
desired bedding treatment, in the proportions indicated by the packaging
instructions. For these
tests, S-1 applied at the rate of 15 ml per pound of zeolite and an untreated
zeolite control were
tested.
Figure 17, comprising Figures 17A-17B, depicts ammonia levels taken over 5-
minute
intervals every 24 hours. Figure 17A depicts the average ammonia levels taken
over 5-minute
intervals every 24 hours. Figure 17B is a graph depicting that the peak
ammonia levels
displayed a similar trend, with Barnyard Bedding-treated bedding showing the
lowest ammonia
production levels. Figure 17B depicts the peak ammonia levels taken from 5-
minute interval
tests every 24 hours.
Figure 18 depicts 1 ft.2 plastic snap-seal-top container filled with pine
shavings (a
commonly used bedding material for large animals) and the desired bedding
treatment, in the
proportions indicated by the packaging instructions. For these tests, S-1
treated, and an untreated
zeolite control were tested.
Figure 19, comprising Figures 19A-19B, depicts ammonia levels taken over 5-
minute
intervals every 24 hours. Figure 19A depicts the average ammonia levels taken
over 5-minute
intervals every 24 hours. Figure 19B is a graph depicting that the peak
ammonia levels
displayed a similar trend, with S-1 treated bedding showing the lowest ammonia
production
levels. Figure 19B depicts peak ammonia levels taken from 5-minute interval
tests every 24
hours.
Figure 20, comprising Figures 20A-20B, depicts images of a scoured calf prior
to and
after treatment. Figure 20A depicts the scoured calf prior to any treatment
with S-X solution.
Figure 20B depicts the calf of Figure 20A after two rounds of treatment with S-
X solution.
Figure 21, comprising Figures 21A-21B, depicts images of a scoured calf prior
to and
after treatment. Figure 21A depicts the scoured calf prior to any treatment
with S-X solution.
Figure 21B depicts the calf of Figure 21A 24 hours after treatment with S-X
solution
6
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Figure 22 is an image depicting dairy cow conditions at Dairy 1.
Figure 23, comprising Figures 23A-23B, depicts images of a scoured calf prior
to and
after treatment. Figure 23A depicts the typical creamy yellow scours exhibited
on calf 919.
Figure 23B depicts calf 919 fully recovered after treatment with S-X solution
Figure 24, comprising Figures 24A-24B, depicts images of calf 166 of Ranch 9
prior to
and after treatment. Figure 24A depicts calf 166 suffering with scours in the
winter of 2014.
Figure 24B depicts the calf one day after treatment with S-X solution, wherein
the animal
recovered and yellow diarrhea subsided.
Figure 25, comprising Figures 25A-25B, depicts images of a sheep suffering
from
mastitis and administration of treatment. Figure 25A depicts the sheep
suffering from mastitis.
Figure 25B depicts administration of the S-3 formula to the animal via
syringe.
Figure 26, comprising Figures 26A-26B, depicts images of raspberries before
and after
treatment. Figure 26A depicts raspberries treated with control bentonite in
the center well. Figure
26B depicts raspberries treated with the S-3 1:10 mixture. Both sets of
raspberries were stored
for 1 week at room temperature. The berries treated with S-3 were edible and
had no decay.
Figure 27, comprising Figures 27A-27B, depicts soil treated with P. ultimatum
or S-3.
Figure 27A is a photograph of soil treated with P. ultimatum alone with seeds
of red beet. Only
one or two seeds were observed to germinate. Figure 27B is a photograph of
soil treated with S-3
on bentonite in the presence of P. ultimatum and red beet seeds. Many of the
seeds were
observed to germinate.
Figure 28, comprising Figures 28A-28D, depicts images of water agar plates for
testing
of S-3 with red beet seed. Figure 28A is an image of an agar plate with red
beet seed, bentonite,
S-3 (1 part to 10 g bentonite), and P. ultimum. S-3 was found to control the
growth of P.
ultimum. Figure 28B is an image of an agar plate with red beet seed and P.
ultimum. Figure 28C
is an image of an agar plate with red beet seed alone. Figure 28D is an image
of an agar plate
demonstrating that S-3 was not harmful to the red beet seed.
DETAILED DESCRIPTION
It is to be understood that the figures and descriptions of the present
invention have been
simplified to illustrate elements that are relevant for a clear understanding
of the present
invention, while eliminating, for the purpose of clarity, many other elements
found in typical
7
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
antimicrobial formulations. Those of ordinary skill in the art may recognize
that other elements
and/or steps are desirable and/or required in implementing the present
invention. However, because
such elements and steps are well known in the art, and because they do not
facilitate a better
understanding of the present invention, a discussion of such elements and
steps is not provided
herein. The disclosure herein is directed to all such variations and
modifications to such elements
and methods known to those skilled in the art.
Unless defined otherwise, all technical and scientific terms used herein have
the same
meaning as commonly understood by one of ordinary skill in the art to which
this invention belongs.
Although any methods and materials similar or equivalent to those described
herein can be used in the
practice or testing of the present invention, the preferred methods and
materials
are described.
As used herein, each of the following terms has the meaning associated with it
in this
section.
The articles "a" and "an" are used herein to refer to one or to more than one
(i.e., to at
least one) of the grammatical object of the article. By way of example, "an
element" means one
element or more than one element.
"About" as used herein when referring to a measurable value such as an amount,
a
temporal duration, and the like, is meant to encompass variations of 20%,
10%, 5%, 1%,
and 0.1% from the specified value, as such variations are appropriate.
"S-1" as used herein refers to any and all formulations of System 1.
= as used herein refers to any and all formulations of System 2.
= as used herein refers to any and all formulations of System 3.
= as used herein refers to any and all formulations of System 4.
= as used herein refers to any and all formulations of System 5.
= as used herein refers to any and all formulations of System X, which may
include
one or more of Systems 1-5 therein.
As used herein, the term "CLOE" refers to a formulation comprising 5-1 or S-5.
As used herein, the term "Barnyard Bedding" refers to a formulation comprising
5-1 or
S-5.
As used herein, the term "pharmaceutical composition" refers to a mixture of
at least one
composition of the invention with other chemical components, such as carriers,
stabilizers,
8
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
diluents, dispersing agents, suspending agents, thickening agents, and/or
excipients. The
pharmaceutical composition facilitates administration of the composition to an
organism.
Multiple techniques of administering a composition exist in the art including,
but not limited to,
intravenous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical
administration.
As used herein, the term "pharmaceutically acceptable" refers to a material,
such as a
carrier or diluent, which does not abrogate the biological activity or
properties of the
composition, and is relatively non-toxic, i.e., the material may be
administered to an individual
without causing undesirable biological effects or interacting in a deleterious
manner with any of
the components of the composition in which it is contained.
As used herein, the term "pharmaceutically acceptable carrier" means a
pharmaceutically
acceptable material, composition or carrier, such as a liquid or solid filler,
stabilizer, dispersing
agent, suspending agent, diluent, excipient, thickening agent, solvent or
encapsulating material,
involved in carrying or transporting a composition useful within the invention
within or to the
patient such that it may perform its intended function. Typically, such
constructs are carried or
transported from one organ, or portion of the body, to another organ, or
portion of the body.
Each carrier must be "acceptable" in the sense of being compatible with the
other ingredients of
the formulation, including the composition useful within the invention, and
not injurious to the
patient. Some examples of materials that may serve as pharmaceutically
acceptable carriers
include: sugars, such as lactose, glucose and sucrose; starches, such as com
starch and potato
starch; cellulose, and its derivatives, such as sodium carboxymethyl
cellulose, ethyl cellulose and
cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such
as cocoa butter and
suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil,
sesame oil, olive oil, corn
oil and soybean oil; glycols, such as propylene glycol; polyols, such as
glycerin, sorbitol, mannitol
and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar;
buffering agents,
such as magnesium hydroxide and aluminum hydroxide; surface active agents;
alginic acid;
pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol;
phosphate buffer solutions;
and other non-toxic compatible substances employed in pharmaceutical
formulations. As used
herein, "pharmaceutically acceptable carrier" also includes any and all
coatings, antibacterial and
antifungal agents, and absorption delaying agents, and the like that are
compatible with the
activity of the composition useful within the invention, and are
physiologically acceptable to the
patient. Supplementary active compositions may also be incorporated into the
compositions. The
"pharmaceutically acceptable carrier" may further include a pharmaceutically
acceptable salt of the
9
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
composition useful within the invention. Other additional ingredients that may
be included in the
pharmaceutical compositions used in the practice of the invention are known in
the art and
described, for example in Remington's Pharmaceutical Sciences (Genaro, Ed.,
Mack Publishing
Co., 1985, Easton, PA), which is incorporated herein by reference.
Throughout this disclosure, various aspects of the invention can be presented
in a range
format. It should be understood that the description in range format is merely
for convenience
and brevity and should not be construed as an inflexible limitation on the
scope of the invention.
Accordingly, the description of a range should be considered to have
specifically disclosed all the
possible subranges as well as individual numerical values within that range.
For example,
description of a range such as from 1 to 6 should be considered to have
specifically disclosed
subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2
to 6, from 3 to 6 etc.,
as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4,
5, 5.3, 6 and any
whole and partial increments therebetween. This applies regardless of the
breadth of the range.
The present invention relates to the discovery of effective and useful
chemical formulae
that, either alone or in combination with certain endophytic fungi, such as
Fusarium spp, have
strong antimicrobial activity and may be particularly suitable for a variety
of uses, such as to
reduce microbial growth from medical facility surfaces or instruments, reduce
microbial growth
on agricultural plant surfaces, or to decontaminate, degrade and deodorize
human and animal
wastes. For example, the formulae of the present invention are suitable for
the treatment of
wastes in any location, such as in latrines, cat litter boxes, animal stalls,
barns, chicken raising
facilities, pig barns, pet stations in homes, zoos and a host of other
locations.
In a preferred embodiment, the appropriate combination of the harmless
formulae
containing ingredients that are on the FDA- GRAS list and an appropriate
fungi, such as an
endophytic fungi Fusarium spp, such as F. subglutinans, are placed together
into a container,
such as a biodegradable plastic bag. Also contained in the bag is an
appropriate amount of a
urine-absorbing polymer that is compatible with the endophytic Fusarium
subglutinans. This
combination of agents represents a safe, rapid and novel treatment process for
the recycling of
ingredients found in human and animal wastes. The presence of these two
ingredients in the bag
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
effectively kills many of the harmful bacteria in the human wastes and at the
same time begins
the process of recycling the organic constituents of the wastes back to a
harmless soil additive.
The present invention can be employed in connection with such activities as
national
emergencies, military maneuvers, marine-related activities, natural disasters,
outdoor sporting
activities (camping, hiking, canoeing, hunting, biking, etc.) and other
activities in which human
wastes need to be properly and safely disposed. It also relates to the
development of much safer
facilities for all livestock and even household pets. As an example, it has
been recently noted that
proper and safe disposal of human waste is an important concern for the
appropriate management
of wildland areas of the world. Aesthetics, as well as health concerns, are
the major issues facing
managers of these areas. Accordingly, the present invention may be suitable
for human and animal
surfaces, plant surfaces, industrial surfaces, machine tools and a host of
other uses.
In one embodiment of the present invention, the formulations of System 1 (5-
1), System
2 (S-2), System 3 (S-3), System 4 (S-4) and/or System 5 (S-5), and optionally
using bentonite,
zeolite or perlite as a carrier (depending on application), are combined
together in the container
and the processes of bacterial killing and/or waste degradation begin
immediately. In another
embodiment, the present invention may be used in animal bedding and stall
treatments, wherein
the chemical mixture (with the carrier) can be applied directly to the areas
housing the animals,
resulting in the almost immediate killing of bacteria that cause harmful odors
such as ammonia.
In another embodiment, the present invention may be applied to a surface, such
as an agricultural
plant surface, a medical facility surface, a medical or industrial tool, or
the like, to eliminate or
otherwise reduce the microbial count on the treated surface.
Antibiotics are compounds that either kill or inhibit the growth of bacteria.
A frequent
misconception is that antibiotics are effective against other microorganisms,
such as fungi and
viruses, when in fact antifungal and antiviral compounds are needed for such
purposes.
Antibiotics work by interfering with key steps in the metabolism and growth of
bacteria and can
be broadly grouped into two main categories, bacterisides and bacteriostatics,
depending on
whether they kill bacteria or simply inhibit their growth, respectively.
Antibiotics are generally
safe for use in humans because the steps they target are either unique to
certain types of bacteria
or are effective against bacteria at very low concentrations considered safe
for humans. Other
classes of chemicals, such as certain alcohols, acids, and peroxides may have
broad inhibitory
and/or killing power because they affect fundamental elements of biochemistry
common to many
11
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
forms of life. These kinds of compounds are classified as antiseptics,
sterilants, disinfectants, and
sanitizers, and preservatives depending on their specific effects on microbial
life, modes of
effective application, and toxicity to humans. The systems of the present
invention, such as Si,
are mixtures consisting primarily of short chain organic acids and esters,
mostly notably propanoic
acid and isoamyl hexanoates. Neither of these molecules is classified as an
antibiotic, but both
possess antimicrobial properties and can be either bactericidal or
bacteriostatic depending on the
concentration and length of application.
The systems of the present invention do not work by the same mechanisms as
antibiotics.
Whereas antibiotics target very specific steps, often by recognizing very
specific structural
motifs, the systems of the present invention kill bacteria and inhibit their
growth by effecting
fundamental biochemical properties required to sustain life. Moreover, the
components of the
systems of the present invention act synergistically such that the effect of
the overall mixture is
greater than sum of its parts. The mechanism of the synergistic effect seen
with these systems is
not understood, but other acid/ester mixtures display the same sort of
exaggerated combined
effect.
One major component of the systems of the present invention, propanoic acid,
is a short
chain organic acid with an established use as a preservative in the food and
agricultural
industries. Most organisms, including humans and many bacterial species, have
metabolic
pathways that facilitate the use of propanoic acid as nutrient and in fact,
one group of bacteria can
even produce the molecule. Thus, at low concentrations propanoic acid is
essentially harmless to
almost all organisms, but at higher concentrations it cannot be degraded fast
enough and begins to
accumulate within the cell. As its concentration within the cell increases, so
too does the acidity
of the cell. When the acidity inside the cell is too high, enzymes cannot
function properly, DNA
and other biological molecules are destroyed, and the cell dies. Recent
studies indicate that
although effects on intracellular acidity are a major antimicrobial mechanism
of weak organic
acids, it is by no means the only mechanism. As acids dissociate and release
protons inside the
cell, they become negatively charged. High concentrations of negatively
charged molecules inside
the cell present a host of detrimental effects on osmolarity, nutrient
storage, and metabolism.
At lower concentrations acids may be inhibitory, but not lethal. Increases in
acidity occur
when an acid dissociates and releases a proton. When the acidity inside a cell
becomes too great,
12
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
the cell can export protons to the outside in an attempt to maintain proper pH
levels. Although
effective, this strategy requires the consumption of a large amount of energy
and can occur
without lethality only at low acid concentrations. Because smaller organisms
are more sensitive
to smaller amounts of propanoic acid, a concentration that is harmless to
humans may be fatal or
inhibitory to bacteria. Propanoic acid is not the only organic acid in Si, but
the antimicrobial
effects of other similarly sized organic acids can be presumed to arise from
essentially the same
mechanism.
The antimicrobial mechanism of esters remains largely unknown. Although not
wishing
to be bound by any particular theory, one possible clue comes from the
observation that for a
given set of esters, those that are able to incorporate more effectively into
the bacterial cell
membrane tend to have increased antimicrobial properties. Incorporation of any
molecule into
the cell membrane changes the chemical and physical properties of the
membrane, which leads
to changes in nutrient uptake, waste export, energy generation, and other
essential cellular
processes. Although not wishing to be bound by any particular theory, this
observation has led to
the suggestion that incorporation of certain esters into the cell membrane
changes its chemical and
physical properties in a way that is detrimental to the organism. Alteration
of the cell membrane is
also a mechanism by which longer chain organic acids are thought to work.
As antibiotics began to be applied on a massive scale during the 20th century,
the problem
of antibiotic resistance emerged as a major clinical issue. In the 21st
century, as the consequences
of antibiotic resistance became more visible and widespread, the term entered
the public
consciousness and was finally recognized for the immense problem that it is.
In a bacterial
population exposed to antibiotics, resistance is either existent in a very
small number of
individuals or initially emerges because of natural mutations and is
subsequently selected for
because individuals resistant to the antibiotic have a survival advantage over
non-resistant
individuals. Antibiotic resistance spreads by both vertical transmission from
a resistant cell to its
progeny and by horizontal transmission (direct transfer of resistance genes
from a resistant cell to
a non-resistant cell). In this way, resistance spreads rapidly and increased
antibiotic usage
consteatutes a selective pressure that increases the survival advantage of
antibiotic resistance.
Bacteria can acquire resistance to a given antibiotic via four primary
mechanisms:
evolving enzymes that inactive the antibiotic, altering the structure of the
target so the antibiotic
can no longer bind, rerouting metabolic pathways to skip antibiotic inhibited
steps, and
13
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
developing efflux pumps that pump the antibiotic outside the cell. Each
mechanism has a genetic
basis and can thus be transferred from the cell that initially developed
resistance to non-resistant
cells. In some cases, a bacterial cell can acquire resistance to several
different kinds of
antibiotics. This is how so called "super-bugs" arise and as the usage of
antibiotics increases in
the agricultural, veterinary, and medical industries, so too will the
prevalence of multi-drug
resistant bacterial strains. In addition, combinations of small organic
molecules, such as acids
and esters, that act in a synergistic manner to yield virtually the same
antimicrobial effect as
antibiotics have been identified. Organic molecules that possess these
properties may be referred
to as "synergistans."
The mechanisms of antibiotics, as well as resistance to them, can be summed up
by one
word- specificity. Antibiotics work by targeting specific structural features,
enzymes, and
macromolecules. Likewise, antibiotic resistance occurs when bacteria develop
an efflux pump
specific for a given antibiotic or alter a particular structural feature,
enzyme, or macromolecule.
If antibiotics are specific, the components of the systems of the present
invention are general.
Organic acids and esters lack specific targets, instead they exert their
antimicrobial effects by
changing the biochemical environment of bacterial cells. They are effective
against a much wider
range of organisms and they interfere with multiple cellular processes.
Organic acids are abundant in nature. Any given bacterial cell will invariably
be exposed
to organic acids at some point in its lifetime and as a result, many bacterial
species possess innate
genetic mechanisms that, upon induction, help them cope with the stresses
brought about by
natural organic acid exposure. Perhaps the best studied of these is the
Salmonella acid tolerance
response. Essentially when a salmonella cell is exposed to a high, but sub-
lethal acid
concentration, it induces the expression of a number of genes such that the
next time it is
exposed to acidic conditions, its chances for survival are much greater. This
has been
demonstrated experimentally by inoculating an acidic medium with previously
exposed and
unexposed salmonella cells. In almost every case, the previously exposed cells
are afforded a
much higher tolerance to the acid. E. coli also has a thoroughly studied acid
tolerance response
and it seems likely that the mechanism is present in many other bacterial
species. In the case of
pathogenic species like E.coli and salmonella, there is great concern that
induction of the acid
tolerance response by exposure to sub-lethal concentrations of organic acid
food preservatives
14
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
could increase bacterial virulence because the bacteria are more likely to
survive exposure to
acidic gastric fluids during digestion.
Nevertheless, there is an important difference between resistance to
antibiotics and
resistance to organic acids. Many of the genes for antibiotic resistance lie
on mobile genetic
elements known as plasmids that are easily transferred between bacterial cells
and bacterial
species. In this way, it is a relatively simple process for any given
bacterial cell to acquire
resistance to numerous antibiotics. Acid resistance mechanisms such as the
acid tolerance
response, on the other hand, are encoded on chromosomal DNA. This kind of
genetic
information can only be transferred to progeny cells and thus the sudden rise
of" super-bugs," as
has been observed with multi-drug resistance bacterial strains, does not
apply. Moreover,
although not wishing to be bound by any particular theory, it is possible that
the synergistic
effects observed when an organic acid is used in conjunction with organic
esters could negate
some acid resistance mechanisms.
In one embodiment, to identify a microbe that could grow on human and animal
wastes
resulting in their degradation, it was essential to formulate a novel
antibiotic mixture that would
kill the microbial contents of the wastes that normally act to break down urea
to ammonia and
uric acid. The ammonia is lethal to most fungi that otherwise would degrade
the solid
constituents of the wastes. Central to this discovery is the known fact that
propanoic acid has
antibacterial activities but only at the inhibitory level, and the same is
true for isobutryic acid.
Thus, these two compounds were the starting ingredients for the new and
effective antibiotic
mixture. What was needed was an additional ingredient to lend microbial
lethality to the mix.
Then, in a completely unexpected manner it was learned that the addition of
certain esters to
these small organic acids would lend to them significantly enhanced
antimicrobial activities.
Microorganisms living in the world's rainforests, in order to survive, must
have evolved
biochemical mechanisms to cope with potential competitors. In this regard,
they developed an
ability to produce molecules that are antimicrobial and compounds that inhibit
and destroy other
microbes. Because new antibiotics are sought after by mankind, researchers
visit rainforests in
search of new microbes and the agents that they produce to inhibit and destroy
other microbial
competitors. Certain rainforest microbes have provided important chemical
clues as to which
compounds have been chosen for Systems 1-4.
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Formulations
In part, the present invention includes a chemical formulation comprising at
least one
organic acid, such as propanoic acid, isobutyric acid, or butyric acid. In one
embodiment, the
chemical formulation has antibacterial activity when applied to human or
animal waste. In
certain embodiments of, the organic acid that is used may contain from 2-5
carbon atoms and
each acid used can vary from 0% to 80% of the bioactive mixture. In a
preferred embodiment,
the organic acid is propanoic acid. In another embodiment, the present
invention includes a
chemical formulation consisting essentially of an organic acid, such as
propanoic acid, isobutyric
acid, or butyric acid. In one embodiment, the chemical formulation consists
essentially of
propanoic acid. In certain embodiments, the chemical formulation comprises two
organic acids.
In one embodiment, the two organic acids are propanoic acid and isobutyric
acid. In one
embodiment, the chemical formulation comprises a combination of two organic
acids and at least
one ester. In one embodiment, the chemical formulation comprises propanoic
acid, isobutryic
acid, and at least one ester. In another embodiment, the two organic acids are
propanoic acid and
isobutyric acid and the at least one ester is isoamyl butyrate. In another
embodiment, the two
organic acids are propanoic acid and isobutyric acid and the at least one
ester is isoamyl
hexanoates. In another embodiment, the two organic acids are propanoic acid
and isobutyric
acid and the at least one ester is isoamyl acetate.
As contemplated herein, the chemical formulation may further comprise at least
one ester.
As contemplated herein, the at least one ester may be any ester listed in
Table 1 or elsewhere
herein. In certain embodiments, the ester can have from 3 to 10 carbon atoms
and any ester or
combination thereof may represent at least 20% of the mixture. In one
embodiment, the ester is
an isoamyl ester. As contemplated herein, embodiments of the present invention
may be
alternatively formulated using an entire family of isoamyl esters ofvarious
acid components
ranging from C-6 (hexanoate) to C-12 (laurate) as well as various aromatic
(acid) esters of
isoamyl alcohol such as cinnamate, benzoate and, phenylacetate. In one
embodiment, the ester is
isoamyl hexanoates. As used herein, the term "hexanoates" may mean a single
type of
hexanoate or may include a mixture of the acid form of hexanoates, including
branched forms.
In another embodiment, the ester is isoamyl formate. In another embodiment,
the ester is
isoamyl butyrate. In another embodiment, the ester is isoamyl acetate. In one
embodiment, the
ester is isoamyl acetate. In one embodiment, the ester is selected from the
group consisting of
16
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
allyl acetate, n-decyl acetate, isoamyl acetate, and phenethyl acetate. In one
embodiment, the
ester is strawberry aldehyde (ethyl 3-methyl-3-phenyl-oxirane-2-carboxylate,
an organic ester).
In certain embodiments, the at least one ester may be any single carbon (acid)
component ester.
In one embodiment, the at least one ester is isoamyl formate. In certain
embodiments, other
compounds can be added as the ester component of the formulations. For
example, the octanoate
ester of isoamyl alcohol is active and so too is the laurate ester.
Accordingly, the formulations of
the present invention may include use of the entire spectrum from 6-12 carbon
(acid)
components of the isoamyl esters. In one embodiment, the ester is the
octanoate ester of isoamyl
alcohol. In another embodiment, the ester is the laurate ester of isoamyl
alcohol. In certain
embodiments, benzene components may be used as well as the benzoate ester, the
cinnamate, and
the salicylate esters. In one embodiment, the chemical formulation comprises
propanoic acid and
at least one 6-12 carbon (acid) component ester.
In certain embodiments, the formulae of the present invention may include
mixtures of at
least one organic acid and at least one ester at any ratio. In one embodiment,
the ratio of the at
least one organic acid to the at least one ester is about 6-7 to about 2-3. In
preferred
embodiments, the ratio of the at least one organic acid and the at least one
ester is about 7:2. In
other embodiments, the formulae of the present invention may include mixtures
of two organic
acids and at least one ester at any ratio. In one embodiment, the ratio of a
first organic acid: a
second organic acid:at least one ester is about 3.5:3.5:2 v/v/v. In another
embodiment, the
mixture of a first organic acid: a second organic acid:at least one ester is
about 7 parts of the two
acids and 2 parts of the selected ester. In one embodiment, the chemical
formulation comprises
propanoic acid and at least one 6-12 carbon (acid) component ester, wherein
the chemical
formulation has a ratio of propanoic acid:ester component of about 7:2 v/v.
As contemplated herein, the present invention may include any chemical
formulation plus
the addition of at least one endophytic fungus. The present invention is not
limited to any
particular fungus, however and endophytic fungus is preferred, and a fungus
from the genus
Fusarium is more preferred. Most preferred is the endophytic fungus of the
species Fusarium
subglutinans. In another embodiment, the endophytic fungus is a fungus from
the genus
Gloeosporium. As contemplated herein, the fungus may be incorporated into any
formulation
via inoculated barley, or other suitable carrier for a fungus as is understood
by those skilled in
the art. In one embodiment, the chemical formulation comprises two organic
acids and at least
17
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
one ester and at least one fungus, wherein the two organic acids and the at
least one ester kills or
reduces bacteria growth on the human or animal waste, and the at least one
fungus increases the
rate of decomposition of the human or animal waste. In another embodiment, the
formulation
comprises propanoic acid, isobutryic acid, at least one ester and at least one
fungus. In certain
embodiments, the formulation may additionally comprise cineole, valencene,
salts or any other
additive, excipient or other component desired to produce a formulation having
the desired
characteristic.
In some embodiments, supplementing a fungal culture with additional compounds
may
enhance its fungal inhibitory properties to an extent greater than either the
agents produced by
the fungus or the compound alone. Such activity is deemed synergism. Thus, the
present
invention also provides chemical formulations comprising at least one fungus
and at least one
synergistan. As used herein, the term "synergistan" refers to any chemical
compound that, when
administered in combination with another compound, displays greater microbial
inhibitory
activity than the activity observed when each compound is administered alone.
In a non-limiting
example, when a synergistan is combined with a fungal culture, the combined
gas phase of the
fungus and the synergistans displays increased antimicrobial activity than
either the gas phase of
the fungus or the synergistan alone.
In certain embodiments, the chemical formulations of the present invention may
be used
in combination with carriers such as zeolite or bentonite as a cat litter
treatment, horse barn,
cattle barn, sheep barn, or small animal bedding treatment. In such
embodiments, the present
invention inhibits microbes that inhabit fecal matter, such as E. coli, and
break down urea in
urine to release ammonia. In another embodiment, the chemical formulations of
the present
invention may be added to a carrier such as, without limitation, bentonite,
zeolite, perlite or other
silica based carriers, in amounts that are effective in killing bacteria and
reducing harmful and
noxious odors.
In certain embodiments, the present invention may be mixed with a foam or
other
dispersing solution and used as an antimicrobial spray or for surfaces that
are contaminated with
bacteria or other microbes, such as for the treatment of surfaces in
hospitals, home food prep
areas, contaminated areas for food processing, including all industrial food
processors, fruits,
meats, and others in which bacterial contamination is commonly a problem.
18
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
In certain embodiments, a composition of the present invention comprises at
least one
chemical formulation or formula of the present invention. In one embodiment,
the compositions
of the invention are formulated using one or more pharmaceutically acceptable
excipients or
carriers. In one embodiment, the pharmaceutical compositions of the invention
comprise a
therapeutically effective amount of a formula of the invention and a
pharmaceutically acceptable
carrier. Examples of pharmaceutically acceptable carriers include cremophor,
or any other
biological surfactant as would be understood by one skilled in the art. In one
embodiment, the
pharmaceutically acceptable carrier is cremophor.
In certain embodiments, the formulae of the present invention, and preferably
S-3, may
be used with a carrier (zeolite or bentonite or talc) to treat soil areas that
are about to receive
either seed or young transplants to reduce or eliminate damping of infections.
In certain embodiments, the formulae of the present invention may be mixed
with
detergents to be used as a carpet scrubbing and bacterial decontamination
agent for animal waste,
human waste or other biofouling of carpet surfaces.
In certain embodiments, the formulae of the present invention may be
administered as a
spray to decontaminate fruits, vegetables, grains and other agricultural
products during planting,
during growth, during harvest and/or during transport.
In certain embodiments, the formulae of the present invention may be applied
to or
formulated, embedded or otherwise integrated within baby diapers, bandages or
other devices in
which bacterial decontamination is desired.
In certain embodiments, the formulae of the present invention may be
additionally
formulated with a detergent to function as a soap for the decontamination of
human and animal
skin.
In certain embodiments, the formulae of the present invention may be
additionally
formulated, embedded or otherwise integrated within a candle wax for area
decontamination via
vapors when lit.
In particular the chemical formulations of the present invention show
remarkable
antibiotic activity against bacteria associated with human and animal wastes.
These mixture can
be specifically delivered to their respective target site via inert carriers
such as, without
limitation, bentonite, zeolite, perlite or other silica based carriers. In
this case, the specific
location for use of the carrier and the antibiotic combination may include,
for example and
19
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
without limitation, the bedding locations of all domestic and zoo related
animals and animals
used as household pets. The mixture can be applied to the stalls, bedding and
places where
animals live in order to reduce the load of bacteria and harmful gases.
It should be appreciated that the formulations of the present invention may
include any
additional salts, excipients, nutritional additive or supplement, and the
like, such that the final
formulation is suitable for topical application, ingestion, inhalation or any
other form of
administration desired.
System 1
As described elsewhere herein, the chemical formulation may comprise two
organic acids
and at least one ester. For example, in one embodiment, the formulation
includes propanoic
acid: isobutryic acid: isoamyl butyrate. In one embodiment, the ratio of
propanoic acid:
isobutryic acid: isoamyl butyrate is about 3.5:3.5:2 v/v/v. In another
embodiment, the mixture of
propanoic acid: isobutryic acid: isoamyl butyrate is about 7 parts of the two
acids and 2 parts of
the selected ester. It should be appreciated that the chemical formulation of
System 1 is not
limited to any particular ratio of such chemical components. In another
embodiment, the
chemical formulation of System 1 consists of only two organic acids and a
single ester. In such an
embodiment, the formulation consists of propanoic acid: isobutryic acid:
isoamyl butyrate at the
ratios described above. In certain embodiments, the formulation may
additionally comprise
cineole, valencene, salts or any other additive, excipient or other component
desired to produce a
formulation having the desired characteristic.
In another embodiment, the chemical formulation of System 1 may be added to a
carrier
such as, without limitation, bentonite, zeolite, perlite or other silica based
carriers, in amounts that
are effective in killing bacteria and reducing harmful and noxious odors. This
rate is usually
1 ml of System 1 to 224 g of the carrier V/W or in other appropriate ratios
that are effective,
without limitation.
System 2
As contemplated herein, the present invention may include any chemical
formulation of
System 1 plus the addition of at least one endophytic fungus. As demonstrated
herein,
endophytic fungi of the group F. subglutinans and others are particularly
suited to grow on and
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
degrade human wastes. In addition, the fungus is only able to grow on the
liquid and solid waste
combination when another antimicrobial mixture such as System 1 is applied and
this mixture
maximally allows for fungal growth whilst killing bacteria and other microbes.
In one
embodiment, the fungus is Fusarium subglutinans. In one embodiment, the fungus
is
incorporated into System 2 via inoculated barley. In certain embodiments, the
formulation may
additionally comprise cineole, valencene, salts or any other additive,
excipient or other
component desired to produce a formulation having the desired characteristic.
In one embodiment, System 2 includes the chemical formulation of System 1,
such as
propanoic acid: isobutryic acid: isoamyl butyrate in the ratio of 3.5:3.5:2
v/v/v, or 7 parts of the
two acids and 2 parts of the ester, which is then added at the rate of 1/10
V/VV of the mixture to
the dry weight of the carrier substance such as bentonite, perlite or zeolite
etc. It should be
appreciated that the chemical formulation of System 2 is not limited to any
particular ratio of
such chemical components. Barley inoculated with Fusarium subglutinans is also
added. This
mixture is then added as 10 g to each container, such as a plastic bag, used
to treat and dispose of
human wastes. It allows for the rapid growth of Fusarium subglutinans in
contrast to System 1
alone, which does not. Other items may also be added to the bag including
liquid absorbing
polymers in appropriate amounts, as would be understood by those skilled in
the art.
System 3
As contemplated herein, the chemical formulation of the present invention may
comprise
at least one organic acid and at least one ester. In a preferred embodiment,
the at least one organic
acid is propanoic acid. In one embodiment, the at least one ester is isoamyl
hexanoate or a
mixture of isoamyl hexanoates. In a preferred embodiment, the at least one
ester is isoamyl
hexanoates. In one embodiment, the chemical formulation comprises propanoic
acid and
isoamyl hexanoates. In certain embodiments, the formulation may additionally
comprise
cineole, valencene, salts or any other additive, excipient or other component
desired to produce a
formulation having the desired characteristic.
In one embodiment, the ratio of propanoic acid: isoamyl hexanoates is about
7:2 v/v. It
should be appreciated that the chemical formulation of System 3 is not limited
to any particular
ratio of such chemical components. In another embodiment, the chemical
formulation of System
3 consists of a single organic acid component and a single ester component. In
another
21
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
embodiment, the chemical formulation of System 3 consists of a single organic
acid component
and a mixture of isoamyl hexanoates. In such an embodiment, the formulation
consists of
propanoic acid: isoamyl hexanoates at the ratios described above. In another
embodiment, the
chemical formulation consists essentially of propanoic acid and isoamyl
hexanoates at a ratio of
propanoic acid:isoamyl hexanoates of about 7:2 v/v.
In another embodiment, the chemical formulation of System 3 may be added to a
carrier
such as, without limitation, bentonite, zeolite, perlite or other silica based
carriers, in amounts
that are effective in killing bacteria and reducing harmful and noxious odors.
This rate is usually between 1.0 to 1.5 ml of System 3 to 224 g of the carrier
V/W or in other
appropriate ratios that are effective, without limitation, such as between 0.1
to 5 ml of System 3
to 224 g of the carrier V/W, or between 0.5 to 2 ml of System 3 to 224 g of
the carrier V/W.
System 4
As contemplated herein, the chemical formulation of the present invention may
comprise
at least one organic acid and at least one ester. In a preferred embodiment,
the at least one acid is
propanoic acid. In one embodiment, the at least one ester is isoamyl formate.
In another
embodiment, the at least one ester may be any single carbon (acid) component
ester. In one
embodiment, the chemical formulation comprises propanoic acid and isoamyl
formate. In
certain embodiments, the formulation may additionally comprise cineole,
valencene, salts or any
other additive, excipient or other component desired to produce a formulation
having the desired
characteristic.
In one embodiment, the ratio of propanoic acid: isoamyl formate is about 7:2
v/v. It
should be appreciated that the chemical formulation of System 4 is not limited
to any particular
ratio of such chemical components. In another embodiment, the chemical
formulation of System
4 consists of a single organic acid component and a single ester component. In
such an
embodiment, the formulation consists of propanoic acid: isoamyl formate at the
ratios described
above. In one embodiment, the chemical formulation consists essentially of
propanoic acid and
isoamyl formate at a ratio of propanoic acid:isoamyl formate of about 7:2 v/v.
As contemplated herein, the present invention may include any chemical
formulation of
System 4 plus the addition of at least one endophytic fungus. As demonstrated
herein,
endophytic fungi of the group F. subglutinans and others are particularly
suited to grow on and
22
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
degrade human wastes. In addition, the fungus is only able to grow on the
liquid and solid waste
combination when another antimicrobial mixture such as System 4 is applied and
this mixture
maximally allows for fungal growth whilst killing bacteria and other microbes.
In one
embodiment, the fungus is Fusarium subglutinans. In yet another embodiment,
the present
invention includes a chemical formulation comprising a 7:2 mixture of
propanoic acid and
isoamyl formate, and optionally with the addition of a Fusarium subglutinans.
In this
embodiment, the propanoic acid/isoamyl formate mixture is suitable for killing
selected
microorganisms without killing the Fusarium spp., which can further enhance
the recycling of a
waste product to which the formulation is applied. In one embodiment, the
fungus is
incorporated into System 4 via inoculated barley.
In one embodiment, System 4 includes propanoic acid: isoamyl formate in the
ratio of 7:
2 v/v, which is then added at the rate of 1/10 VM/ of the mixture to the dry
weight of the carrier
substance such as bentonite, perlite or zeolite etc. Barley inoculated with
Fusarium subglutinans
may also be added. This mixture is then added to a container, such as a
plastic bag, used to treat
and dispose of human wastes. It allows for the rapid growth of Fusarium
subglutinans. Other
items may also be added to the bag including liquid absorbing polymers in
appropriate amounts,
as would be understood by those skilled in the art.
System 5
As described elsewhere herein, the chemical formulation may comprise two
organic acids
and at least one ester. For example, in one embodiment, the formulation
includes propanoic
acid: isobutryic acid: isoamyl hexanoates. In one embodiment, the ratio of
propanoic acid:
isobutryic acid: isoamyl hexanoates is about 3.5:3.5:2 v/v/v. In another
embodiment, the mixture
of propanoic acid: isobutryic acid: isoamyl hexanoates is about 7 parts of the
two acids and 2
parts of the selected ester. It should be appreciated that the chemical
formulation of System 5 is
not limited to any particular ratio of such chemical components. In another
embodiment, the
chemical formulation of System 5 consists of only two organic acids and a
single ester. In such
an embodiment, the formulation consists of propanoic acid: isobutryic acid:
isoamyl hexanoates
at the ratios described above. In certain embodiments, the formulation may
additionally
comprise cineole, valencene, salts or any other additive, excipient or other
component desired to
produce a formulation having the desired characteristic.
23
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
In another embodiment, the chemical formulation of System 5 may be added to a
carrier
such as, without limitation, bentonite, zeolite, perlite or other silica based
carriers, in amounts
that are effective in killing bacteria and reducing harmful and noxious odors.
System X
As contemplated herein, the present invention may include any chemical
formulation of
Systems 1-5 in combination with at least one of a salt, excipient, nutritional
additive or
supplement. In a preferred embodiment, the chemical formulation is System 3.
As demonstrated
herein, a chemical formulation comprising System 3, at least one nutritional
supplement, and at
least one salt is useful for treating diseases and disorders associated with a
microbial infection.
Examples of nutritional supplements include, but are not limited to, sugars
such as glucose,
sucrose, or fructose, amino acids such as glycine, and protein sources such as
whey protein. Any
protein source may be used, as would be understood by one skilled in the art.
Non-limiting
examples of salts include potassium chloride, sodium chloride, magnesium
sulfate,
monopotassium phosphate, potassium sulfate, and magnesium acetate. Salts are
useful in the
formulations of the invention as they enhance electrolyte balance in a
subject. Any amount of
salt may be used in the compositions of the inventions. It is preferred that
the amount of salt is
greater than 0%. The presence of System 3 inhibits and kills pathogenic
bacteria. In one
embodiment, System X includes the chemical formulation of System 3, glucose,
whey protein,
potassium chloride, magnesium sulfate, and sodium chloride. In another
embodiment, System X
includes the chemical formulation of System 3, glucose, glycine, potassium
chloride, sodium
chloride, and magnesium acetate. In another embodiment, System X includes the
chemical
formulation of System 3, glucose, glycine, potassium chloride, sodium
chloride, magnesium
acetate, and monopotassium phosphate. It should be appreciated that the
chemical formulation
of System X is not limited to any particular ratio of such chemical
components. In one
embodiment, the amount of organic acid is about 100% and the amount of ester
is 0%. In
another embodiment, the amount of organic acid is about 99% and the amount of
ester is about
1%. In another embodiment, the amount of organic acid is about 1% and the
amount of ester is
about 99%.
In certain embodiments, System X is formulated using one or more
pharmaceutically
acceptable excipients or carriers. Examples of pharmaceutically acceptable
carriers include
24
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
cremophor, or any other biological surfactant as would be understood by one
skilled in the art. In
one embodiment, the pharmaceutically acceptable carrier is cremophor. In one
embodiment,
System X includes the chemical formulation of System 3 and cremophor.
In certain embodiments, Systems 2 and 4 may be used with or without a carrier
to treat
animal wastes (including human waste) in the presence of Fusarium
subglutinans. In such
embodiments, the present invention inhibits and kills bacteria while at the
same time allowing for
the growth of the F. subglutinans that will eventually break down or cause
decay of the solid
material in the human waste.
In certain embodiments, the formulae of the present invention are used to
fumigate seeds
that are contaminated with a microorganism.
In certain embodiments, the formulae of the present invention are administered
as a
gaseous formula without water or any additional carriers.
Methods
Decontaminating human wastes is only one problem associated with the waste
treatment
process. An additional problem addressed by the present invention is the need
to begin the
immediate degradation process of the organic material in the solid and liquid
wastes. The
biology and biochemistry that occurs when solid and liquid wastes combine is
complex. It turns
out the urea in urine is immediately attacked by the enzyme urease found in
most microbes
associated with solid waste with the concomitant production of ammonia gas.
The gas itself is
harmful and produces an awful odor. Also it is lethal to most fungi as it
causes an increase in pH.
Thus if one wishes to cause waste degradation, it is essential to stop ammonia
production which is
desirable for fungal growth and for ammonia remediation in the environment.
Each of Systems
1-4 cause killing and inhibition of bacterial growth and subsequent ammonia
production, and
Systems 2 and 4 further allows for the ready growth of Fusarium subglutinans
which then
degrades the waste. Thus, Systems 1 and 3 are particularly suited to treat
animal bedding, wastes
etc. with the reduction of ammonia.
The discovery of the appropriate microorganism to bring about the rapid decay
of human
and animal waste began with the consideration that microbes living within
plants (namely, the
endophytes) would be an appropriate place to begin the search. Endophytes are
the first microbes
that are involved in the degradation of a plant when it dies of either natural
causes or
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
environmental damage. They have a set of enzymes that degrades the cellulose,
lignin and
hemicelluloses found in plant materials. These are the same complex organic
materials that are
found in human solid wastes; therefore, in order to tackle the problem with
which the present
application is concerned, namely, the degradation of human and animal wastes,
a number of
endophytic microbes were located and tested for their ability to grow on both
solid and liquid
human wastes. In order for the microbe to degrade the waste it must either be
insensitive to the
ammonia that is produced or the ammonia must be eliminated from the equation.
Therefore,
using Systems 2 and/or 4, which allows for the growth of Fusarium spp. and the
elimination of
ammonia production, it is possible to devise a useable and logical means to
treat liquid and solid
wastes.
In one aspect, the present invention includes a method of treating human or
animal waste.
In one embodiment, the method comprises contacting human or animal waste with
a composition
of the present invention, wherein the composition kills or reduces bacteria
growth on the human or
animal waste. In one embodiment, the composition comprises a chemical
formulation of the
present invention. In one embodiment, the chemical formulation further
comprises at least one
fungus. In another embodiment, the at least one fungus increases the rate of
decomposition of
the human or animal waste.
In another aspect, the present invention includes a method of eliminating or
reducing
microbial growth at a treatment site. In one embodiment, the method comprises
contacting the
treatment site with a composition of the present invention, wherein the
composition kills or
reduces bacteria growth on the human or animal waste. In one embodiment, the
composition
comprises a chemical formulation of the present invention. In one embodiment,
the chemical
formulation further comprises at least one fungus.
In another aspect, the present invention includes a method of eliminating or
reducing odor
formation at a treatment site. In one embodiment, the method comprises
contacting the treatment
site with a composition of the present invention, wherein the composition
eliminates or reduces
odor formation on the human or animal waste.
In another aspect, the present invention includes a method of eliminating or
reducing the
amount of ammonia at a treatment site. In one embodiment, the method comprises
contacting
the treatment site with a composition of the present invention, wherein the
composition
eliminates or reduces the amount of ammonia on the human or animal waste.
26
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
In another aspect, the present invention includes a method of fumigating seeds
that are
contaminated with a microorganism. In one embodiment, the method comprises
contacting the
seeds with a composition of the present invention, wherein the composition
reduces or eliminates
microbial growth on the seeds, and in some embodiments, reduces or eliminates
microbial
growth on the seeds without significantly disrupting germination.
In certain embodiments, the formulae of the present invention may be used in
hospital
areas to treat human wastes in combination with a carrier to be placed in bed
pans to stop
contamination of the area with fecal bacteria. In certain embodiments the
formulae of the
present invention may be used as an antiseptic to treat cuts and wounds and
surface infections in
animals and people. For example, the present invention may be used to treat
bacterial and viral
gut infections in people and animals. It is to be noted that all ingredients
of Systems 1-4 are
GRAS listed and as such are safe. In particular, 10 ml of S-3 has been
consumed by a human
with no adverse effects. The compositions and formulations of the present
invention may also
be used to treat or disinfect the surfaces of inanimate or non-living objects,
or to spray or apply
topically to all types of plants, such as agricultural fruits, vegetables,
grains and the like, or to be
applied topically, ingested or inhaled by any type of animal, such as
livestock or humans.
In one aspect, the present invention includes a method of preserving a fruit.
In one
embodiment, the method comprises administering to the fruit an effective
amount of a
composition of the present invention. In one embodiment, the fruit is a
raspberry or a grape.
In certain embodiments, the formulae of the present invention, and preferably
S-3, may
be used to disinfest corn that is used for the fermentation to alcohol.
Mastitis is an infection of the tissues of a cow's udder. Almost any bacterial
or mycotic
organism that can opportunistically invade tissue and cause infection can
cause mastitis. It
represents one of the most important problems in dairy production. Most
mastitis infections are
caused by various species of streptococci, staphylococci, and gram-negative
rods, especially
lactose-fermenting organisms of enteric origin, commonly termed coliforms and
these include
such organisms as E. coli and Staphlycoccus aureus. From an epidemiologic
standpoint, the
source of infection may be regarded as contagious or environmental and cows
are in constant
threat of getting infected with these agents.
Except for Mycoplasma spp, which may spread from cow to cow through aerosol
transmission and invade the udder subsequent to bacteremia, contagious
pathogens are spread
27
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
during milking by milkers' hands or the liners of the milking unit. The chief
bacterial species that
utilize this mode of transmission include Staphylococcus aureus, Streptococcus
agalactiae, and
Corynebacterium bovis. Most other species are opportunistic invaders from the
cow's
environment, although some other streptococci and staphylococci may also have
a contagious
component.
Intramammary infections are often described as subclinical or clinical
mastitis.
Subclinical mastitis is the presence of an infection without apparent signs of
local inflammation
or systemic involvement. Although transient episodes of abnormal milk or udder
inflammation
may appear, these infections are for the most part asymptomatic and, if the
infection persists for
at least 2 months, are termed chronic. Once established, many of these
infections persist for entire
lactations or the life of the cow. Detection is best done by examination of
milk for somatic cell
counts (predominantly neutrophils) using either the California Mastitis Test
or automated
methods provided by dairy herd improvement organizations. Somatic cell counts
are positively
correlated with the presence of infection. Although variable (especially if
determined on a single
analysis), cows with a somatic cell count of2:280,000 cells/mL (2: a linear
score of 5) have a
>80% chance of being infected. Likewise, the higher the somatic cell count in
a herd bulk tank,
the higher the prevalence of infection in the herd. Causative agents must be
identified by
bacterial culture of milk.
Clinical mastitis is an inflammatory response to infection causing visibly
abnormal milk
(eg, color, fibrin clots). As the extent of the inflammation increases,
changes in the udder
(swelling, heat, pain, redness) may also be apparent. Clinical cases that
include only local signs
are referred to as mild or moderate. If the inflammatory response includes
systemic involvement
(fever, anorexia, shock), the case is termed severe. If the onset is very
rapid, as often occurs with
severe clinical cases, it is termed an acute case of severe mastitis. More
severely affected cows
tend to have more serous secretions in the affected quarter.
Although any number of quarters can be infected simultaneously in subclinical
mastitis,
typically only one quarter at a time will display clinical mastitis. However,
it is not uncommon
for clinical episodes caused by Mycoplasma to affect multiple quarters.
Gangrenous mastitis can
also occur, particularly when subclinical, chronic infections of S aureus
become severe at times
of immunosuppression (eg, at parturition). As with subclinical mastitis,
culture of milk samples
28
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
collected from affected quarters is the only reliable method to determine the
etiology of clinical
cases.
All dairy herds have cows with subclinical mastitis; however, the prevalence
of infected
cows varies from 15-75%, and quarters from 5-40%. Many different pathogens can
establish a
chronic infection that will only on occasion manifest clinical signs of
mastitis. The primary focus
of most subclinical mastitis programs is to reduce the prevalence of the
contagious pathogens
Streptococcus agalactiae and Staphylococcus aureus, as well as other gram-
positive cocci, most
notably Streptococcus dysgalactiae (which may also be contagious or an
environmental pathogen),
Streptococcus uberis, enterococci, and numerous other coagulase-negative
staphylococci,
including S hyicus, S epidermidis, S xylosus, and S intermedius.
For contagious pathogens, adult lactating cattle are most at risk for
infection, either while
lactating or during the dry period. The primary reservoir of infection is the
mammary gland;
transmission occurs at milking with either milkers' hands or milking equipment
acting as
fomites. Primiparous heifers have been reported to be infected with
staphylococci and
streptococci prior to calving, although the prevalence varies greatly among
herds and geographic
regions. Teat-end dermateatis caused by the hom fly, Haematobia irritans,
which can harborS
aureus, has been associated with increased risk of infection in heifers,
especially in warmer
climates.
Commonly used treatments include the use of antibiotics, which pose a threat
to the milk
being acquired from the animal since the antibiotics will make their way into
the udder. Milk
cannot be used for at least 3 days after the administration of the antibiotic.
The use of
immunization is not possible since there are a large number of potential
pathogens involved in
the mastitis disease. The general recommendation is for sanitation practices
to be intensified
with cleanliness in the milking parlor and in the areas frequented by the
animals. Currently, no
available treatment has been found to be both effective and safe for the
treating mastitis.
In one aspect, the present invention includes a method of treating an animal
having a
disease or disorder associated with a microbial infection. In one embodiment,
the method
comprises administering to the animal an effective amount of a composition of
the present
invention. In another embodiment, the method comprises administering to the
animal an
effective amount of a composition comprising an organic acid. Such diseases
and disorders may
include, without limitation, diarrheal diseases such as scours, food
poisoning, or stomach flu, or
29
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
intramammary infections such as subclinical or clinical mastitis. It should be
further appreciated
that the formulae and compositions of the present invention are not limited to
treatment of any
particular type of subject. As contemplated herein, the subject may be any
animal, preferably a
mammal, and more preferably livestock, such as cattle, sheep, or swine, or
even a human. In one
embodiment, the animal is bovine, porcine, or ovine. In another embodiment,
the animal is
human.
In another aspect, the present invention includes a method of treating a cow
having
scours. In one embodiment, the method comprises administering to the cow an
effective amount
of a composition of the present invention.
In another aspect, the present invention includes a method of treating a pig
having scours.
In one embodiment, the method comprises administering to the pig an effective
amount of a
composition of the present invention.
In another aspect, the present invention includes a method of treating a cow
having
mastitis. In one embodiment, the method comprises administering to the cow an
effective
amount of a composition of the present invention.
In another aspect, the present invention includes a method of treating a sheep
having
mastitis. In one embodiment, the method comprises administering to the sheep
an effective
amount of a composition of the present invention.
In another aspect, the present invention includes a method of treating a human
having a
diarrheal disease. In one embodiment, the method comprises administering to
the human an
effective amount of a composition of the present invention. In one embodiment,
the diarrheal
disease is food poisoning or stomach flu.
Combination Therapy
The compositions of the present invention are intended to be useful in
combination with
one or more additional compounds. In non-limiting examples, the compositions
of the invention
may be used in combination with one or more therapeutic agents (or a salt,
solvate or prodrug
thereof). Non-limiting examples of therapeutic agents include antibiotics such
as Baytril,
sulfonamides, Nuflor, Tylan 40-50, Excede, Noromycin LA, Draxxin, and
tetracycline, vaccines
such as Inforce 3, multivitamins, probiotics, and toxin absorbants such as
Toxiban, or other
therapeutic agents such as Suprio.
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
In another embodiment, the compositions of the invention may be used in
combination
with a detergent. In one embodiment, the detergent acts as a solubilizing
agent for the
composition while removing unwanted bacterial laden debris from the area of
infection of the
subject, and any other possible sources of infection, such as bedding, tools,
or places where the
subject lives. In a non-limiting example, the compositions of the present
invention are useful for
treating the udder, the bedding used for housing cattle, which is the primary
source of
environmental pathogens, as well as tools used in the milking process which
have all been
identified as potential sources of infection, such as contaminated teat dips,
intramammary
infusions, water hoses used for udder preparation during milking, water ponds
or mud holes, skin
lesions, teat trauma, and flies. Non-limiting examples of detergents include
Sucragel CF,
Chemoxide CAW, BioSoft D40, Lathanol LAL, BioTerge AS-40, Nacconol 90G, and
potassium
cocoate.
Pharmaceutical Compositions and Therapies
Administration of a composition useful within the invention may be achieved in
a number
of different ways, using methods known in the art. The therapeutic and
prophylactic methods of
the invention thus encompass the use of pharmaceutical compositions comprising
the
compositions useful within the invention to practice the methods of the
invention. The
pharmaceutical compositions useful for practicing the invention may be
administered to deliver a
dose of 1 ng/kg/day to 100 mg/kg/day.
The relative amounts of the active ingredient, the pharmaceutically acceptable
carrier,
and any additional ingredients in a pharmaceutical composition of the
invention will vary,
depending upon the identeaty, size, and condition of the subject treated and
further depending
upon the route by which the composition is to be administered. By way of
example, the
composition may comprise between 0.1% and 100% (w/w) active ingredient.
Although the description of pharmaceutical compositions provided herein are
principally
directed to pharmaceutical compositions that are suitable for ethical
administration to humans, it
will be understood by the skilled artisan that such compositions are generally
suitable for
administration to animals of all sorts. Modification of pharmaceutical
compositions suitable for
administration to humans in order to render the compositions suitable for
administration to
various animals is well understood, and the ordinarily skilled veterinary
pharmacologist can
31
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
design and perform such modification with merely ordinary, if any,
experimentation. Subjects to
which administration of the pharmaceutical compositions of the invention is
contemplated
include, but are not limited to, humans and other primates, mammals including
commercially
relevant mammals such as non-human primates, cattle, pigs, horses, sheep,
cats, and dogs.
Typically, dosages which may be administered in a method of the invention to
an animal,
preferably a human, range in amount from 0.5 !lg to about 50 mg per kilogram
of body weight of
the animal. While the precise dosage administered will vary depending upon any
number of
factors, including but not limited to, the type of animal and type of disease
state being treated,
the age of the animal and the route of administration, the dosage of the
composition will
preferably vary from about 1 !lg to about 10 mg per kilogram ofbody weight of
the animal.
More preferably, the dosage will vary from about 3 !lg to about 1 mg per
kilogram of body
weight of the animal.
Pharmaceutical compositions that are useful in the methods of the invention
may be
prepared, packaged, or sold in compositions suitable for oral, parenteral,
topical, buccal, or
another route of administration. Other contemplated compositions include
projected
nanoparticles, liposomal preparations, resealed erythrocytes containing the
active ingredient, and
immunologically-based compositions.
The pharmaceutical compositions described herein may be prepared by any method
known or hereafter developed in the art of pharmacology. In general, such
preparatory methods
include the step of bringing the active ingredient into association with a
pharmaceutically
acceptable carrier or one or more other accessory ingredients, and then, if
necessary or desirable,
shaping or packaging the product into a desired single- or multi-dose unit.
A pharmaceutical composition of the invention may be prepared, packaged, or
sold in
bulk, as a single unit dose, or as a plurality of single unit doses. As used
herein, a "unit dose" is
discrete amount of the pharmaceutical composition comprising a predetermined
amount of the
active ingredient. The amount of the active ingredient is generally equal to
the dosage of the
active ingredient that would be administered to a subject or a convenient
fraction of such a
dosage such as, for example, one-half or one-third of such a dosage.
In one embodiment, the compositions of the invention are formulated using one
or more
pharmaceutically acceptable excipients or carriers. In one embodiment, the
pharmaceutical
compositions of the invention comprise a therapeutically effective amount of a
composition of
32
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
the invention and a pharmaceutically acceptable carrier. Pharmaceutically
acceptable carriers
that are useful, include, but are not limited to, glycerol, water, saline,
ethanol and other
pharmaceutically acceptable salt solutions such as phosphates and salts of
organic acids.
Examples of these and other pharmaceutically acceptable carriers are described
in Remington's
Pharmaceutical Sciences (1991, Mack Publication Co., New Jersey).
The carrier may be a solvent or dispersion medium containing, for example,
water,
ethanol, polyol (for example, glycerol, propylene glycol, and liquid
polyethylene glycol, and the
like), suitable mixtures thereof, and vegetable oils. The proper fluidity may
be maintained, for
example, by the use of a coating such as lecithin, by the maintenance of the
required particle size
in the case of dispersion and by the use of surfactants. Prevention of the
action of
microorganisms may be achieved by various antibacterial and antifungal agents,
for example,
parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In
many cases, it will be
preferable to include isotonic agents, for example, sugars, sodium chloride,
or polyalcohols such
as mannitol and sorbitol, in the composition. Prolonged absorption of the
injectable
compositions may be brought about by including in the composition an agent
that delays
absorption, for example, aluminum monostearate or gelatin. In one embodiment,
the
pharmaceutically acceptable carrier is not DMSO alone.
Compositions may be employed in admixtures with conventional excipients, i.e.,
pharmaceutically acceptable organic or inorganic carrier substances suitable
for oral, parenteral,
nasal, intravenous, subcutaneous, enteral, or any other suitable mode of
administration, known to
the art. The pharmaceutical preparations may be sterilized and if desired
mixed with auxiliary
agents, e.g., lubricants, preservatives, stabilizers, wetting agents,
emulsifiers, salts for
influencing osmotic pressure buffers, coloring, flavoring and/or aromatic
substances and the like.
They may also be combined where desired with other active agents, e.g., other
analgesic agents.
As used herein, "additional ingredients" include, but are not limited to, one
or more of the
following: excipients; surface active agents; dispersing agents; inert
diluents; granulating and
disintegrating agents; binding agents; lubricating agents; sweetening agents;
flavoring agents;
coloring agents; preservatives; physiologically degradable compositions such
as gelatin; aqueous
vehicles and solvents; oily vehicles and solvents; suspending agents;
dispersing or wetting
agents; emulsifying agents, demulcents; buffers; salts; thickening agents;
fillers; emulsifying
agents; antioxidants; antibiotics; antifungal agents; stabilizing agents; and
pharmaceutically
33
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
acceptable polymeric or hydrophobic materials. Other "additional ingredients"
that may be
included in the pharmaceutical compositions of the invention are known in the
art and described,
for example in Genaro, ed. (1985, Remington's Pharmaceutical Sciences, Mack
Publishing Co.,
Easton, PA), which is incorporated herein by reference.
The pharmaceutical composition of the invention may comprise a preservative
from about
0.005% to 2.0% by total weight of the composition. The preservative is used to
prevent spoilage
in the case of exposure to contaminants in the environment. Examples of
preservatives useful in
accordance with the invention included but are not limited to those selected
from the group
consisting of benzyl alcohol, sorbic acid, parabens, imidurea and combinations
thereof A
particularly preferred preservative is a combination of about 0.5% to 2.0%
benzyl alcohol and
0.05% to 0.5% sorbic acid.
The pharmaceutical composition preferably includes an anti-oxidant and a
chelating
agent that inhibits the degradation of the formulation. Preferred antioxidants
for some
formulation are BHT, BHA, alpha-tocopherol and ascorbic acid in the preferred
range of about
0.01% to 0.3% and more preferably BHT in the range of 0.03% to 0.1% by weight
by total
weight of the composition. Preferably, the chelating agent is present in an
amount of from
0.01% to 0.5% by weight by total weight ofthe composition. Particularly
preferred chelating
agents include edetate salts (e.g. disodium edetate) and citric acid in the
weight range of about
0.01% to 0.20% and more preferably in the range of0.02% to 0.10% by weight by
total weight
of the composition. The chelating agent is useful for chelating metal ions in
the composition that
may be detrimental to the shelf life of the formulation. While BHT and
disodium edetate are the
particularly preferred antioxidant and chelating agent respectively for some
formulations, other
suitable and equivalent antioxidants and chelating agents may be substeatuted
therefore as would
be known to those skilled in the art.
Liquid suspensions may be prepared using conventional methods to achieve
suspension
of the active ingredient in an aqueous or oily vehicle. Aqueous vehicles
include, for example,
water, and isotonic saline. Oily vehicles include, for example, almond oil,
oily esters, ethyl
alcohol, vegetable oils such as arachis, olive, sesame, or coconut oil,
fractionated vegetable oils,
and mineral oils such as liquid paraffin. Liquid suspensions may further
comprise one or more
additional ingredients including, but not limited to, suspending agents,
dispersing or wetting
agents, emulsifying agents, demulcents, preservatives, buffers, salts,
flavorings, coloring agents,
34
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
and sweetening agents. Oily suspensions may further comprise a thickening
agent. Known
suspending agents include, but are not limited to, sorbitol syrup,
hydrogenated edible fats,
sodium alginate, polyvinylpyrrolidone, gum tragacanth, gum acacia, and
cellulose derivatives
such as sodium carboxymethylcellulose, methylcellulose,
hydroxypropylmethylcellulose. Known
dispersing or wetting agents include, but are not limited to, naturally-
occurring phosphatides such
as lecithin, condensation products of an alkylene oxide with a fatty acid,
with
a long chain aliphatic alcohol, with a partial ester derived from a fatty acid
and a hexitol, or with
a partial ester derived from a fatty acid and a hexitol anhydride (e.g.,
polyoxyethylene stearate,
heptadecaethyleneoxycetanol, polyoxyethylene sorbitol monooleate, and
polyoxyethylene
sorbitan monooleate, respectively). Known emulsifying agents include, but are
not limited to,
lecithin, and acacia. Known preservatives include, but are not limited to,
methyl, ethyl, or n-
propyl-para- hydroxybenzoates, ascorbic acid, and sorbic acid. Known
sweetening agents
include, for example, glycerol, propylene glycol, sorbitol, sucrose, and
saccharin. Known
thickening agents for oily suspensions include, for example, beeswax, hard
paraffin, and cetyl
alcohol.
Liquid solutions of the active ingredient in aqueous or oily solvents may be
prepared in
substantially the same manner as liquid suspensions, the primary difference
being that the active
ingredient is dissolved, rather than suspended in the solvent. As used herein,
an "oily" liquid is
one which comprises a carbon-containing liquid molecule and which exhibits a
less polar
character than water. Liquid solutions of the pharmaceutical composition of
the invention may
comprise each of the components described with regard to liquid suspensions,
it being understood
that suspending agents will not necessarily aid dissolution of the active
ingredient in the solvent.
Aqueous solvents include, for example, water, and isotonic saline. Oily
solvents include, for
example, almond oil, oily esters, ethyl alcohol, vegetable oils such as
arachis, olive, sesame, or
coconut oil, fractionated vegetable oils, and mineral oils such as liquid
paraffin.
Powdered and granular formulations of a pharmaceutical preparation of the
invention
may be prepared using known methods. Such formulations may be administered
directly to a
subject, used, for example, to form tablets, to fill capsules, or to prepare
an aqueous or oily
suspension or solution by addition of an aqueous or oily vehicle thereto. Each
of these
formulations may further comprise one or more of dispersing or wetting agent,
a suspending
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
agent, and a preservative. Additional excipients, such as fillers and
sweetening, flavoring, or
coloring agents, may also be included in these formulations.
A pharmaceutical composition of the invention may also be prepared, packaged,
or sold
in the form of oil-in-water emulsion or a water-in-oil emulsion. The oily
phase may be a
vegetable oil such as olive or arachis oil, a mineral oil such as liquid
paraffin, or a combination
of these. Such compositions may further comprise one or more emulsifying
agents such as
naturally occurring gums such as gum acacia or gum tragacanth, naturally-
occurring
phosphatides such as soybean or lecithin phosphatide, esters or partial esters
derived from
combinations of fatty acids and hexitol anhydrides such as sorbitan
monooleate, and
condensation products of such partial esters with ethylene oxide such as
polyoxyethylene
sorbitan monooleate. These emulsions may also contain additional ingredients
including, for
example, sweetening or flavoring agents.
Methods for impregnating or coating a material with a chemical composition are
known
in the art, and include, but are not limited to methods of depositing or
binding a chemical
composition onto a surface, methods of incorporating a chemical composition
into the structure
of a material during the synthesis of the material (i.e., such as with a
physiologically degradable
material), and methods of absorbing an aqueous or oily solution or suspension
into an absorbent
material, with or without subsequent drying.
Controlled- or sustained-release formulations of a composition of the
invention may be
made using conventional technology, in addition to the disclosure set forth
elsewhere herein. In
some cases, the dosage forms to be used can be provided as slow or controlled-
release of one or
more active ingredients therein using, for example, hydropropylmethyl
cellulose, other polymer
matrices, gels, permeable membranes, osmotic systems, multilayer coatings,
microparticles,
liposomes, or microspheres or a combination thereof to provide the desired
release profile in
varying proportions. Suitable controlled-release formulations known to those
of ordinary skill in
the art, including those described herein, can be readily selected for use
with the compositions of
the invention.
Controlled-release of an active ingredient can be stimulated by various
inducers, for
example pH, temperature, enzymes, water, or other physiological conditions or
compounds. The
term "controlled-release component" in the context of the present invention is
defined herein as a
compound or compounds, including, but not limited to, polymers, polymer
matrices, gels,
36
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
permeable membranes, liposomes, nanoparticles, or microspheres or a
combination thereof that
facilitates the controlled-release of the active ingredient.
Administration/Dosing
The regimen of administration may affect what consteatutes an effective
amount. The
therapeutic formulations may be administered to the subject either prior to or
after a diagnosis of
disease. Further, several divided dosages, as well as staggered dosages may be
administered
daily or sequentially, or the dose may be continuously infused, or may be a
bolus injection.
Further, the dosages of the therapeutic formulations may be proportionally
increased or decreased
as indicated by the exigencies of the therapeutic or prophylactic situation.
Administration of the compositions of the present invention to a subject,
preferably a
mammal, more preferably a human, may be carried out using known procedures, at
dosages and
for periods of time effective to prevent or treat disease. An effective amount
of the therapeutic
composition necessary to achieve a therapeutic effect may vary according to
factors such as the
activity of the particular composition employed; the time of administration;
the rate of excretion
of the composition; the duration of the treatment; other drugs, compositions
or materials used in
combination with the composition; the state of the disease or disorder, age,
sex, weight,
condition, general health and prior medical history of the subject being
treated, and like factors
well-known in the medical arts. Dosage regimens may be adjusted to provide the
optimum
therapeutic response. For example, several divided doses may be administered
daily or the dose
may be proportionally reduced as indicated by the exigencies of the
therapeutic situation. A non-
limiting example of an effective dose range for a therapeutic composition of
the invention is from
about 1 and 5,000 mg/kg of body weight/per day. One of ordinary skill in the
art would be able
to study the relevant factors and make the determination regarding the
effective amount of the
therapeutic composition without undue experimentation.
The composition may be administered to an animal as frequently as several
times daily,
or it may be administered less frequently, such as once a day, once a week,
once every two
weeks, once a month, or even less frequently, such as once every several
months or even once a
year or less. The frequency of the dose will be readily apparent to the
skilled artisan and will
depend upon any number of factors, such as, but not limited to, the type and
severity of the
disease being treated, the type and age of the animal, etc. The compositions
of the
37
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
pharmaceutical compositions described herein may be prepared by any method
known or
hereafter developed in the art of pharmacology. In general, such preparatory
methods include
the step of bringing the active ingredient into association with a carrier or
one or more other
accessory ingredients, and then, if necessary or desirable, shaping or
packaging the product into
a desired single- or multi-dose unit.
Actual dosage levels of the active ingredients in the pharmaceutical
compositions of this
invention may be varied so as to obtain an amount of the active ingredient
that is effective to
achieve the desired therapeutic response for a particular subject,
composition, and mode of
administration, without being toxic to the subject.
A medical doctor, e.g., physician or veterinarian, having ordinary skill in
the art may
readily determine and prescribe the effective amount of the pharmaceutical
composition
required. For example, the physician or veterinarian could start doses of the
compositions of the
invention employed in the pharmaceutical composition at levels lower than that
required in order
to achieve the desired therapeutic effect and gradually increase the dosage
until the desired effect
is achieved.
In particular embodiments, it is especially advantageous to formulate the
composition in
dosage unit form for ease of administration and uniformity of dosage. Dosage
unit form as used
herein refers to physically discrete units suited as unitary dosages for the
subjects to be treated;
each unit containing a predetermined quanteaty of therapeutic composition
calculated to produce
the desired therapeutic effect in association with the required pharmaceutical
vehicle. The dosage
unit forms of the invention are dictated by and directly dependent on (a) the
unique
characteristics of the therapeutic composition and the particular therapeutic
effect to be achieved,
and (b) the limitations inherent in the art of compounding/formulating such a
therapeutic
composition for the treatment of a disease in a subject.
In one embodiment, the compositions of the invention are administered to the
subject in
dosages that range from one to five times per day or more. In another
embodiment, the
compositions of the invention are administered to the subject in range of
dosages that include, but
are not limited to, once every day, every two, days, every three days to once
a week, and once
every two weeks. It will be readily apparent to one skilled in the art that
the frequency of
administration of the various combination compositions of the invention will
vary from subject
to subject depending on many factors including, but not limited to, age,
disease or disorder to be
38
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
treated, gender, overall health, and other factors. Thus, the invention should
not be construed to
be limited to any particular dosage regime and the precise dosage and
composition to be
administered to any subject will be determined by the attending physical
taking all other factors
about the subject into account.
Compositions ofthe invention for administration may be in the range offrom
about 0.1
mg to about 1,000 mg, about 0.2 mg to about 950 mg, about 0.4 mg to about 900
mg, about 1 mg
to about 850 mg, about 5 mg to about 750 mg, about 20 mg to about 700 mg,
about 30 mg to
about 600 mg, about 50 mg to about 500 mg, about 75 mg to about 400 mg, about
100 mg to
about 300 mg, about 120 mg to about 250 mg, and any and all whole or partial
increments
therebetween.
In some embodiments, the dose of a composition of the invention is from about
1 mg and
about 2,500 mg. In some embodiments, a dose of a composition of the invention
used in
compositions described herein is less than about 10,000 mg, or less than about
8,000 mg, or less
than about 6,000 mg, or less than about 5,000 mg, or less than about 3,000 mg,
or less than about
2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than
about 200 mg, or
less than about 50 mg. Similarly, in some embodiments, a dose of a second
composition (i.e., a
drug used for treating the same or another disease as that treated by the
compositions of the
invention) as described herein is less than about 1,000 mg, or less than about
800 mg, or less
than about 600 mg, or less than about 500 mg, or less than about 400 mg, or
less than about 300
mg, or less than about 200 mg, or less than about 100 mg, or less than about
50 mg, or less than
about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than
about 20 mg, or less
than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less
than about 2 mg, or
less than about 1 mg, or less than about 0.5 mg, and any and all whole or
partial increments
thereof
In one embodiment, the present invention is directed to a packaged
pharmaceutical
composition comprising a container holding a therapeutically effective amount
of a composition
of the invention, alone or in combination with a second pharmaceutical agent;
and instructions
for using the composition to treat, prevent, or reduce one or more symptoms of
a disease in a
subject.
Routes of Administration
39
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Routes of administration of any of the compositions of the invention include
oral, nasal,
rectal, parenteral, sublingual, transdermal, transmucosal (e.g., sublingual,
lingual, (trans)buccal,
(trans)urethral, vaginal (e.g., trans- and perivaginally), (intra)nasal, and
(trans)rectal),
intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal,
subcutaneous,
intramuscular, intradermal, intra-arterial, intravenous, intrabronchial,
inhalation, and topical
administration.
Suitable compositions and dosage forms include, for example, tablets,
capsules, caplets,
pills, gel caps, troches, dispersions, suspensions, solutions, syrups,
granules, beads, transdermal
patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters,
lotions, discs,
suppositories, liquid sprays for nasal or oral administration, dry powder or
aerosolized
formulations for inhalation, compositions and formulations for intravesical
administration and
the like. It should be understood that the formulations and compositions that
would be useful in
the present invention are not limited to the particular formulations and
compositions that are
described herein.
Oral Administration
For oral application, particularly suitable are tablets, dragees, liquids,
drops, suppositories,
or capsules, caplets and gelcaps. Other formulations suitable for oral
administration include, but
are not limited to, a powdered or granular formulation, an aqueous or oily
suspension, an aqueous
or oily solution, a paste, a gel, toothpaste, a mouthwash, a coating,
an oral rinse, or an emulsion. The compositions intended for oral use may be
prepared according
to any method known in the art and such compositions may contain one or more
agents selected
from the group consisting of inert, non-toxic pharmaceutically excipients that
are suitable for the
manufacture of tablets. Such excipients include, for example an inert diluent
such as lactose;
granulating and disintegrating agents such as cornstarch; binding agents such
as starch; and
lubricating agents such as magnesium stearate.
Tablets may be non-coated or they may be coated using known methods to achieve
delayed disintegration in the gastrointestinal tract of a subject, thereby
providing sustained
release and absorption of the active ingredient. By way of example, a material
such as glyceryl
monostearate or glyceryl distearate may be used to coat tablets. Further by
way of example,
tablets may be coated using methods described in U.S. Patents numbers
4,256,108; 4,160,452;
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
and 4,265,874 to form osmotically controlled release tablets. Tablets may
further comprise a
sweetening agent, a flavoring agent, a coloring agent, a preservative, or some
combination of
these in order to provide for pharmaceutically elegant and palatable
preparation.
Hard capsules comprising the active ingredient may be made using a
physiologically
degradable composition, such as gelatin. Such hard capsules comprise the
active ingredient, and
may further comprise additional ingredients including, for example, an inert
solid diluent such as
calcium carbonate, calcium phosphate, or kaolin.
Soft gelatin capsules comprising the active ingredient may be made using a
physiologically degradable composition, such as gelatin. Such soft capsules
comprise the active
ingredient, which may be mixed with water or an oil medium such as peanut oil,
liquid paraffin,
or olive oil.
For oral administration, the compositions of the invention may be in the form
of tablets or
capsules prepared by conventional means with pharmaceutically acceptable
excipients such as
binding agents; fillers; lubricants; disintegrates; or wetting agents. If
desired, the tablets may be
coated using suitable methods and coating materials such as OPADRYTM film
coating systems
available from Colorcon, West Point, Pa. (e.g., OPADRYTM OY Type, OYC Type,
Organic
Enteric OY-P Type, Aqueous Enteric 0Y-A Type, OY-PM Type and OPADRYTM White,
32K18400).
Liquid preparation for oral administration may be in the form of solutions,
syrups or
suspensions. The liquid preparations may be prepared by conventional means
with
pharmaceutically acceptable additives such as suspending agents (e.g.,
sorbitol syrup, methyl
cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or
acacia); non-aqueous
vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives
(e.g., methyl or propyl
para-hydroxy benzoates or sorbic acid). Liquid formulations of a
pharmaceutical composition of
the invention which are suitable for oral administration may be prepared,
packaged, and sold
either in liquid form or in the form of a dry product intended for
reconsteatution with water or
another suitable vehicle prior to use.
A tablet comprising the active ingredient may, for example, be made by
compressing or
molding the active ingredient, optionally with one or more additional
ingredients. Compressed
tablets may be prepared by compressing, in a suitable device, the active
ingredient in a
free-flowing form such as a powder or granular preparation, optionally mixed
with one or more
41
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
of a binder, a lubricant, an excipient, a surface active agent, and a
dispersing agent. Molded
tablets may be made by molding, in a suitable device, a mixture of the active
ingredient, a
pharmaceutically acceptable carrier, and at least sufficient liquid to moisten
the mixture.
Pharmaceutically acceptable excipients used in the manufacture of tablets
include, but are not
limited to, inert diluents, granulating and disintegrating agents, binding
agents, and lubricating
agents. Known dispersing agents include, but are not limited to, potato starch
and sodium starch
glycollate. Known surface-active agents include, but are not limited to,
sodium lauryl sulphate.
Known diluents include, but are not limited to, calcium carbonate, sodium
carbonate, lactose,
microcrystalline cellulose, calcium phosphate, calcium hydrogen phosphate, and
sodium
phosphate. Known granulating and disintegrating agents include, but are not
limited to, corn
starch and alginic acid. Known binding agents include, but are not limited to,
gelatin, acacia,
pre-gelatinized maize starch, polyvinylpyrrolidone, and hydroxypropyl
methylcellulose. Known
lubricating agents include, but are not limited to, magnesium stearate,
stearic acid, silica, and
talc.
Granulating techniques are well known in the pharmaceutical art for modifying
starting
powders or other particulate materials of an active ingredient. The powders
are typically mixed
with a binder material into larger permanent free-flowing agglomerates or
granules referred to as
a "granulation." For example, solvent-using "wet" granulation processes are
generally
characterized in that the powders are combined with a binder material and
moistened with water
or an organic solvent under conditions resulting in the formation of a wet
granulated mass from
which the solvent must then be evaporated.
Melt granulation generally consists in the use of materials that are solid or
semi-solid at
room temperature (i.e. having a relatively low softening or melting point
range) to promote
granulation of powdered or other materials, essentially in the absence of
added water or other
liquid solvents. The low melting solids, when heated to a temperature in the
melting point range,
liquefy to act as a binder or granulating medium. The liquefied solid spreads
itself over the
surface of powdered materials with which it is contacted, and on cooling,
forms a solid
granulated mass in which the initial materials are bound together. The
resulting melt granulation
may then be provided to a tablet press or be encapsulated for preparing the
oral dosage form.
Melt granulation improves the dissolution rate and bioavailability of an
active (i.e. drug) by
forming a solid dispersion or solid solution.
42
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
U.S. Patent No. 5,169,645 discloses directly compressible wax-containing
granules
having improved flow properties. The granules are obtained when waxes are
admixed in the
melt with certain flow improving additives, followed by cooling and
granulation of the
admixture. In certain embodiments, only the wax itself melts in the melt
combination of the
wax(es) and additives(s), and in other cases both the wax(es) and the
additives(s) will melt.
The present invention also includes a multi-layer tablet comprising a layer
providing for
the delayed release of one or more compositions of the invention, and a
further layer providing
for the immediate release of a medication for treatment of a disease. Using a
wax/pH-sensitive
polymer mix, a gastric insoluble composition may be obtained in which the
active ingredient is
entrapped, ensuring its delayed release.
Parenteral Administration
As used herein, "parenteral administration" of a pharmaceutical composition
includes any
route of administration characterized by physical breaching of a tissue of a
subject and
administration of the pharmaceutical composition through the breach in the
tissue. Parenteral
administration thus includes, but is not limited to, administration of a
pharmaceutical
composition by injection of the composition, by application of the composition
through a
surgical incision, by application of the composition through a tissue-
penetrating non-surgical
wound, and the like. In particular, parenteral administration is contemplated
to include, but is
not limited to, intraocular, intravitreal, subcutaneous, intraperitoneal,
intramuscular, intrasternal
injection, intratumoral, and kidney dialytic infusion techniques.
Formulations of a pharmaceutical composition suitable for parenteral
administration
comprise the active ingredient combined with a pharmaceutically acceptable
carrier, such as sterile
water or sterile isotonic saline. Such formulations may be prepared, packaged,
or sold in a form
suitable for bolus administration or for continuous administration. Injectable
formulations may be
prepared, packaged, or sold in unit dosage form, such as in ampules or in
multi-dose containers
containing a preservative. Formulations for parenteral administration include,
but are not limited
to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and
implantable
sustained-release or biodegradable formulations. Such formulations may further
comprise one or
more additional ingredients including, but not limited to, suspending,
stabilizing, or dispersing agents. In one embodiment of a formulation for
parenteral
43
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
administration, the active ingredient is provided in dry (i.e. powder or
granular) form for
reconsteatution with a suitable vehicle (e.g. sterile pyrogen-free water)
prior to parenteral
administration of the reconsteatuted composition.
The pharmaceutical compositions may be prepared, packaged, or sold in the form
of a
sterile injectable aqueous or oily suspension or solution. This suspension or
solution may be
formulated according to the known art, and may comprise, in addition to the
active ingredient,
additional ingredients such as the dispersing agents, wetting agents, or
suspending agents
described herein. Such sterile injectable formulations may be prepared using a
non-toxic
parenterally-acceptable diluent or solvent, such as water or 1,3-butanediol,
for example. Other
acceptable diluents and solvents include, but are not limited to, Ringer's
solution, isotonic
sodium chloride solution, and fixed oils such as synthetic mono- or di-
glycerides. Other
parentally-administrable formulations that are useful include those which
comprise the active
ingredient in microcrystalline form, in a liposomal preparation, or as a
component of a
biodegradable polymer systems. Compositions for sustained release or
implantation may
comprise pharmaceutically acceptable polymeric or hydrophobic materials such
as an emulsion,
an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble
salt.
Topical Administration
A pharmaceutical composition of the invention may be prepared, packaged, or
sold in a
formulation suitable for topical administration. There are several advantages
to delivering
compositions, including drugs or other therapeutic agents, into the skin
(dermal drug delivery) or
into the body through the skin (transdermal drug delivery). Transdermal
composition delivery
offers an attractive alternative to injections and oral medications. Dermal
composition delivery
offers an efficient way to deliver a composition to the skin of a mammal, and
preferably a
human, and provides a method of treatment of the skin, or otherwise provides a
method of
affecting the skin, without the need to break or damage the outer layer of the
skin. In the present
invention, dermal delivery, by way of a dermally-acting composition ofthe
invention, provides
these advantages for treatment of a skin-related condition, disorder or
disease.
A number of compounds, including some drugs, will penetrate the skin
effectively simply
because the molecules are relatively small and potent at small doses of 0.1 mg
to 15 mg/day
(Kanikkannan et al., 2000, Curr. Med. Chern. 7:593-608). Many other compounds
and drugs can
44
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
be delivered only when an additional enhancement system is provided to "force"
them to pass
through the skin. Among several methods of transdermal drug delivery are
electroporation,
sonophoresis, iontophoresis, permeation enhancers (cyclodextrins), and
liposomes. While the
aforementioned methods are also included in the present invention for dermal
delivery of the
compositions of the invention, liposomes represent a preferred dermal delivery
method.
The composition of the invention may consist of the active ingredient alone,
in a form
suitable for administration to a subject, or the composition may comprise at
least one active
ingredient and one or more pharmaceutically acceptable carriers, one or more
additional
ingredients, or some combination of these. The active ingredient may be
present in the
composition in the form of a physiologically acceptable ester or salt, such as
in combination with
a physiologically acceptable cation or anion, as is well known in the art.
Compositions of the
invention will also be understood to encompass pharmaceutical compositions
useful for
treatment of other conditions, disorders and diseases associated with the
skin.
In one aspect, a dermal delivery vehicle of the invention is a composition
comprising at
least one first compound that can facilitate dermal delivery of at least one
second compound
associated with, or in close physical proximity to, the composition comprising
the first
compound. As will be understood by the skilled artisan, when armed with the
disclosure set
forth herein, such delivery vehicles include, but should not be limited to,
liposomes, nanosomes,
phospholipid-based non-liposome compositions (eg., selected cochleates), among
others.
Formulations suitable for topical administration include, but are not limited
to, liquid or
semi-liquid preparations such as liniments, lotions, oil-in-water or water-in-
oil emulsions such as
creams, ointments or pastes, and solutions or suspensions. Topically-
administrable formulations
may, for example, comprise from about 0.001% to about 90% (w/w) active
ingredient, although
the concentration of the active ingredient may be as high as the solubility
limit of the active
ingredient in the solvent. Formulations for topical administration may further
comprise one or
more of the additional ingredients described herein.
In one aspect of the invention, a dermal delivery system includes a liposome
delivery
system, and that the present invention should not be construed to be limited
to any particular
liposome delivery system. Based on the disclosure set forth herein, the
skilled artisan will
understand how to identify a liposome delivery system as being useful in the
present invention.
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
The present invention also encompasses the improvement of dermal and
transdermal drug
delivery through the use of penetration enhancers (also called sorption
promoters or accelerants),
which penetrate into skin to reversibly decrease the barrier resistance. Many
compounds are
known in the art for penetration enhancing activity, including sulphoxides
(such as
dimethylsulphoxide, DMSO), azones (e.g. laurocapram), pyrrolidones (for
example 2-
pyrrolidone, 2P), alcohols and alkanols (ethanol, or decanol), glycols (for
example propylene
glycol, PG, a common excipient in topically applied dosage forms), surfactants
(also common in
dosage forms) and terpenes. Other enhancers include oleic acid, oleyl alcohol,
ethoxydiglycol,
laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-
methyl-2-pyrrolidone.
In alternative embodiments, the topically active pharmaceutical or cosmetic
composition
may be optionally combined with other ingredients such as moisturizers,
cosmetic adjuvants,
anti-oxidants, chelating agents, surfactants, foaming agents, conditioners,
humectants, wetting
agents, emulsifying agents, fragrances, viscosifiers, buffering agents,
preservatives, sunscreens
and the like. In another embodiment, a permeation or penetration enhancer is
included in the
composition and is effective in improving the percutaneous penetration of the
active ingredient
into and through the stratum corneum with respect to a composition lacking the
permeation
enhancer. Various permeation enhancers, including oleic acid, oleyl alcohol,
ethoxydiglycol,
laurocapram, alkanecarboxylic acids, dimethylsulfoxide, polar lipids, or N-
methyl-2-pyrrolidone,
are known to those of skill in the art.
In another aspect, the composition may further comprise a hydrotropic agent,
which
functions to increase disorder in the structure of the stratum corneum, and
thus allows increased
transport across the stratum corneum. Various hydrotropic agents such as
isopropyl alcohol,
propylene glycol, or sodium xylene sulfonate, are known to those of skill in
the art. The
compositions of this invention may also contain active amounts ofretinoids
(i.e., compounds that
bind to any members of the family of retinoid receptors), including, for
example, tretinoin, retinol,
esters of tretinoin and/or retinol and the like.
The composition of the invention may comprise a preservative from about 0.005%
to
2.0% by total weight of the composition. The preservative is used to prevent
spoilage in the case
of an aqueous gel because of repeated patient use when it is exposed to
contaminants in the
environment from, for example, exposure to air or the patient's skin,
including contact with the
fingers used for applying a composition of the invention such as a therapeutic
gel or cream.
46
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Examples of preservatives useful in accordance with the invention included but
are not limited to
those selected from the group consisting of benzyl alcohol, sorbic acid,
parabens, imidurea and
combinations thereof A particularly preferred preservative is a combination of
about 0.5% to
2.0% benzyl alcohol and 0.05% to 0.5% sorbic acid.
The composition preferably includes an antioxidant and a chelating agent which
inhibit
the degradation of the composition for use in the invention in the aqueous gel
formulation.
Preferred antioxidants for some compounds are BHT, BHA, alpha-tocopherol and
ascorbic acid
in the preferred range of about 0.01% to 5% and BHT in the range of 0.01% to
I% by weight by
total weight of the composition. Preferably, the chelating agent is present in
an amount of from
0.01% to 0.5% by weight by total weight ofthe composition. Particularly
preferred chelating
agents include edetate salts (e.g. disodium edetate) and citric acid in the
weight range of about
0.01% to 0.20% and more preferably in the range of0.02% to 0.10% by weight by
total weight
of the composition. The chelating agent is useful for chelating metal ions in
the composition
which may be detrimental to the shelf life of the formulation. While BHT and
disodium edetate
are the particularly preferred antioxidant and chelating agent respectively
for some compounds,
other suitable and equivalent antioxidants and chelating agents may be
substeatuted therefore as
would be known to those skilled in the art.
Additional components may include, but should not be limited to those
including water,
oil (eg., olive oil/PEG7), biovera oil, wax (eg., jojoba wax), squalene,
myristate (eg., isopropyl
myristate), triglycerides (eg., caprylic triglyceride), Solulan 98, cocoa
butter, shea butter, alcohol
(eg., behenyl alcohol), stearate (eg., glycerol-monostearate), chelating
agents (eg., EDTA),
propylene glycol, SEPIGEL (Seppic, Inc., Fairfield, NJ), silicone and silicone
derivatives (eg.,
dimethicone, cyclomethicone), vitamins (eg., vitamin E), among others.
Buccal Administration
A pharmaceutical composition of the invention may be prepared, packaged, or
sold in a
formulation suitable for buccal administration. Such formulations may, for
example, be in the
form of tablets or lozenges made using conventional methods, and may, for
example, 0.1 to 20%
(w/w) active ingredient, the balance comprising an orally dissolvable or
degradable composition
and, optionally, one or more of the additional ingredients described herein.
Alternately,
formulations suitable for buccal administration may comprise a powder or an
aerosolized or
47
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
atomized solution or suspension comprising the active ingredient. Such
powdered, aerosolized,
or aerosolized formulations, when dispersed, preferably have an average
particle or droplet size
in the range from about 0.1 to about 200 nanometers, and may further comprise
one or more of
the additional ingredients described herein.
Rectal Administration
A pharmaceutical composition of the invention may be prepared, packaged, or
sold in a
formulation suitable for rectal administration. Such a composition may be in
the form of, for
example, a suppository, a retention enema preparation, and a solution for
rectal or colonic
irrigation.
Suppository formulations may be made by combining the active ingredient with a
non-
irritating pharmaceutically acceptable excipient which is solid at ordinary
room temperature (i.e.,
about 20 C) and which is liquid at the rectal temperature of the subject
(i.e., about 37 OC in a
healthy human). Suitable pharmaceutically acceptable excipients include, but
are not limited to,
cocoa butter, polyethylene glycols, and various glycerides. Suppository
formulations may
further comprise various additional ingredients including, but not limited to,
antioxidants, and
preservatives.
Retention enema preparations or solutions for rectal or colonic irrigation may
be made by
combining the active ingredient with a pharmaceutically acceptable liquid
carrier. As is well
known in the art, enema preparations may be administered using, and may be
packaged within, a
delivery device adapted to the rectal anatomy of the subject. Enema
preparations may further
comprise various additional ingredients including, but not limited to,
antioxidants, and
preservatives.
Additional Administration Forms
Additional dosage forms of this invention include dosage forms as described in
U.S.
Patents Nos. 6,340,475; 6,488,962; 6,451,808; 5,972,389; 5,582,837 and
5,007,790. Additional
dosage forms of this invention also include dosage forms as described in U.S.
Patent
Applications Nos. 20030147952, 20030104062, 20030104053, 20030044466,
20030039688, and
20020051820. Additional dosage forms of this invention also include dosage
forms as described
in PCT Applications Nos. WO 03/35041, WO 03/35040, WO 03/35029, WO 03/35177,
WO
48
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
03/35039, WO 02/96404, WO 02/32416, WO 01/97783, WO 01/56544, WO 01/32217, WO
98/55107, WO 98/11879, WO 97/47285, WO 93/18755, and WO 90/11757.
Controlled Release Formulations and Drug Delivery Systems
Controlled- or sustained-release formulations of a pharmaceutical composition
of the
invention may be made using conventional technology, using for example
proteins equipped
with pH sensitive domains or protease-cleavable fragments. In some cases, the
dosage forms to
be used can be provided as slow or controlled-release of one or more active
ingredients therein
using, for example, hydropropylmethyl cellulose, other polymer matrices, gels,
permeable
membranes, osmotic systems, multilayer coatings, micro-particles, liposomes,
or microspheres or
a combination thereof to provide the desired release profile in varying
proportions. Suitable
controlled-release formulations known to those of ordinary skill in the art,
including those
described herein, can be readily selected for use with the pharmaceutical
compositions of the
invention. Thus, single unit dosage forms suitable for oral administration,
such as tablets,
capsules, gel-caps, and caplets, which are adapted for controlled-release are
encompassed by the
present invention.
Most controlled-release pharmaceutical products have a common goal of
improving drug
therapy over that achieved by their non-controlled counterparts. Ideally, the
use of an optimally
designed controlled-release preparation in medical treatment is characterized
by a minimum of
drug substance being employed to cure or control the condition in a minimum
amount of time.
Advantages of controlled-release formulations include extended activity of the
drug, reduced
dosage frequency, and increased subject compliance. In addition, controlled-
release formulations
can be used to affect the time of onset of action or other characteristics,
such as blood level of the
drug, and thus can affect the occurrence of side effects.
Most controlled-release formulations are designed to initially release an
amount of drug
that promptly produces the desired therapeutic effect, and gradually and
continually release of
other amounts of drug to maintain this level of therapeutic effect over an
extended period of
time. In order to maintain this constant level of drug in the body, the drug
must be released from
the dosage form at a rate that will replace the amount of drug being
metabolized and excreted
from the body.
49
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Controlled-release of an active ingredient can be stimulated by various
inducers, for
example pH, temperature, enzymes, water or other physiological conditions or
compounds. The
term "controlled-release component" in the context of the present invention is
defined herein as a
compound or compounds, including, but not limited to, polymers, polymer
matrices, gels,
permeable membranes, liposomes, or microspheres or a combination thereof that
facilitates the
controlled-release of the active ingredient.
In certain embodiments, the formulations of the present invention may be, but
are not
limited to, short-term, rapid-offset, as well as controlled, for example,
sustained release, delayed
release and pulsatile release formulations.
The term sustained release is used in its conventional sense to refer to a
drug formulation
that provides for gradual release of a drug over an extended period oftime,
and that may,
although not necessarily, result in substantially constant blood levels of a
drug over an extended
time period. The period of time may be as long as a month or more and should
be a release that
is longer that the same amount of agent administered in bolus form.
For sustained release, the compositions may be formulated with a suitable
polymer or
hydrophobic material that provides sustained release properties to the
compositions. As such,
the compositions for use the method of the invention may be administered in
the form of
microparticles, for example, by injection or in the form of wafers or discs by
implantation.
In a preferred embodiment of the invention, the compositionss of the invention
are
administered to a subject, alone or in combination with another pharmaceutical
agent, using a
sustained release formulation.
The term delayed release is used herein in its conventional sense to refer to
a drug
formulation that provides for an initial release of the drug after some delay
following drug
administration and that mat, although not necessarily, includes a delay of
from about 10 minutes
up to about 12 hours.
The term pulsatile release is used herein in its conventional sense to refer
to a drug
formulation that provides release of the drug in such a way as to produce
pulsed plasma profiles
of the drug after drug administration.
The term immediate release is used in its conventional sense to refer to a
drug
formulation that provides for release of the drug immediately after drug
administration.
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
As used herein, short-term refers to any period of time up to and including
about 8 hours,
about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours,
about 2 hours, about 1
hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all
whole or partial
increments thereof after drug administration after drug administration.
As used herein, rapid-offset refers to any period of time up to and including
about 8
hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3
hours, about 2 hours,
about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any
and all whole or
partial increments thereof after drug administration.
Accordingly, in one embodiment, the present invention relates to a chemical
formulation
comprising propanoic acid, isobutyric acid, at least one ester, and at least
one carrier, wherein the
chemical formulation has antibacterial activity when applied to human or
animal waste. In another
embodiment, the at least one ester is isoamyl butyrate. In another embodiment,
the at least one
carrier is a silica based carrier. In another embodiment, the at least one
carrier is
selected from the group consisting ofbentonite, zeolite and perlite. In
another embodiment, the
ratio of propanoic acid: isobutryic acid: isoamyl butyrate is about 3.5:3.5:2
v/v/v. In another
embodiment, the ratio of propanoic acid, isobutryic acid and isoamyl butyrate
is about 7 parts of
the two acids and 2 parts of isoamyl butyrate. In another embodiment, the
chemical formulation
consists essentially of propanoic acid, isobutryic acid, isoamyl butyrate and
a carrier. In another
embodiment, the carrier is selected from the group consisting of bentonite,
zeolite and perlite. In
another embodiment, the chemical formulation has antibacterial activity when
applied to human
or animal waste.
In another embodiment, the present invention relates to a chemical formulation
comprising, propanoic acid, isobutryic acid, at least one ester, at least one
carrier, and at least
one fungus. In another embodiment, the at least one ester is isoamyl butyrate.
In another
embodiment, the at least one carrier is a silica based carrier. In another
embodiment, the at least
one carrier is selected from the group consisting of bentonite, zeolite and
perlite. In another
embodiment, the ratio of propanoic acid: isobutryic acid: isoamyl butyrate is
about 3.5:3.5:2
v/v/v. In another embodiment, the ratio of propanoic acid, isobutryic acid and
isoamyl butyrate is
about 7 parts of the two acids and 2 parts of isoamyl butyrate. In another
embodiment, the at
least one fungus is an endophyte. In another embodiment, the endophyte is of
the genus
Fusarium. In another embodiment, the endophyte is F. sub glutinans.
51
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
In another embodiment, the present invention relates to a chemical formulation
comprising propanoic acid and at least one 6-12 carbon (acid) component ester,
wherein the
chemical formulation has a ratio of propanoic acid:ester component of about
7:2 v/v. In another
embodiment, the at least one ester is isoamyl hexanoates. In another
embodiment, the
formulation further includes at least one nutritional supplement and at least
one salt. In another
embodiment, the formulation comprises glucose, whey protein, potassium
chloride, magnesium
sulfate, and sodium chloride. In another embodiment, the formulation comprises
glucose,
glycine, potassium chloride, sodium chloride, and magnesium acetate. In
another embodiment,
the formulation comprises glucose, glycine, potassium chloride, sodium
chloride, magnesium
acetate, and monopotassium phosphate. In another embodiment, the formulation
includes at least
one pharmaceutically acceptable carrier. In another embodiment, the carrier is
cremophor. In
another embodiment, the formulation consists essentially of propanoic acid and
isoamyl
hexanoates at a ratio of propanoic acid:isoamyl hexanoates of about 7:2 v/v.
In another
embodiment, the present invention relates to a chemical formulation consisting
essentially of
propanoic acid, isoamyl hexanoates and a carrier.
In another embodiment, the present invention relates to a chemical formulation
comprising propanoic acid and a single carbon (acid) component ester, wherein
the chemical
formulation has a ratio of propanoic acid:ester component of about 7:2 v/v. In
another
embodiment, the at least one ester is isoamyl formate. In another embodiment,
the formulation
consists essentially of propanoic acid and isoamyl formate at a ratio of
propanoic acid:isoamyl
formate of about 7:2 v/v. In another embodiment, the formulation includes at
least one carrier. In
another embodiment, the at least one carrier is a silica based carrier. In
another embodiment, the
at least one carrier is selected from the group consisting of bentonite,
zeolite and perlite. In
another embodiment, the chemical formulation consists essentially of propanoic
acid, isoamyl
formate and a carrier.
In another embodiment, the present invention includes a chemical formulation
comprising propanoic acid, isoamyl formate, and at least one fungus. In
another embodiment, the
ratio of propanoic acid: isoamyl formate is about 7:2 v/v. In another
embodiment, the at least
one fungus is an endophyte. In another embodiment, the endophyte is of the
genus Fusarium. In
another embodiment, the endophyte is F. sub glutinans.
52
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
In another embodiment, the present invention relates to a method of treating
human or
animal waste, comprising contacting human or animal waste with a composition
comprising
propanoic acid, isobutryic acid and at least one ester, wherein the
composition kills or reduces
bacteria growth on the human or animal waste. In another embodiment, the
present invention
relates to a method of treating human or animal waste, comprising contacting
human or animal
waste with a composition comprising propanoic acid, isobutryic acid, at least
one ester and at
least one fungus, wherein the propanoic acid, isobutryic acid and at least one
ester kills or
reduces bacteria growth on the human or animal waste, and the at least one
fungus increases the
rate of decomposition of the human or animal waste. In another embodiment, the
present
invention relates to a method of eliminating or reducing microbial growth at a
treatment site,
comprising contacting the treatment site with a composition comprising
propanoic acid and at
least one ester at a ratio of propanoic acid:ester of about 7:2, wherein the
ester is isoamyl formate
or isoamyl hexanoates and the composition kills or reduces bacteria growth on
the human or
animal waste. In another embodiment, the present invention relates to a method
of treating
human or animal waste, comprising contacting human or animal waste with a
composition
comprising propanoic acid, isoamyl formate at a ratio of propanoic
acid:isoamyl formate of about
7:2, and at least one fungus, wherein the propanoic acid and isoamyl formate
mixture kills
or reduces microbial growth on the human or animal waste, and the at least one
fungus increases
the rate of decomposition of the human or animal waste. In another embodiment,
the present
invention relates to a method of treating an animal having a disease or
disorder associated with a
microbial infection, comprising administering to the animal an effective
amount of a
composition comprising at least one organic acid. In another embodiment, the
composition
consists essentially of an organic acid. In another embodiment, the
composition consists of an
organic acid. In another embodiment, the at least one organic acid is
propanoic acid. In another
embodiment, the at least one organic acid is isobutyric acid. In another
embodiment, the animal
is a human. In another embodiment, the disease or disorder is a diarrheal
disease. In another
embodiment, the animal is bovine, porcine, or ovine. In another embodiment,
the disease or
disorder is selected from the group consisting of a diarrheal disease and an
intramammary
infection. In another embodiment, the diarrheal disease is scours. In another
embodiment, the
intramammary infection is subclinical mastitis or clinical mastitis. In
another embodiment, the
composition further comprises at least one ester. In another embodiment, the
at least one ester is
53
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
isoamyl hexanoates. In another embodiment, the composition further comprises
at least one
nutritional supplement and at least one salt. In another embodiment, the
composition comprises
glucose, whey protein, potassium chloride, magnesium sulfate, and sodium
chloride. In another
embodiment, the composition comprises glucose, glycine, potassium chloride,
sodium chloride,
and magnesium acetate. In another embodiment, the composition comprises
glucose, glycine,
potassium chloride, sodium chloride, magnesium acetate, and monopotassium
phosphate. In
another embodiment, the composition further comprises at least one
pharmaceutically acceptable
carrier. In another embodiment, the carrier is cremophor. In another
embodiment, the composition
comprises propanoic acid and isoamyl hexanoates at a ratio of propanoic
acid:isoamyl hexanoates
of about 7:2 v/v. In another embodiment, the at least one ester is
isoamyl hexanoates. In another embodiment, the ratio of propanoic acid:
isobutryic acid: isoamyl
hexanoates is about 3.5:3.5:2 v/v/v. In another embodiment, the ratio of
propanoic acid,
isobutryic acid and isoamyl hexanoates is about 7 parts of the two acids and 2
parts of isoamyl
butyrate.
In another embodiment, the present invention relates to a chemical formulation
consisting
essentially of propanoic acid, isobutryic acid, isoamyl hexanoates and a
carrier. In another
embodiment, the carrier is selected from the group consisting of bentonite,
zeolite and perlite. In
another embodiment, the chemical formulation has antibacterial activity when
applied to human
or animal waste.
Those skilled in the art will recognize, or be able to ascertain using no more
than routine
experimentation, numerous equivalents to the specific procedures, embodiments,
claims, and
examples described herein. Such equivalents were considered to be within the
scope of this
invention and covered by the claims appended hereto. For example, it should be
understood, that
modifications in reaction conditions, including but not limited to reaction
times, reaction
size/volume, and experimental reagents, such as solvents, catalysts,
pressures, atmospheric
conditions, e.g., nitrogen atmosphere, and reducing/oxidizing agents, with art-
recognized
alternatives and using no more than routine experimentation, are within the
scope of the present
application.
It is to be understood that wherever values and ranges are provided herein,
all values and
ranges encompassed by these values and ranges, are meant to be encompassed
within the scope
54
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
of the present invention. Moreover, all values that fall within these ranges,
as well as the upper
or lower limits of a range of values, are also contemplated by the present
application.
The following examples further illustrate aspects of the present invention.
However, they
are in no way a limitation of the teachings or disclosure of the present
invention as set forth
herein.
EXPERIMENTAL EXAMPLES
The invention is now described with reference to the following Examples. These
Examples are provided for the purpose of illustration only, and the invention
is not limited to
these Examples, but rather encompasses all variations that are evident as a
result of the teachings
provided herein.
Example 1
Discussed below are the various experiments that resulted in the discovery of
F.
subglutinans and the Systems 1 and 2 which can be used in various human and
animal waste
treatment devices along with animal bedding, stalls etc.
Table 1. Shows the inhibition activities of various esters (used in
combination with a 1:1
v/v mix of propanoic acid and isobutryic acid and thus the two acids to esters
is 7:2 v/v) to a
series of test fungi and bacteria that are commonly used organisms to screen
for antibiotic
activities. From these data, the Systems 1 and 2 were selected for use in this
invention (see
highlighted areas on the Table).
Table 2. Molecular genetics data assembled on the various new Fusarium spp.
isolates
that grow on human wastes in the presence of the System 2 mixture (with
carrier ofbentonite or
zeolite) as described above. From this it is obvious that any of these
organisms are nearly equal
or, in most cases better than Fusarium culmorum (P2-24), the subject of and
earlier patent. A
Data set on P2-24 is also included.
Table 3. The growth ofvarious fusaria on human wastes causes a reduction of
the dry
weight of the mass during the course of a 7 week experiment. The experimental
set- up contained
0.5 g of bentonite with System 2 on a water agar plate having about 100 mg wet
weight of
human waste and a small agar plug with the test fusarium on it. The incubation
period was 7
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
weeks at 22 C. The remains of the human waste were physically removed and
dried for 4 hr at
80 OC and then weighed.
Figure 1. Indicates how the assays were done to yield the data sets in Table
1. The
various esters were combined with a 1:1 mixture of propanoic acid and
isobutryic acid and these
were added 7:2 V/V with the ester to be tested. Then 9 111 were placed in the
center well with the
individual test organism agar plugs in the periphery as indicated in the
Figure.
Figure 2. Demonstrates the effectiveness of System 1 (above) in killing and
inhibiting
human waste associated bacteria. Fresh wastes were collected and then
approximately 5 mg were
evenly spread on the surface of a potato dextrose agar plate. The plates were
incubated for 2 days
and then photographed. The panel on the right is an untreated control, the
middle contains
bentonite 0.5 g with no antibiotic and the left contains 0.5 g with System 1.
Figure 3. Demonstrates the effectiveness of System 2 (above) in killing and
inhibiting
human waste associated bacteria. Fresh wastes were collected and then
approximately 5 mg were
evenly spread on the surface of a potato dextrose agar plate. The plates were
incubated for 2 days
and then photographed. The panel on the right is an untreated control, the
middle contains
bentonite 0.5 g with no antibiotic and the left contains 0.5 g with System 2.
Figure 4. An illustration of how treatment with System 1 can eliminate odors.
Two cat
litter boxes with cat fecal matter each from 5 different cats ca. 140 g. The
box on the left had
been treated with System 1 on bentonite with (0.5 ml / 100 g bentonite). After
5 days the
ammonia readings were 14 ppm on the control (left) and 0 ppm on the treated
right. The overall
odor was significantly reduced in the treated box.
Figure 5. Illustrates how the fungus can grow on fresh human waste and reduce
the level
of odor. Treatment of ca. 140 g of human waste in the presence of urine with
Fusarium
subglutinans 06-1 in the presence of System 2 ( 1 ml on 10 g of zeolite).
After 3 weeks there was
substantial growth of the F. subglutinans (white mycelium in the right
container). The ammonia
level was 71.4 in the control on the left and 12.1 in the treated container on
the right.
Figure 6. The growth of various new isolates of Fusarium spp. as compared to
the growth
of F. culmorum (P-2-24) on human waste are shown here. The progressive growth
of Fusarium
spp on small dollops of human waste are shown here ca. 100 mg (fresh weight)
over the course of
many days. The growth of newly isolated and characterized Fusarium spp. are
each compared to
P2-24 which is Fusarium culmorum, the subject of a previous patent on this
topic.
56
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
The new Fusarium spp. especially E06-1 and E06-5 do grow faster on the waste.
Growth was
measured from the extent of the mycelium moving out from the agar plug placed
on the dollop of
waste.
Figure 7. Top- A six day old culture of Fusarium subglutinans E06-1 the
preferred
fungus to be used to treat human and animal wastes in combination with System
2.Bottom a light
microscopic view of spores and hyphae of F. subglutinans. The spores are
slightly curved and
are 9.8 -12 x 2.5!J..
Figure 8. Fusarium subglutinans (E06-8) growing profusely on human waste in
the
presence of System 2. Please note the inhibition of bacterial growth to the
right side of the
culture plate which is influenced by the vapors of System 2 emanating from the
bentonite
particles on the left side of the plate allowing for fungal growth. There were
0.5 g of treated
bentonite added, ca 100 mg of human waste and the plate had incubated for 12
days. See Figure
6 for comparative growth measurements.
Method 1- Experimental procedure for isolating Fusarium spp endophytes
Isolates of Fusarium spp. may be collected according to standard protocols
understood by
those skilled in the art. In brief, twig pieces were thoroughly soaked in 70%
aqueous ethanol
solution for surface disinfection and then outer bark/epidermis was removed
with sterile scalpel.
Small pieces of inner bark were aseptically transferred to the surface of
water agar (WA) and
glycerol- arginine medium (GAM). After incubation for several days at 25 C,
hyphal tips of
developing fungi should be aseptically removed and placed on potato dextrose
agar (PDA). Pure
fungal cultures were acquired in this manner. In particular isolates that have
a pink to reddish
coloration and possessing sickle shaped spores are likely to be endophytic
Fusarium spp. Further
characterization by molecular techniques can be made as understood by those
skilled in the art.
This procedure was used to find each of the organisms used and described
herein.
Shown in Table 1, are the inhibition and killing effects of propanoic acid,
and isobutryic
acid together and alone and with various esters. The tests were conducted over
the course of 30
hr at 22 C. Measurements were made on appropriate controls and thus the
percentage of
inhibition calculations could be made on treatments vs the growth on a control
organism (non-
treated). The bacteria and yeast like organisms were evaluated on the basis of
relative growth
rates after 30 hr. Those highlighted areas on the table show those compounds
(esters) having the
57
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
most compatibility with propanoic and isobutryic acid 1:1 v/v mixtures with
the appropriate
esters at a 7:2 ratio- Systems 1 and 2 above. It is from this test that
Systems 1 and 2 were
discovered. The acids were added at 7!J.1 individually and combination of the
esters with the
acids were added at the 9 !J.11evel in the plate assay.
Table 1.
Test Organism
Cercospora Phytophthora Verticillium Sclerotinia Pythium
Compound tested beticola cinnamomi dahliae
sclerotiorum ultimum
Control 0% 0% 0% 0% 0%
Isobutyric Acid+
95% 87% 70% 20% 89%
Propanoic Acid
Isobutyric Acid 95% 100% 90% 40%
100%
Propanoic Acid 95% 67% 96% 60% 91%
Ethyl Isobutyrate 95% 100% 80% 90%
100%
Isopropyl
95% -33% 96% 30%
100%
Isobutyrate
Isobutyl Isobutyrate 95% 0% 92% 75%
100%
Butyl Isobutyrate 95% 0% 60% 0%
100%
Isobutyl Butyrate 100% 33% 96% 70%
100%
Isoamyl Butyrate 100% 100% 100% 95%
100%
Isoamyl Isobutyrate 95% 97% 96% 80%
100%
Isobutyl Propionate 100% 33% 88% 80%
100%
Isobutyl Acetate 95% 67% 60% 20%
100%
Propyl Isobutyrate 95% 87% 88% 40% 98%
Isobutyl Isovalerate
58
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
95% 100% 96% 0%
100%
Fusarium Trichoderma Rhizoctonia
Aspergillus
subglutinans viridae solani
fumigatus
Control 0% 0% 0% 0%
Isobutyric Acid+
-3% 20% 86% 0%
Propanoic Acid
Isobutyric Acid 67% 27% 86%
90%
Propanoic Acid 83% 53% 100% 80%
Ethyl Isobutyrate 67% 67% 100% 80%
Isopropyl
33% 20% 43% 0%
Isobutyrate
Isobutyl Isobutyrate 50% 47% 86% 80%
Butyl Isobutyrate 0% 40% 97% 0%
Isobutyl Butyrate 33% 47% 100% 0%
Isoamyl Butyrate 100% 90% 100%
90%
Isoamyl Isobutyrate 67% 67% 100% 80%
Isobutyl Propionate 67% 40% 100% 80%
Isobutyl Acetate 67% 20% 57% 0%
Propyl Isobutyrate 50% 33% 97%
50%
Isobutyl Isovalerate 67% 20% 94% 0%
59
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Saccharomyces
Candida albicans Escherichia coli Bacillus subtilis
cerevicae
Control
Growth Observed Growth Observed Growth Observed Growth Observed
Isobutyric Acid+
Growth Observed Inhibited Inhibited
Inhibited
Propanoic Acid
Isobutyric Acid Growth Observed No Growth No Growth
Growth Observed
Propanoic Acid Growth Observed No Growth No Growth
Growth Observed
Ethyl Isobutyrate Growth Observed No Growth No Growth
Growth Observed
Isopropyl
Growth Observed No Growth No Growth
Growth Observed
Isobutyrate
Isobutyl Isobutyrate Growth Observed Inhibited Inhibited
Growth Observed
Butyl Isobutyrate Growth Observed No Growth No Growth
Growth Observed
Isobutyl Butyrate Growth Observed No Growth No Growth
Growth Observed
Isoamyl Butyrate No Growth No Growth No Growth
Growth Observed
Isoamyl Isobutyrate Growth Observed No Growth No Growth
Growth Observed
Isobutyl Propionate Growth Observed No Growth No Growth
Growth Observed
Isobutyl Acetate Growth Observed Inhibited Inhibited
Growth Observed
Propyl Isobutyrate Growth Observed Inhibited Inhibited
Growth Observed
Isobutyl Isovalerate Growth Observed Inhibited Inhibited
Growth Observed
Note: when No Growth or 100% inhibition is noted the organisms were dead and
not
able to be revived.
Shown in Table 2 is a description of the molecular genetics data (below)
obtained on the
new isolates of fusarium that were tested for their ability to degrade human
wastes. Each of these
isolates is so designated on the heading. Details of the data acquisition are
provided at the end of
the table.
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
Table 2.
E 06-05 Fusarium subglutinans
Sequence (480 bases):
AACATACCAATTGTTGCCTCGGCGGATCAGCCCGCTCCCGGTAAAACGGGACGGCC
CGCCAGAGGACCCCTAAACTCTGTTTCTATATGTAACTTCTGAGTAAAACCATAAAT
AAATCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCA
AAATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGC
ACATTGCGCCCGCCAGTATTCTGGCGGGCATGCCTGTTCGAGCGTCATTTCAACCCT
CAAGCCCAGCTTGGTGTTGGGACTCGCGAGTCAAATCGCGTTCCCCAAATTGATTGG
CGGTCACGTCGAGCTTCCATAGCGTAGTAGTAAAACCCTCGTTACTGGTAATCGTCG
CGGCCACGCCGTTAAACCCCAACTTCTGAATGTTGACCTCGGATCAGGTAGGAATAC
CCGCTGAACTTAAGCATATCAATAA (SEQ ID NO: 1)
NCBI BLAST Matches:
Description Max Total Query E Max Accession
Score Score Cover Value Ident
Fusarium verticillioides voucher
UOA/HCPF 14862 18S ribosomal RNA
gene, partial sequence; internal transcribed
spacer 1,5.8S ribosomal RNA gene, and 887 887 100% 0.0
100% KC709665.1
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence
Fungal sp. AM2013 strain 186_Jm internal
transcribed spacer 1, partial sequence; 5.8S
ribosomal RNA gene and internal
887 887 100% 0.0 100% KC506334.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Fusarium subglutinans strain HI 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 887 887 100% 0.0
100% JX960431.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Fusarium sacchari internal transcribed
spacer 1, partial sequence; 5.8S ribosomal 887 887 100%
0.0 100% JN997445.1
RNA gene and internal transcribed spacer
61
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
2, complete sequence; and 28S ribosomal
RNA gene, partial sequence
Fusarium sp. PRE4b 18S ribosomal RNA
gene, partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene, and
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence >gbiKC254039.1I
Gibberella intermedia culture-collection 887 887 100%
0.0 100% JN254793.1
U0A/HCPF<GRC>: 12610 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
Gibberella moniliformis isolate FM2 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 887 887 100% 0.0
100% JF499676.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Gibberella moniliformis genes for 18S
rRNA, ITS1, 5.8S rRNA, ITS2, 28S rRNA, 887 887 100%
0.0 100% AB587012.1
partial and complete sequence, strain:
MAFF 240085
Gibberella moniliformis genes for 18S
rRNA, ITS1, 5.8S rRNA, ITS2, 285 rRNA, 887 887 100%
0.0 100% AB587010.1
partial and complete sequence, strain: CBS
576.78
Fusarium subglutinans genes for 18S
rRNA, ITS1, 5.8S rRNA, ITS2, 285 rRNA, 887 887 100%
0.0 100% AB587008.1
partial and complete sequence, strain:
ATCC 38016
Gibberella moniliformis strain Gm3 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 887 887 100% 0.0
100% HQ718417.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
62
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
E 06-08 Fusarium subglutinans
Sequence (478 bases):
CATACCAATTGTTGCCTCGGCGGATCAGCCCGCTCCCGGTAAAACGGGACGGCCCG
CCAGAGGACCCCTAAACTCTGTTTCTATATGTAACTTCTGAGTAAAACCATAAATAA
ATCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCAAA
ATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCAC
ATTGCGCCCGCCAGTATTCTGGCGGGCATGCCTGTTCGAGCGTCATTTCAACCCTCA
AGCCCAGCTTGGTGTTGGGACTCGCGAGTCAAATCGCGTTCCCCAAATTGATTGGCG
GTCACGTCGAGCTTCCATAGCGTAGTAGTAAAACCCTCGTTACTGGTAATCGTCGCG
GCCACGCCGTTAAACCCCAACTTCTGAATGTTGACCTCGGATCAGGTAGGAATACCC
GCTGAACTTAAGCATATCAATAA (SEQ ID NO: 2)
NCBI BLAST Matches:
Description Max Total Query E Max Accession
Score Score Cover Value Ident
Fusarium verticillioides voucher
UOA/HCPF 14862 18S ribosomal RNA
gene, partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene, and 883 883 100%
0.0 100% KC709665.1
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence
Fungal sp. AM2013 strain 186_Jm
internal transcribed spacer 1, partial
sequence; 5.8S ribosomal RNA gene and
883
883 100% 0.0 100% KC506334.1
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence
Fungal sp. AM2013 strain 165_Gbp
internal transcribed spacer 1, partial
sequence; 5.8S ribosomal RNA gene and
883
883 100% 0.0 100% KC506316.1
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence
Fusarium subglutinans strain HI 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 883 883 100% 0.0
100% JX960431.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
63
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Fusarium sacchari internal transcribed
spacer 1, partial sequence; 5.8S ribosomal
RNA gene and internal transcribed spacer 883 883 100%
0.0 100% JN997445.1
2, complete sequence; and 28S ribosomal
RNA gene, partial sequence
Gibberella moniliformis isolate FM11
internal transcribed spacer 1, partial
sequence; 5.8S ribosomal RNA gene and
883 883
100% 0.0 100% HQ995666.1
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence
Fusarium sp. PRE4b 18S ribosomal RNA
gene, partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene, and
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence >gbiKC254039.1I
Gibberella intermedia culture-collection 883 883 100%
0.0 100% JN254793.1
U0A/HCPF<GRC>: 12610 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
Gibberella moniliformis isolate FM2 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 883 883 100% 0.0
100% JF499676.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Gibberella moniliformis genes for 18S
rRNA, ITS1, 5.8S rRNA, ITS2, 28S
883
883 100% 0.0 100% AB587012.1
rRNA, partial and complete sequence,
strain: MAFF 240085
Gibberella moniliformis genes for 18S
rRNA, ITS1, 5.8S rRNA, ITS2, 28S
883
883 100% 0.0 100% AB587010.1
rRNA, partial and complete sequence,
strain: CBS 576.78
64
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
E 4-5 Fusarium sp.
Sequence (488 bases):
CTTAATGTTGCCTCGGCGGATCAGCCCGCGCCCCGTAAAACGGGACGGCCCGCCAG
AGGACCCAAACTCTAATGTTTCTTATTGTAACTTCTGAGTAAAACAAACAAATAAAT
CAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCAAAAT
GCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCACAT
TGCGCCCGCTGGTATTCCGGCGGGCATGCCTGTTCGAGCGTCATTTCAACCCTCAAG
CCCCCGGGTTTGGTGTTGGGGATCGGCTCTGCCTTCTGGCGGTGCCGCCCCCGAAAT
ACATTGGCGGTCTCGCTGCAGCCTCCATTGCGTAGTAGCTAACACCTCGCAACTGGA
ACGCGGCGCGGCCATGCCGTAAAACCCCAACTTCTGAATGTTGACCTCGGATCAGGT
AGGAATACCCGCTGAACTTAAGCATATCAATAG (SEQ ID NO: 3)
NCBI BLAST Matches:
Description Max Total Query E Max Accession
Score Score Cover Value Ident
Uncultured Fusarium clone R1 12 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 900 900 99% 0.0
100% KC753424.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Uncultured Fusarium genomic DNA
containing 18S rRNA gene, ITS1, 5.8S
900 900 99% 0.0 100% HE977525.1
rRNA gene, ITS2 and 28S rRNA gene,
clone RRA10
Fusarium tricinctum isolate XSCZO7
internal transcribed spacer 1, partial
sequence; 5.8S ribosomal RNA gene and
900 900 99% 0.0 100% JQ676180.1
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence
Uncultured fungus clone Hyp12 internal
transcribed spacer 1, partial sequence;
5.8S ribosomal RNA gene and internal
900 900 99% 0.0 100% JQ618507.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Fusarium tricinctum isolate UASWS0796
18S ribosomal RNA gene, internal
transcribed spacer 1, 5.8S ribosomal RNA 900 900 99%
0.0 100% JN662408.1
gene, internal transcribed spacer 2, and
28S ribosomal RNA gene, region
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Fusarium sp. NRRL 52933 internal
transcribed spacer I, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2, 900 900 99%
0.0 100% JF740937.I
complete sequence; and 28S ribosomal
RNA gene, partial sequence
Fusarium sp. NRRL 52714 internal
transcribed spacer I, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2, 900 900 99%
0.0 100% JF740911.I
complete sequence; and 28S ribosomal
RNA gene, partial sequence
Fusarium sp. NRRL 25129 internal
transcribed spacer I, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
>gbiJF740916.II Fusarium sp. NRRL
52726 internal transcribed spacer I, 5.8S
ribosomal RNA gene, and internal
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence >gb LIF740917.II Fusarium sp. 900 900 99%
0.0 100% JF740895.I
NRRL 52727 internal transcribed spacer
I, 5.8S ribosomal RNA gene, and internal
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence >gb LIF740918.11 Fusarium sp.
NRRL 52730 internal transcribed spacer
I, 5.8S ribosomal RNA gene, and internal
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Fusarium sp. NRRL 25128 internal
transcribed spacer I, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2, 900 900 99%
0.0 100% JF740894.I
complete sequence; and 28S ribosomal
RNA gene, partial sequence
Gibberella avenacea isolate 3214 I8S
ribosomal RNA gene, partial sequence;
internal transcribed spacer I, 5.8S
ribosomal RNA gene, and internal 900 900 99% 0.0
100% FJ224099.I
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
66
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
PC-2-24 (Control) Fusarium culmorum
Sequence (477 bases):
CATACCTTATGTTGCCTCGGCGGATCAGCCCGCGCCCCGTAAAAAGGGACGGCCCG
CCGCAGGAACCCTAAACTCTGTTTTTAGTGGAACTTCTGAGTATAAAAAACAAATAA
ATCAAAACTTTCAACAACGGATCTCTTGGTTCTGGCATCGATGAAGAACGCAGCAAA
ATGCGATAAGTAATGTGAATTGCAGAATTCAGTGAATCATCGAATCTTTGAACGCAC
ATTGCGCCCGCCAGTATTCTGGCGGGCATGCCTGTTCGAGCGTCATTTCAACCCTCA
AGCCCAGCTTGGTGTTGGGAGCTGCAGTCCTGCTGCACTCCCCAAATACATTGGCGG
TCACGTCGAGCTTCCATAGCGTAGTAATTTACATATCGTTACTGGTAATCGTCGCGG
CCACGCCGTTAAACCCCAACTTCTGAATGTTGACCTCGGATCAGGTAGGAATACCCG
CTGAACTTAAGCATATCAATAG (SEQ ID NO: 4)
NCBI BLAST Matches:
Description Max Total Query E Max Accession
Score Score Cover Value Ident
Fusarium sp. 0TU930 internal transcribed
spacer 1, partial sequence; 5.8S ribosomal
RNA gene and internal transcribed spacer 881 990 100%
0.0 100% GU934527.1
2, complete sequence; and 28S ribosomal
RNA gene, partial sequence
Fusarium culmorum isolate 149 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 880 880 99% 0.0
100% KC989094.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Fusarium cerealis genes for contains 18S
rRNA, ITS1, 5.8S rRNA, ITS2, 28S
880 880 99% 0.0 100% AB820718.1
rRNA, partial and complete sequence,
strain: MAFF 101144
Fusarium culmorum genes for 18S rRNA,
ITS1, 5.8S rRNA, ITS2, 28S rRNA,
partial and complete sequence, strain:
MAFF 241212 >dbjiAB820717.11
880 880 99% 0.0 100% AB586990.1
Fusarium cerealis genes for contains 18S
rRNA, ITS1, 5.8S rRNA, ITS2, 28S
rRNA, partial and complete sequence,
strain: MAFF 241212
Fusarium cerealis strain FC3 18S
ribosomal RNA gene, internal transcribed
spacer 1, 5.8S ribosomal RNA gene, 880 880 99% 0.0
100% JF303876.1
internal transcribed spacer 2, and 28S
ribosomal RNA gene, region
67
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Fusarium cerealis strain FC2 I8S
ribosomal RNA gene, internal transcribed
spacer I, 5.8S ribosomal RNA gene, 880 880 99% 0.0
100% JF303871.I
internal transcribed spacer 2, and 28S
ribosomal RNA gene, region
Fusarium cerealis strain FCI I8S
ribosomal RNA gene, internal transcribed
spacer I, 5.8S ribosomal RNA gene, 880 880 99% 0.0
100% JF303867.I
internal transcribed spacer 2, and 28S
ribosomal RNA gene, region
Fusarium culmorum strain G5 I8S
ribosomal RNA gene, partial sequence;
internal transcribed spacer I, 5.8S
ribosomal RNA gene, and internal 880 880 99% 0.0
100% GU566271.I
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Uncultured Hypocreales clone
B2_i_ITS IF internal transcribed spacer I,
partial sequence; 5.8S ribosomal RNA 880 880 99% 0.0
100% EU754930.I
gene, complete sequence; and internal
transcribed spacer 2, partial sequence
Uncultured Hypocreales clone
B3 I c_ITS IF internal transcribed spacer
I, partial sequence; 5.8S ribosomal RNA 880 880 99%
0.0 100% EU754928.I
gene, complete sequence; and internal
transcribed spacer 2, partial sequence
68
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
E 30 -14 Fusarium avenaceum
Sequence (485 bases):
CAGAAGTTGGGGTTTTACGGCATGGCCGCGCCGCGTTCCAGTTGCGAGGTGTTAGCT
ACTACGCAATGGAGGCTGCAGCGAGACCGCCAATGTATTTCGGGGGCGGCACCGCC
AGAAGGCAGAGCCGATCCCCAACACCAAACCCGGGGGCTTGAGGGTTGAAATGACG
CTCGAACAGGCATGCCCGCCGGAATACCAGCGGGCGCAATGTGCGTTCAAAGATTC
GATGATTCACTGAATTCTGCAATTCACATTACTTATCGCATTTTGCTGCGTTCTTCAT
CGATGCCAGAACCAAGAGATCCGTTGTTGAAAGTTTTGATTTATTTGTTTGTTTTACT
CAGAAGTTACAATAAGAAACATTAGAGTTTGGGTCCTCTGGCGGGCCGTCCCGTTTT
ACGGGGCGCGGGCTGATCCGCCGAGGCAACATTAAGGTATGTTCACAGGGGTTTGG
GAGTTGTAAACTCGGTAATGATCCCTCCGCA (SEQ ID NO: 5)
NCBI BLAST Matches:
Description Max Total Query E Max Accession
Score Score Cover Value Ident
Fusarium avenaceum 18S ribosomal RNA
gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2, 896 896 100%
0.0 100% JX402184.1
complete sequence; and 28S ribosomal
RNA gene, partial sequence
>gbiJX402187.11
Fusarium avenaceum 18S ribosomal RNA
gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
896 896 100% 0.0 100% JX402183.1
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
Fusarium avenaceum 18S ribosomal RNA
gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
896 896 100% 0.0 100% JX402180.1
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
Fusarium avenaceum 18S ribosomal RNA
gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
896 896 100% 0.0 100% JX402179.1
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
69
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Fusarium tricinctum strain wxm38 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 896 896 100% 0.0 100%
HM037940.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Fusarium tricinctum genes for 18S rRNA,
ITS1, 5.8S rRNA, ITS2, 28S rRNA,
896 896 100% 0.0 100% AB470855.1
partial and complete sequence, isolate:
TS08-58-2
Fusarium tricinctum genes for 18S rRNA,
ITS1, 5.8S rRNA, ITS2, 28S rRNA,
partial and complete sequence, isolate:
TS08-86-1 >dbjiAB470818.1I Fusarium
tricinctum genes for 18S rRNA, ITS1,
5.8S rRNA, ITS2, 28S rRNA, partial and
complete sequence, isolate: TS08-70-1
896 896 100% 0.0 100% AB470859.1
>gbiGU586834.1I Fusarium tricinctum
isolate Ppf30 18S ribosomal RNA gene,
partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene, and
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence
Gibberella avenacea isolate FA37 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal 896 896 100% 0.0 100%
FJ602983.1
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence
Gibberella avenacea isolate FA18 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence >gbiFJ602975.1I Gibberella
896 896 100% 0.0 100% FJ602964.1
avenacea isolate FA29 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
>gbiFJ603000.1I Gibberella avenacea
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
isolate FA54 18S ribosomal RNA gene,
partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene, and
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence
Gibberella avenacea isolate FA17 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence >gbiFJ602968.11 Gibberella
avenacea isolate FA22 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
>gbiFJ602973 .11 Gibberella avenacea
isolate FA27 18S ribosomal RNA gene,
partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene, and 896 896 100%
0.0 100% FJ602963.1
internal transcribed spacer 2, complete
sequence; and 28S ribosomal RNA gene,
partial sequence >gbiFJ602981.11
Gibberella avenacea isolate FA35 18S
ribosomal RNA gene, partial sequence;
internal transcribed spacer 1, 5.8S
ribosomal RNA gene, and internal
transcribed spacer 2, complete sequence;
and 28S ribosomal RNA gene, partial
sequence >gbiFJ602999.11 Gibberella
avenacea isolate FA53 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal RNA
gene, and internal transcribed spacer 2,
complete sequence; and 28S ribosomal
RNA gene, partial sequence
71
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
E 06-7 Fusarium sub glutinans
Sequence (469 bases):
CAGAAGTTGGGGTTTAACGGCGTGGCCGCGACGATTACCAGTAACGAGGGTTTTACT
ACTACGCTATGGAAGCTCGACGTGACCGCCAATCAATTTGGGGAACGCGATTTGACT
CGCGAGTCCCAACACCAAGCTGGGCTTGAGGGTTGAAATGACGCTCGAACAGGCAT
GCCCGCCAGAATACTGGCGGGCGCAATGTGCGTTCAAAGATTCGATGATTCACTGA
ATTCTGCAATTCACATTACTTATCGCATTTTGCTGCGTTCTTCATCGATGCCAGAACC
AAGAGATCCGTTGTTGAAAGTTTTGATTTATTTATGGTTTTACTCAGAAGTTACATAT
AGAAACAGAGTTTAGGGGTCCTCTGGCGGGCCGTCCCGTTTTACCGGGAGCGGGCT
GATCCGCCGAGGCAACAATTGGTATGTTCACAGGGGTTTGGGAGTTGTAAACTCGGT
AATGATCCCTCCGC (SEQ ID NO: 6)
NCBI BLAST Matches:
Description Max Total Query E Max Accession
Score Score Cover Value Ident
Fusarium verticillioides voucher
UOA/HCPF 14862 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
867 867 100% 0.0
100% KC709665.1
RNA gene, and internal transcribed
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium subglutinans strain AAFC-
Fcir-012 18S ribosomal RNA gene,
partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene,
867 867 100% 0.0
100% KC464632.1
and internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Gibberella moniliformis genomic
DNA containing 18S rRNA gene,
867 1017 100% 0.0
100% HF570008.1
ITS1, 5.8S rRNA gene, ITS2 and 28S
rRNA gene, strain DBT-112
Gibberella moniliformis isolate
SIDV20110221051 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
867 867 100% 0.0
100% KC143121.1
RNA gene, and internal transcribed
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence
72
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
Gibberella intermedia voucher LFG4-
3BBRS internal transcribed spacer 1,
5.8S ribosomal RNA gene, and 867 867 100% 0.0 100%
JQ272470.1
internal transcribed spacer 2-like
gene, partial sequence; mitochondrial
Gibberella moniliformis strain CB 1
18S ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
867 867 100% 0.0 100%
JX511973.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium sp. CHTAG40 18S
ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
867 867 100% 0.0 100%
JF773630.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium sp. CHTAG38 18S
ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
867 867 100% 0.0 100%
JF773629.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium sp. CHTAG34 18S
ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
867 867 100% 0.0 100%
JF773628.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium sp. CHTAG32 18S
ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
867 867 100% 0.0 100%
JF773627.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
73
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
74
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
E-30 -7 Fusarium avenaceum
Sequence (480 bases):
GAAGTTGGGGTTTTACGGCATGGCCGCGCCGCGTTCCAGTTGCGAGGTGTTAGCTAC
TACGCAATGGAGGCTGCAGCGAGACCGCCAATGTATTTCGGGGGCGGCACCGCCAG
AAGGCAGAGCCGATCCCCAACACCAAACCCGGGGGCTTGAGGGTTGAAATGACGCT
CGAACAGGCATGCCCGCCGGAATACCAGCGGGCGCAATGTGCGTTCAAAGATTCGA
TGATTCACTGAATTCTGCAATTCACATTACTTATCGCATTTTGCTGCGTTCTTCATCG
ATGCCAGAACCAAGAGATCCGTTGTTGAAAGTTTTGATTTATTTGTTTGTTTTACTCA
GAAGTTACAATAAGAAACATTAGAGTTTGGGTCCTCTGGCGGGCCGTCCCGTTTTAC
GGGGCGCGGGCTGATCCGCCGAGGCAACATTAAGGTATGTTCACAGGGGTTTGGGA
GTTGTAAACTCGGTAATGATCCCTCC (SEQ ID NO: 7)
NCBI BLAST Matches:
Description Max Total Query E Max Accession
Score Score Cover Value Ident
Fusarium avenaceum isolate 143 18S
ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
887 887 100% 0.0
100% KC989099.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Uncultured Fusarium clone R1 12
18S ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
887 887 100% 0.0
100% KC753424.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium avenaceum strain Fk 15
small subunit ribosomal RNA gene,
partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene,
887 887 100% 0.0
100% KC464345.1
and internal transcribed spacer 2,
complete sequence; and large subunit
ribosomal RNA gene, partial
sequence
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
Fusarium avenaceum 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
RNA gene, and internal transcribed
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence >gbiJX402187.11 Fusarium
avenaceum 18S ribosomal RNA
gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
RNA gene, and internal transcribed
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence >gbiJX402188.1I Fusarium
avenaceum 18S ribosomal RNA
gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
RNA gene, and internal transcribed 887 887 100%
0.0 100% JX402184.1
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence >gbiJX402189.1I Fusarium
avenaceum 18S ribosomal RNA
gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
RNA gene, and internal transcribed
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence >gbiJX402190.1I Fusarium
avenaceum 18S ribosomal RNA
gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
RNA gene, and internal transcribed
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium avenaceum 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
RNA gene, and internal transcribed 887 887 100%
0.0 100% JX402183.1
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium avenaceum 18S ribosomal
RNA gene, partial sequence; internal
887 887 100% 0.0 100%
JX402180.1
transcribed spacer 1, 5.8S ribosomal
RNA gene, and internal transcribed
76
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium avenaceum 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
RNA gene, and internal transcribed 887 887
100% 0.0 100% JX402179.1
spacer 2, complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Uncultured Fusarium genomic DNA
containing 18S rRNA gene, ITS1,
887 887 100% 0.0
100% HE977545.1
5.8S rRNA gene, ITS2 and 28S
rRNA gene, clone RRF01
Fusarium sp. CHTAM47 18S
ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
887 887 100% 0.0
100% JF773662.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium sp. CHTAM2 18S
ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
887 887 100% 0.0
100% JF773634.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
77
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
E 06-01 Fusarium subglutinans
Sequence (468 bases):
GAAGTTGGGGTTTAACGGCGTGGCCGCGACGATTACCAGTAACGAGGGTTTTACTAC
TACGCTATGGAAGCTCGACGTGACCGCCAATCAATTTGGGGAACGCGATTTGACTCG
CGAGTCCCAACACCAAGCTGGGCTTGAGGGTTGAAATGACGCTCGAACAGGCATGC
CCGCCAGAATACTGGCGGGCGCAATGTGCGTTCAAAGATTCGATGATTCACTGAATT
CTGCAATTCACATTACTTATCGCATTTTGCTGCGTTCTTCATCGATGCCAGAACCAAG
AGATCCGTTGTTGAAAGTTTTGATTTATTTATGGTTTTACTCAGAAGTTACATATAGA
AACAGAGTTTAGGGGTCCTCTGGCGGGCCGTCCCGTTTTACCGGGAGCGGGCTGATC
CGCCGAGGCAACAATTGGTATGTTCACAGGGGTTTGGGAGTTGTAAACTCGGTAATG
ATCCCTCCGCA (SEQ ID NO: 8)
NCBI BLAST Matches:
Description Max Total Query E Max Accession
Score Score Cover Value Ident
Fusarium verticillioides voucher
UOA/HCPF 14862 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
865 865 100% 0.0 100%
KC709665.1
RNA gene, and internal transcribed
spacer 2, complete sequence; and
28S ribosomal RNA gene, partial
sequence
Gibberella moniliformis genomic
DNA containing 18S rRNA gene,
865 1016 100% 0.0 100%
HF570008.1
ITS1, 5.8S rRNA gene, ITS2 and
28S rRNA gene, strain DBT-112
Gibberella moniliformis isolate
SIDV20110221051 18S ribosomal
RNA gene, partial sequence; internal
transcribed spacer 1, 5.8S ribosomal
865 865 100% 0.0 100%
KC143121.1
RNA gene, and internal transcribed
spacer 2, complete sequence; and
28S ribosomal RNA gene, partial
sequence
Gibberella moniliformis strain CB1
18S ribosomal RNA gene, partial
sequence; internal transcribed spacer
1, 5.8S ribosomal RNA gene, and
865 865 100% 0.0 100%
JX511973.1
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
78
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Gibberella moniliformis isolate
FM13 I8S ribosomal RNA gene,
partial sequence; internal transcribed
spacer I, 5.8S ribosomal RNA gene,
865 865 100% 0.0 100%
HQ995667.I
and internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Gibberella moniliformis isolate FM2
I8S ribosomal RNA gene, partial
sequence; internal transcribed spacer
I, 5.8S ribosomal RNA gene, and
865 865 100% 0.0 100%
JF499676.I
internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Fusarium sp. Ljf00I I8S ribosomal
RNA gene, partial sequence; internal
transcribed spacer I, 5.8S ribosomal
RNA gene, and internal transcribed 865 865 100% 0.0 100%
HQ025928.1
spacer 2, complete sequence; and
28S ribosomal RNA gene, partial
sequence
Gibberella sp. FLS-20I0 isolate FS-
74(3) I8S ribosomal RNA gene,
partial sequence; internal transcribed
spacer I, 5.8S ribosomal RNA gene,
and internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence >gb IHQ023214.11
Gibberella sp. FLS-20I0 isolate FS-
78(3) I8S ribosomal RNA gene,
partial sequence; internal transcribed
865 865 100% 0.0 100%
HQ023213.1
spacer I, 5.8S ribosomal RNA gene,
and internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence >gb IHQ023215 .11
Aspergillus sp. FLS-20I0 isolate FS-
55(3) I8S ribosomal RNA gene,
partial sequence; internal transcribed
spacer I, 5.8S ribosomal RNA gene,
and internal transcribed spacer 2,
complete sequence; and 28S
79
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
ribosomal RNA gene, partial
sequence
Gibberella sp. FLS-2010 isolate FS-
48.5(1) 18S ribosomal RNA gene,
partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene,
865 865 100% 0.0
100% HQ023211.1
and internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
Gibberella sp. FLS-2010 isolate FS-
82(3) 18S ribosomal RNA gene,
partial sequence; internal transcribed
spacer 1, 5.8S ribosomal RNA gene,
865 865 100% 0.0
100% HQ023203.1
and internal transcribed spacer 2,
complete sequence; and 28S
ribosomal RNA gene, partial
sequence
ITS based phylogenetic analysis
Phylogenetic analysis of these organisms was carried out by the acquisition of
the ITS-
5.8 S ribosomal gene sequence. The fungus was grown on PDA for 7 days and DNA
templates
were prepared by using the Prepman Ultra Sample Preparation Reagent (Applied
Biosystems,
USA) according to the manufacturer's guidelines. The ITS regions of the fungus
were amplified
with the universal ITS primers ITS1 (5' TCCGTAGGTGAACCTGCGG 3'; SEQ ID NO: 9)
and
ITS4 (5'TCCTCCGCTTATTGATATGC 3'; SEQ ID NO: 10) using Polymerase Chain
Reaction
(PCR). The PCR conditions used were as follows: initial denaturation at 94 C
for 3 min followed
by 30 cycles of 94 C for 15 sec., 50 C for 30 sec., 72 C for 45 sec., and a
final extension at 72 C
for 5 min. The 50 111 reaction mixture contained lx PCR buffer, 200 each_
dNTP, 1.5 mM
MgCh, 10 pmol of each primer, 1-5 ng of DNA and 2.5 U of Taq DNA polymerase.
The
amplified product (5 !J.1) was visualized on 1% (w/v) agarose gel to confirm
the presence of a
single amplified band. The amplified products were purified by Amicon Ultra
columns
(Millipore, USA) and 20-40 ng were used in a 10 111 sequencing reaction using
the Big Dye
Terminator sequencing kit (v. 3.1), with 2 pmoles of the forward or the
reverse primer in the
cycle sequencing reaction. Twenty cycles of 96 OC for 10 s, 50 OC for 5 s and
60 OC for 4 min
were performed and the extension products were purified by ethanol
precipitation, dissolved in
111 ofHiDi Formamide, incubated at 95 OC for 1 min and loaded on ABI Prism 377
Genetic
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Analyzer (Perkin-Elmer, USA) for sequencing. All the reagents for sequencing
were from
Applied Biosystems, USA The amplified products were sequenced and aligned with
the
sequences in the GenBank by BLASTN program (Altschul et al., 1997). Sequencing
was
performed at the U Calif, Berkeley.
Shown in Table 3 is the growth of various fusaria on human wastes causes a
reduction of
the dry weight of the mass during the course of a 7 week experiment. The
experimental set- up
contained 0.5 g of bentonite with System 2 on a water agar plate having about
100 mg wet
weight of human waste and a small agar plug with the test fusarium on it. The
incubation period
was 7 weeks at 22 C. The remains of the human waste were physically removed
and dried for 4
hr at 80 OC and then weighed.
Table 3.
Fusarium isolate designation Dry weight of the human waste remaining
after
7 weeks. mg.
Control- no fusarium 43
EC-4-5 14
E06-7 23
E 06-7 25
P2-24 Fusarium culmorum Original control 24
E30-2 18
E 30-7 27
E06-1 16
E 30 -14 15
E06-8 14
Example 2
Establishment of S-3 and S-4 mixes
81
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Tests were conducted as similarly described for Systems 1 and 2 above (Figure
9) to
ascertain the biological activities of various test mixtures against a panel
of test microbes. A
small plug of each organism was placed in the periphery of the PDA plate. In
the center well was
placed the test solution in the plastic cup holder. A control plate (A) was
also set up. After 30 hr
the growth of the test organisms was compared to that of the control and the %
inhibition was
calculated. The (B) plate contained the test mixture. Measurements were made
30 hr after plate
set up.
It is to be noted that the System 1 and 2 mixtures described herein contain
about 3.5 parts
of propanoic acid along with 3.5 parts ofisobutryic acid and finally two parts
of an ester- either
isoamyl butryate (System 1) or isoamyl isobutryate (System 2). It is realized
that while these
mixtures are effective in a number of applications there may be other mixtures
that are even
more effective by virtue of their range of biological activities, their
utility and their effectiveness
at low doses. To this end, a search was conducted using the standard propanoic
acid as a starting
point whilst omitting isobutryic acid (because of its offensive odor) and now
including larger
molecular weight esters as the ester component. Quite surprisingly and
unexpectedly, it was
discovered that the use of propanoic acid (7) parts and Isoamyl Hexonates (2)
parts produced a
volatile mixture with biological activities that exceeded that of either B-23
(see below), and S-1
as shown in Table 4. This new mixture is designated as System 3, while the
formulation
comprising propanoic acid (7) and formate (2) is designated System 4. It is to
be noted that
System 4 is less active against most of the test organisms than System 3, but
System 4 does kill E
coli while allowing for the growth of Fusarium. To this end, System 4 is an
effective mixture to
be used as a human waste treatment along with Fusarium spp.
Table 4. The effects ofvarious esters and propanoic acid on the growth of test
organisms
measured at 30 hr at room temperature. The effect is represented as percent
inhibition of the
growth when directly compared to the growth of an uninoculated control.
Measurements
(average of two) were made as the hyphal growth from the edge of the inoculum
plug.
Cercospora Phytophthora Verticillium Sclerotinia Pythium
beticola cm. namomi dahliae sclerotiorum
ultimum
5-1 Solution
100 72 92 0 100
B-23** 92 89 42 66 100
82
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Isoamyl Hexonates
83 13 0 66 28
(2 41)
Propanoic Acid 66 38 83 0 100
Propanoic Acid
with Isoamyl 100 72 100 0 100
Formate (7:2)= S-4
Propanoic Acid
with Isobutyl 100 79 98 0 100
Formate (7:2)
Propanoic Acid
with Isoamyl
100 100 100 100 100
Hexonates (7:2) =
S-3*
Propanoic Acid
with Isoamyl
100 92 100 94 100
Formate & Cineole
(7: 1: 1)
Propanoic Acid
with equal mix of
95 89 100 50 100
formates &
valencene (7:2:0.5)
Propanoic Acid
with equal mix of 98 92 100 64 100
formates (7:2)
Propanoic Acid
with Hexyl Formate 100 88 87 60 100
(7:2:)
Fusarium Trichoderma Rhizoctonia Aspergillus
solani viridae solani flavus
S-1 Solution 72 56 100 86
B-23** 32 32 81 29
Isoamyl Hexonates
83 13 0 66
(2 III)
Propanoic Acid 17 45 81 52
83
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
Propanoic Acid with
Isoamyl Formate 53 25 85 0
(7:2) = S-4
Propanoic Acid
with Isobutyl 0 32 47 29
Formate (7:2)
Propanoic Acid with
Isoamyl Hexonates
95 58 100 83
S-
3*
Propanoic Acid
with Isoamyl
69 35 74 0
Formate & Cineole
(7: 1: 1)
Propanoic Acid
with equal mix of
74 35 77 43
formates &
valencene (7:2:0.5)
Propanoic Acid
with equal mix of 58 30 77 29
formates (7:2)
Propanoic Acid
with Hexyl Formate 86 49 93 90
(7:2:)
84
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Activity against yeasts and bacteria
Yes= Growth
Medium = Some Growth
No= No Growth
Candida Escherichia Bacillus Saccharomyces
albicans coli subtilus cerevlceae
5-1 Solution Some growth No No Yes
B-23** Yes No No Medium
Isoamyl Hexonates (2
Ill) Yes Yes Yes Yes
Propanoic Acid Medium No No Yes
Propanoic Acid with
Isoamyl Formate (7:2) Medium No No Yes
S-4
Propanoic Acid with
Yes No No Yes
Isobutyl Formate (7:2)
Propanoic Acid with
Isoamyl Hexonates Trace No No Yes
(7:2) S-3*
Propanoic Acid with
Isoamyl Formate & No No No Yes
Cineole (7:1:1)
Propanoic Acid with
equal mix of formates Yes Medium No Medium
& valencene (7:2:0.5)
Propanoic Acid with
equal mix of formates Yes No No Medium
(7:2)
Propanoic Acid with
Yes No No Medium
Hexyl Formate (7:2:)
S-3 tests were run for 30 hr at room temp and then measured and photographed.
Measurements made from edge of
inoculation block to edge of colony. Two measurements made and then averaged.
The tests were run at room temp.
The results show that S-3 was the most biological active mixture of the
solutions tested. Also Note S3 -Inhibiting
Erwinia carotovora: 80 ¨ 90% and inhibiting Lactobacillus sp. ca. 50%.
**
B-23 formula tested is as follows: 1.39 parts acetaldehyde; 2.83 parts 2-
butanone; 30.56 parts propanoic acid, 2-
methyl-,methyl ester; 2.29 parts acetic acid, 2-methylpropyl ester; 1.09 parts
propanoic acid, 2-methyl-, 2-
methylpropyl ester; 1.78 parts 1-propanol, 2-methyl-; 1.51 parts 2-butenal, 2-
methyl-, (E)-; 4.79 parts 1-butanol, 3-
methyl-, acetate; 4.78 parts propanoic acid, 2-methyl-, 2-methylbutyl ester;
5.38 parts 1-butanol, 3-methyl-; 351.18
parts propanoic acid, 2-methyl-; 1.31 parts acetic acid, 2-phenylethyl ester.
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
It is to be noted that the S-3 mixture gave 100 % inhibition to many of the
organisms
tested (Table 4). The effect was greater than with Isoamyl Hexonatess or
propanoic acid alone.
Thus in some cases it appeared to be strongly synergistic ie. Sclerotina
sclerotiorum 66% with
hexanoates, 0% with propanoic and 100% when the two were combined. Some other
organisms
also reacted in the same manner such as Rhizoctonia solani. In addition it
appeared that S-3 was
more active than 5-1, as well as B-23 and of course the Isoamyl Hexonates or
propanoic acid
alone (Table 4). Other combinations of propanoic acid and other esters or
combinations of esters
and terpenoids such as cineole or valencene were not as effective (Table 4).
The S-4 formulation,
although not as active as S-3, did not cause such a great effect on Fusarium
but it was inhibitory
to other microbes and thus it may be best suited as a useful agent in to treat
human wastes in
combination with the Fusarium. S-3 did kill both bacterial test organisms in
the tests (Table 4).
S-3 also affected Erwinia and Lactobacillus sp. (Table 4).
Establishment of the appropriate ratios of ingredients for S-3
The mixes of propanoic acid to Isoamyl Hexonates were varied and subsequently
tested
according to the procedures outlined above. It turns out that the most
favorable mixture was the
7:2 ratio of the two ingredients (Table 5). All others gave lower inhibition
values (Table 5). The
addition ofterpenoids such as valencene did not promote biological activity.
Thus, the ratio of
7:2 v/v of the two ingredients is the most preferred for practical
application.
Table 5. Effects ofvarious ratios of propanoic acid to Isoamyl Hexonates on a
panel of test
orgamsms. All tests were came d out as desedbed m Table 4
Sclerotinia
Cercospora Phytophthor Verticillium sclerotioru Pythium
beticola a cinnamomI dahliae m ultimum
Propanoic Acid
with Isoamyl
100 100 100 100 100
Hexonates (7:2) =
S-3
Propanoic Acid
with Isoamyl 86 95 100 70 100
Hexonates (5:4)
Propanoic Acid
with Isoamyl 95 95 94 60 100
Hexonates (3:6)
86
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Propanoic Acid
with Isoamyl
100 95 94 20 100
Hexonates &
Valencene (6.21)
Fusarium Trichoderma Rhizoctonia Aspergillus
solani viridae solani flavus
Propanoic Acid
with Isoamyl 95 58 100 83
Hexonates (7:2)
Propanoic Acid
with Isoamyl 58 59 89 50
Hexonates (5:4)
Propanoic Acid
with Isoamyl 72 62 93 50
Hexonates ( 3 :6)
Propanoic Acid
with Isoamyl
72 59 93 50
Hexonates &
Valencene (6:2:1)
Yes= Growth
Medium = Some Growth
No= No Growth
Candida Escherichia Bacillus Saccharomyces
albicans coli subtilus cerevlceae
Propanoic Acid
with Isoamyl Yes No No Some
Hexonates (7:2)
Propanoic Acid
with Isoamyl Yes Trace No Some
Hexonates (5:4)
Propanoic Acid
with Isoamyl Yes Yes Trace Some
Hexonates ( 3 :6)
Propanoic Acid
with Isoamyl
Yes Some No Some
Hexonates &
Valencene (6:2: 1)
87
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
C. Testing of Other Esters with Propanoic acid
As shown in Table 6 below, alternative esters were tested for mixture with
propanoic acid
at a ratio of7:2 propanoic acid:ester. These formulations are in addition to
formulations S-1, S-
2, S-3 and S-4, and accordingly form part of the formulations of the present
invention. It should
also be appreciated that the present invention may include multiple esters or
combinations of any
of the esters described hereinthroughout, in conjunction with propanoic acid,
preferably at a ratio
of 7:2 propanoic acid:ester mixture.
Table 6. Testing of Esters
B. C. D. E.
Cercospora Phytophthora Verticillium Sclerotinia Pythium
beticola Cinnamomi* dahliae sclerotiorum ultimum
Test solution
Propanoic acid with
Isoamyl benzoate 96 - 100 80 100
(7:2)
Propanoic acid with
Isoamyl phenylacetate 80 - 100 59 100
(7:2)
Propanoic acid with
96 - 100 59 100
isoamyl cinnamate
Propanoic acid with
Isoamyl octanoate 96 - 100 54 100
(7:2)
Propanoic acid with
Isoamyl salicylate 88 - 100 49 100
(7:2)
Propanoic acid with
72 - 100 45 100
Isoamyllaurate (7:2)
Orgamsm not available
88
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
F. G. H. I.
Fusarium Trichoderma Rhizoctonia Aspergillus
solani viridae solani flavus
Propanoic acid with
Isoamyl benzoate 0 77 74 92
(7:2)
Propanoic acid with
Isoamyl 0 60 54 92
phenylacetate (7:2)
Propanoic acid
with isoamyl 74 66 64 96
cinnamate
Propanoic acid with
Isoamyl octanoate 66 64 62 96
(7:2)
Propanoic acid with
Isoamyl salicylate 0 64 43 92
(7:2)
Propanoic acid
with Isoamyl 0 47 62 20
laurate (7:2)
Yes= Growth
Medium = Some Growth
No= No Growth
Lactobacillus Envinia
C. Bacillus S. carotovora
albicans E. coli subtilus cerev I ceae
Propanoic acid
with Isoamyl Trace No No Trace Medium No
benzoate (7:2)
Propanoic acid with
Isoamyl Trace
No No Medium Medium No
phenylacetate (7:2)
Propanoic acid with
Trace No No Medium Trace No
isoamyl cinnamate
Propanoic acid with
Isoamyl octanoate Trace No No Trace Trace No
(7:2)
Propanoic acid with
Isoamyl salicylate Yes No No Trace Trace No
(7:2)
89
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Propanoic acid with
Isoamyllaurate Yes No No Trace Trace No
(7:2)
Control Yes Yes Yes Yes Yes Yes
All testing was done according to the methods in Table 4
Example 3
Corn Decontamination tests
Corn is fermented to make ethanol. It is ground, heated to a mash and treated
with
enzymes prior to the addition of yeast cells to make a final preparation. Also
added are one or
more antibiotic preparations that tend to suppress otherwise competing
microbes that would foul
the fermentation process. As such antibiotics are being removed from the
market place, other
antimicrobial treatment processes are needful. To determine if the S-3
preparation has efficacy
against corn contaminating microbes the following was done:
Approximately 5 g of ground corn (cracked corn) was treated for 1 hr with 10
ml of 0%
(control), 0.25 %, 0.5% and 1% solutions of S-3 made with 7:2 v/v plus 10
microliters oftriton-
x 100 (per 10 m1). The treatment was for 1 hr and the product was damp dried
on paper tissue to
remove excess liquid. About 2 grams of material was placed directly on a PDA
plate and
incubated for 2 days prior to being photographed. In another case, the cracked
seed was dried
under a hood and then plated on PDA.
The results demonstrated that the treatment levels of 0.5% and 1.0% S-3 for 1
hr
completely removed the bacterial contamination of the cracked corn particles
(Fig. 10). When
the corn particles were blotted dry and further dried and tested in the same
manner, the results
were virtually the same.
Overall, the results indicate that the S-3 solution can be used to
decontaminate
agriculturally and food based products and materials. This would likewise
apply to instruments,
equipment, clothing and food being processed for consumption.
Example 4
Use of S-4 in treatment of human waste with Fusarium subglutinans.
Testing of formulae S-3 and S-4 was done to learn of their efficacy in
treating human
waste bacteria. The testing was done using 0.5 g ofbentonite having a rate of
1 ml S-1, S-2, S-3
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
or S-4 or B-23 per 10 g of bentonite. The control was no mixture of compounds.
Barley seeds
contaminated with Fusarium subglutinans (same one as previously used) were
placed on PDA
plates. The mid plate was streaked with a pure culture ofE coli obtained from
human waste. Cap
and seal with parafilm and then incubate for 3 days and photograph. The S-3
and S-4 killed the E
coli but there was less effect with B-23. The fusarium grew in the presence of
S-3 and better with
S-4. TheE coli grew in the control and slightly in the presence ofB-23 all as
illustrated in Fig.
11. It is to be noted that S-4 in bentonite resulted in complete killing ofE
coli and the growth of
the Fusarium did occur. This was also true of the S-1 and S-3 treatments but
the Fusarium was
more inhibited. The B-23 as a control was also effective in killing E. coli
but not to the same
degree. The results show that the S-4 is a good and reasonable treatment of
human wastes to kill
enteric bacteria with the concomitant use of Fusarium to allow for the
breakdown of human
waste materials.
Example 5
Treatment of animal wastes with S-3
S-3 was applied at the rate of 3 ml per lb of zeolite. To test its efficacy in
treating animal
wastes with control of bacterial growth the following experiments were done.
The treated zeolite
(0.5g) was placed in a center well of a PDA plate (cut out). The plate had
been completely
streaked and covered with a suspension of bacterial cells made from chicken,
goat, cat and horse
manure. The plates were covered and sealed with parafilm and then observed
after 3 -4 days of
incubation and photographed. The results in all cases showed that the S-3 was
an effective
antimicrobial mixture by virtue of the zone of inhibition that it caused on
the plates. This effect
was also noted with the case of horse, goat and cat fecal matter bacteria
spread on the plates (Fig.
12). The results suggest that the S-3 zeolite combination has the potential to
be used as a cat litter
treatment or a treatment for chicken coops or as an animal bedding
application.
Example 6
The efficacy of S-3 as a cat litter treatment and as an animal bedding
treatment was
further tested.
91
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Cat Litter Treatment Comparative Efficacy Testing
A 1 ft.2 plastic snap-seal-top container was filled with the desired litter
treatment plus
untreated bentonite in the proportions indicated by the packaging instructions
(Figure 13). For
these tests, CLOE (used at the rate of 4 ml per lb) and an untreated bentonite
control were tested.
A constant temperature was maintained in the testing facility for the duration
of the tests (e.g.
70 F). About 50 g of cat feces and 5 mL urine were added to treated
containers. At 24 hour
intervals, the ammonia level was measured in each box using the Z-800 ammonia
meter. The
measurements were done by placing the meter inside each box at respective 5-
minute intervals,
minimizing the amount of time the container spent open. The ammonia meter
yielded an average
ammonia level over the five minutes, as well as a peak ammonia level achieved
during the five
minutes. After the measurements were complete, the day-old fecal matter was
removed, and
approximately 50 g of fresh fecal matter and 5 mL of urine were added. The
containers were
resealed. These steps were continued daily for 1 week to determine relative
efficacies of the
products. A one-time one-hour-interval ammonia reading was taken on each of
the containers.
After 8 days, the average ammonia level readings taken over 5-minute intervals
every 24
hours showed that ammonia production was much lower on the CLOE-treated litter
than on the
untreated control (see Figures 14A and 14B).
Example 7
Microbiology analysis
Microbiological studies were done to demonstrate that the processes of odor
formation
are directly related to microbiological activity in the waste and waste
environment. Inhibiting or
controlling microbial activity should have a beneficial effect on the
reduction of odors. CLOE
has a direct effect on this microbial activity, rather than ameliorating the
odors by absorbing
them, as other cat litter treatment products do. To demonstrate this quality,
approximately 0.5 g
of CLOE were placed in the center well of a potato dextrose agar (PDA) plate,
which had been
covered with a lawn of bacteria derived from fresh solid cat waste. The plates
were incubated at
23 C for 1 week and photographed. The series of photographs shown in Figures
15A and 15B
indicate that the bentonite control (15A) had massive amounts of bacterial
colonies growing all
over the plate, including in those areas close to the well containing the
litter. In contrast, the
CLOE treatment (4 ml S3 per pound of carrier, 15B) was virtually free
ofbacterial colonies
92
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
around the well of the plate, but it did sport some growth of Penicillium sp.,
which is inherent to
the carrier substance and does not contribute to odor production. Please also
note the Penicillium
sp. in the control well.
Clearly, the antimicrobial activity of the CLOE product is directly related to
its
effectiveness as a cat litter treatment and its ability to reduce ammonia and
other odors emanating
from animal (specifically cat) waste, as manifested by many users. This is
also confirmed by the
ability of the product to inhibit and kill waste-associated microbes such as
E. coli. The CLOE
formula is absorbed by the carrier substances, but it is also slowly released
over time, and, as
such, can effectively act at some distance from the point source of the
bentonite or zeolite carrier
particulate.
Example 8
Chicken Litter Amendment Comparative Efficacy Testing
1 ft.2 plastic snap-seal-top containers were filled with pine shavings and the
desired
bedding treatment, in the proportions indicated by the packaging instructions
(Figure 16). For
these tests, Barnyard Bedding at the rate of 15 ml per lb of zeolite and an
untreated zeolite control
were tested, as these products are the more popular items on the market. A
constant temperature
was maintained in the testing facility for the duration of the tests (e.g. 70
F). About
50 g of chicken feces were added to treated containers and sprayed with about
2 mL of water. At
24 hour intervals, the ammonia level in each box was measured using the Z-800
ammonia meter.
The measurements were done by placing the ammonia meter inside each box for
respective 5-
minute intervals, minimizing the amount of time the container spent open. The
ammonia meter
yielded an average ammonia level over the five minutes, as well as a peak
ammonia level
achieved during the five minutes. About 50 g of fresh fecal matter and 2 mL of
water were added
each day after measurements were complete, and container was resealed. These
steps were
continued for 3 weeks to determine relative efficacy of the formula. A one-
time one-hour-
interval ammonia reading was taken on each of the containers.
After 8 days, the average ammonia level readings taken over 5-minute intervals
every 24
hours showed that ammonia production was highest on the zeolite control and
lowest on the
Barnyard Bedding-treated bedding (Figure 17A and 17B).
93
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Example 9
Large Animal Stall Litter Amendment Comparative Efficacy Testing
1 ft.2 plastic snap-seal-top container was filled with pine shavings (a
commonly used
bedding material for large animals) and the desired bedding treatment, in the
proportions
indicated by the packaging instructions (Figure 18). For these tests, Barnyard
Bedding, and an
untreated zeolite control were tested. A constant temperature was maintained
in the testing
facility for the duration of the tests (e.g. 70 F). About 100 g of fresh horse
manure and about 10
mL of urine were added to treated containers. After 24 hours, the Z-800
ammonia meter was
placed inside each box to make measurements at respective 5-minute intervals,
minimizing the
amount of time the container was open. The ammonia meter yielded an average
ammonia level
over the five minutes, as well as a peak ammonia level achieved during the
five minutes. After
measurements were complete, the day-old manure and urine-soaked pine bedding
were removed.
The recommended proportion of bedding treatment for wet spots plus about 100 g
fresh manure
and about 10 mL of urine were added, and each container was resealed. These
steps were
continued for 1 week to determine relative efficacy of the products. A one-
time one-hour-interval
ammonia reading was taken on each of the containers.
After 8 days, the average ammonia level readings taken over 5-minute intervals
every 24
hours showed that ammonia production was highest on the control bedding and
lowest on the
Barnyard Bedding-treated bedding (Figures 19A and 19B).
Example 10
Treatment of Calf Scours with Formula S-3
Calf Scours is a calf diarrheal disease caused primarily by viral and
bacterial infection of
the calf In some instances, scours can occur in upwards of 70% of calves in a
herd, and cause
death to 50% of the infected calves. Although there is a viral etiology to
these events, the most
common cause is one of more pathogenic bacterial strains of Escherichia coli,
followed by
strains of Cryposporidia and Salmonella.
The minimum inhibitory concentration (MIC) of S-3 to E. coli is< 0.00125 %.
Also see
Table 5, above. Accordingly, a solution of about 1% S-3 at 50 ml may be
effective to treat a calf
suffering with scours. A solution (S-X) was prepared for testing on calves
diagnosed with the
classical symptoms of scours.
94
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
The S-X formula contains the following ingredients:
Per 100 ml:
1 g glucose
1 g whey protein
0.25 g KC1
0.25 g MgSO4
0.5 gNaC1
1 ml ofS-3
Glucose and whey protein were added to provide a nutritional supplement to the
treated
animals, whereas the other salts were added to enhance the electrolyte balance
to the animal. The
S-3 component is present to inhibit and kill pathogenic bacteria.
A first test was done on 5 newly born Holstein calves not having scours in
order to learn if
the S-X solution was toxic or was producing any side effects. Each healthy
calf was administered
50 ml of the S-X solution and after 1 day, and into several weeks later, no
adverse side effects
were noted, and particularly, no signs of chemical side effects or abnormal
behavior..
Arrangements were then made to do in vivo animal testing with the S-X mixture
at a ranch
in Bozeman, Montana. Scouring animals (Angus breed) were first reported during
cold damp
weather several weeks prior. Each scoured animal had all of the symptoms
associated with this
disease. Doses for each animal were set at 50 ml per animal per treatment.
Fifteen calves authenticated as having scours were treated with 50 ml of
solution via the
oral cavity by tubing. Thirteen calves, having been treated with 1 dose,
recovered overnight.
Two animals required a second dose and recovered overnight after the second
dose. Figure 20A
shows one of the two scoured calves (tag 166) that had to receive a second 50
ml treatment of the
S-X solution (image taken prior to administration of S-X solution). Note the
large pile of
excrement in the lower right hand corner and the head and ears down and
drooped (Figure 20A).
One day after the second treatment with S-X solution, the calf was ambulatory
and free of diarrhea
(Figure 20B). The second day after the second S-X treatment, the calf was
nursing its mother.
No deaths were reported in this experiment. The ranch owners reported that the
S-X
solution was far superior to all other treatments they had used to-date.
Accordingly, S-X
solution represents a safe, fast and effective treatment of scours.
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Example 11
Livestock scours treatment
A scours treatment formula was developed that contained the S-3 formulation
plus sugar,
amino acids, sodium and potassium chloride and magnesium acetate. Many animals
having
infectious scours (caused by a pathogen) were treated. Typically, if the
infectious scours is
involved the stools are yellow to brownish to somewhat greenish. Also if a
parasite is causing
scours, the fecal matter contains blood and this is evident. If non-infectious
scours (milk scours)
is involved, the fecal matter is whitish. In this study at least two animals
had milk scours and did
not recover. Likewise, it appeared that one animal had parasitic scours and it
too did not recover.
Basically, all other animals (having viral or bacterial caused scours) did
recover when given S-X
treatments. In about 90% of the cases recovery was within 12-24 hr with signs
of recovery
occurring within 3-4 hr. In a few cases, recovery took two days requiring a
second treatment.
This is unlike any other treatment available. The material is delivered orally
via stomach tube or
syringe. Other treatments using antibiotics and nutrient electrolyte solutions
do manage to assist
the animal but recovery is not certain as is mostly the case with the S-3
treatment.
Exemplary formulation and treatment of Scours in calves
Per 90 ml of water:
1 g of glucose
1 g glycine
0.5 g ofNaC1
0.25 g KC1
0.25 g Mg acetate
1 ml of S-3 containing 0.7m1 of propanoic acid and 0.2 ml of isoamyl
hexanoates.
50 ml per animal was administered via syringe or stomach tube per treatment
and some
re-treatment was necessary if the animal did not recover in 24 hr.
Exemplary formulation and treatment of Scours in piglets
Per 90 ml of water:
96
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
1 g of glucose
1 g glycine
0.5 g ofNaC1
0.25 g KCl
0.25 g Mg acetate
0.1 gKH2PO4
2 ml of S-3 containing 0.7 ml of propanoic acid and 0.2 ml of isoamyl
hexanoates.
1-2 ml per piglet administered via a syringe.
S-X Scours Treatment Field Study
Case I -Ranch I
May 16, 2014- One calf had come down with scours on the 6th ofMay and had been
treated with Banomine and given two shots ofLA-200 9 (an anti-infectious
drug). Electrolyte
solutions were also given on a daily basis in the dosage of 1 pint; however,
the animal did not
recover and languished for 9 to 10 days with chronic scours. The S-X solution
was sent on the
morning of May 17th and the scouring calf was administered 50 ml orally by
syringe. It was
noted that the calf was dramatically improved in condition by the evening and
completely better
on the morning of May 18th. The calf showed no further signs of scours as of
May 22, 2014.
These results demonstrate that virtually all scours treatments on this animal
had failed and that it
was not in a recovery stage until the S-3 treatment was given.
Case 2 -Ranch 2
Ranch 2 experienced an influx of scouring calves and mortality in the late
winter of2014.
The S-X technology solution was provided to them, and the ranchers used the
solution for
treatment of calves via stomach tubing. Three calves were treated in this
manner. Recovery
from scours for these calves occurred within 24 hours after treatment, and
there were no other
known medications administered at the same time as the S-X treatments that
could have
contributed to recovery. Sick animals were taken into the barn and
photographed during their
recovery. One of these animals is pictured in Figure 21.
97
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Case 3 -Ranch 3
Ranch 3 experienced a particularly cold winter during the calving season,
including high
winds and a large amount of snow fall. These conditions make scouring a more
common
occurrence for calves.
S-X treatments for scouring calves were administered at this ranch from April
2 to April
24, 2014. Eleven animals were treated with 50 ml dosages using the stomach
tubing method.
Results were successful, with one dose in nine head; while one animal had to
be treated a second
time and another one needed three separate treatments. In some cases, S-X was
not the only
treatment given. Some of the animals also presented with symptoms of pneumonia
and needed
does ofB aytril, sulpha pills, or Nuflor. All animals that were treated with
the S-X solution
recovered while most (9) recovered within twenty-four hours after treatment.
Case 4 -Dairy I
May 15, 2014- Dairy 1 is a holstein dairy cow operation. This dairy houses 300
animals
whose health and everyday needs must be met. Dairy has been shown to have the
rotavirus as a
source for scours, which was noted by the veterinary center located near their
dairy. The S-X
treatment was administered to 7 young animals that had scours by oral syringe
application. All
of the animals that were given the S-X treatment recovered. All of the animals
except one
recovered within 24 hours, and one after the second treatment of S-X.
According to Dairy 1, in December of2013, 30 of their calves were lost to
scours, even
though these calves had been given multiple electrolyte treatments as well as
antibiotics.
Treatment of these calves usually took 5-7 days with multiple treatments, as
compared to the 1
day of 1-2 dosages of S-X treatments. Administration of the treatment via oral
drench was
preferred by Dairy 1 and proved to be effective.
The operator of Dairy 1 remarked, "Need more, since the stuff really works."
She was
referring to the S-X solution and their success with these treatments. The
dairy will continue
treating calf scours with the S-X technology as well as providing information
on animals that are
subsequently tested with the S-X formula.
Case 5 -Ranch 4
98
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
The S-X technology was also tested at a Hutterite swine production facility
the week of
April 14th, 2014 where hundreds of piglets were exhibiting scours. The
presence of the PED
virus in this pig population was confirmed by Newport Labs, Worthington, MN.
According to
the producer, over 850 piglets had died in the previous three weeks, which
represents nearly a
100 percent fatality in infected piglets.
The producer was interviewed about the results of his trial with the piglet
formula of the
S-X technology for use on scouring pigs on April 19, 2014. The producer noted
that on or
around the 12th of April, 2014 an 8-day old piglet with scours was
administered 6 ml of the S-X
formula orally via syringe. After 5 hours the piglet was better and the next
day there was no
evidence of scours. Furthermore, on the 15th of April, 10 piglets that were
all 14 days old showed
evidence of scouring with the classic symptom of dark yellow loose stools.
These piglets were
administered 4 ml of S-X solution orally through a syringe, and within 24
hours each animal was
completely "dry." The producer also indicated that from his previous
experiences with the
disease, he would have expected many fatalities.
Additionally, on or around April 19th 10 piglets that were 3 days old showed
signs of
scours and were given 2 ml of the S-X solution via syringe. All of these
piglets also remained
alive after several weeks. Another treatment was administered for 30 piglets
that were 3 days
old showing signs of scouring. These 30 piglets were given 3 ml of the S-X
solution and all
piglets remained alive. If the treatment had not been administered, the
producer would have
expected mortality for nearly all of these animals, based on his previous
experiences. The
producer also administered Tylan 40-50 to each of the 3 day old piglets in the
study whose
treatments were on April 15th and 19th. Tylan is an antibiotic that is used to
treat pneumonia. The
producer felt that the Tylan-40 paired with the S-X treatment was responsible
for the survival of
these young animals; however, according to professionals in the field,
antibiotics are generally
not effective against intestinal viral and bacterial infections. Although not
wishing to be bound
by any particular theory, in this case, Tylan-40 likely had no effect on the
survival of the piglets.
Since using the S-X solution to treat his piglets, the producer has not lost
any animals to
scours. Additionally, as of May 27, 2014, samples from the piglets that had
been sent to Norwalk
labs after the addition of S-X treatments confirmed that PED was no longer
present. This finding
indicates that the S-X solution is successful at treating scours in pigs at
the Harlowton colony.
99
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Furthermore, the disappearance of the PED virus from the area may be
attributed to the S-X
treatments since all piglets with scours were treated with the technology and
recovered.
Case 6- Ranch 5
Ranch 5 near the Canadian border participated in S-X treatments for scours for
their beef
cattle ranch. The temperatures during calving season were particularly low
during the past winter
with driving winds and high snow falls. The S-X solution was provided early in
April and the
first date of treatment that followed was on April 6, 2014. Twenty-one animals
were treated only
with the S-X solution for conditions of scouring and animals were treated by
stomach tube
administration of 50 ml of S-X solution. After 24 hours, 18 of the calves that
had been treated
with the S-X solution recovered from scouring; however, 3 animals needed a
dosage re-
administration. These animals soon recovered after the treatment. Of the 21
animals treated, 8
expressed symptoms of pneumonia and were given Nuflor. Recovery of animals
treated with S-
X was not related to the treatment for the incidence of pneumonia. The last
date of treatment was
on April 18, 2014. In all, approximately 85 percent of the animals treated
with the S-X
technology recovered with one dose of the solution. These results demonstrate
that S-X
technology required less time and was more effective than traditional forms of
treatment for
scouring animals.
Case 7-Ranch 6
Ranch 6 is a dairy operation that used the S-X technology as a scours
treatment in mid-
April of2014. The dairy has about 100 head ofHolstein milk cattle with various
other animals,
including beef cattle. The incidence of scours on the ranch is particularly
high and most animals
acquire scours soon after birth. The S-X formula was given to the dairy and it
was administered
to both beef calves and Holstein calves in 50 ml doses through oral syringes.
Initial treatments of the S-X formula were given to 8 calves in 50 ml doses
via syringe, 7
of which had displayed the typical creamy yellow scouring, and 1 calf (number
80) with white
pasty scouring that developed into watery scours after two days. This calfs
condition was
typical of milk scours. This particular calfwas treated with S-X well after
its symptoms had
developed, and it died 4 days later. It was suspected that this particular
calfs scours was
nutritionally caused because of the characteristics of the diarrhea, in which
case the S-X
100
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
technology would not have been effective. Most of the animals that were
treated with the S-X
solution recovered and were completely better within 24 hours; however, one
holstein calf took
48 hours to fully recover. Additionally, one beef calf (number 34 as an
untreated control) at the
ranch was noted to have scours and was not given a dose of the S-X solution
along with the other
animals and it died within two weeks. Figure 23 is a series of images showing
a calf treated with
S-X before and after treatment.
Case 8 -Ranch 7
The owners of Ranch 7 were interested in using S-X technology in the early
spring of
2014 for treating newborn calves that developed scours. The S-X solution was
given to the owners
and over the course of several weeks, calves that showed signs of scouring
were immediately
treated in the pasture with 50 ml of the S-X solution in two doses of25 ml in
an oral syringe. At
least 15 calves were treated with the S-X solution and every one of them
except for one recovered
in 24 hr. The one calf that did not recover in 24 hours had white feces that
could have been
attributed to "milk scours." This calf also had pneumonia so it was also
treated with Nuflor and a
drench. It was also administered two additional treatments of the S-X
solution. The calf did
recover from scours and is now in normal condition. The owner noted that most
of the time calves
recovered within 3 to 4 hours after treatments of the S-X solution. The owner
also commented
that improvement was recognized with the calves' stoppage of "teeth grinding,"
and in their
general increase in alertness. The owner noted that the oral syringe method of
S-X solution
treatment was very easy for her to administer dosages to the 100 lb calves.
These results
demonstrate that administration of S-X can be performed using either the
stomach tube or the
syringe method.
Case 9 -Ranch 8
Experiments on beef calves with scours took place at Ranch 8 in at an
elevation of 4,459
feet, from May 4, 2013 to May 21, 2014, concentrated in the spring of 2013 and
the winter and
spring of2014. On this ranch, 300 calves are born in the spring and 300 are
born in the fall.
One hundred and forty two distinct calves were treated with an S-X solution or
a combination of
S-X solution and other medications. The initial S-X formula was used through
January 2014,
after which an improved formula of the S-X technology scours treatment was
used.
101
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Temperatures varied from -20 F to up to 50 F in the months of February and
March. Significant
snow and winds were observed during this time period with dramatic temperature
swings reported.
A large number of calves exhibited clinical signs of scours (droopy ears,
sullen eyes, and
profuse diarrhea). These calves were given 50 mL of the S-X solution through a
stomach tube
system and checked approximately six hours later to determine if they were
recovering or if re-
administration of the drug was needed. Of the 243 calves treated, 36 were
either given only the
solution for the first or second dose or the solution plus a vitamin
supplement, while the rest
were administered standard antibiotics along with the S-X scours treatment.
Twelve of the S-X-
only treatments were administered as a second or third dose within the same
day. In all, 243
treatments included the S-X solution and 29 of those were treated either 2 or
3 times. Total
individual calf numbers that were treated with both formulae numbered 142.
Drugs that were
typically given along with the S-X treatment included: Excede (treats
respiratory infection),
probiotics, Toxiban (absorbs toxins with charcoal), Noromycin LA (antibiotic
for use on pinkeye,
foot rot, and other infections), multivitamins, Inforce 3 (a three-way
respiratory vaccine),
Draxxin (antibiotic for pinkeye, foot rot, or respiratory disease), and sulpha
tablets (sulfonamides
for anti-bacterial treatments).
The owners of Ranch 8 were interviewed on March 3, 2014 on their experiences
with the
S-X treatment for scours. Scours was first reported for the calving season on
February 27, 2014,
and 40 doses were supplied at 50 mL each. From February 27 until March 3, 15
calves with
signs of scouring had been treated with S-X technology. Thirteen of those 15
recovered
overnight after one dose, while 2 required a second dose and recovered
overnight with no
mortality in either instance. Half of the calves were treated in the pasture
with only 6 brought in
to the barn. Normal treatment for scours includes electrolytes, IV
administration of fluids, and
some antibiotics such as tetracycline.
The producers observed that some of the calves treated had pneumonia and other
medications were administered; however, it was also noted that the S-X
treatments were far
superior to other medications and credited its use with a quick and full
recovery. It was
estimated that without the S-X, one-third or more of the calves with scours
would have died.
Additional observations of the S-X treatment were that it was easy to use and
carry when
working the herd, that it was a quick treatment option and that antibiotic
treatment was not
102
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
required if the scours was caught quickly enough. Figure 24 is a series of
images showing a calf
treated with S-X before and after treatment.
Table 7 depicts the S-X treatments administered at Ranches 3, 5, and 8 without
any
additional medications given besides vitamin supplements.
Table 7: S-X Treatments without other medications
Ranch S-X Date Calf Treatment
number
8 S-1 5/4/2013 Y122 1st
8 5-1 5/4/2013 Y306B 1st
8 5-1 5/6/2013 Y350a 1st
8 5-3 2/24/2014 Y3742 1st
8 5-3* 2/27/2014 Y26262 1st
8 5-3* 2/27/2014 Y321 1st
8 5-3* 2/27/2014 Y383 1st
8 5-3 3/2/2014 R18361 1st
8 5-3 3/2/2014 Y3730 1st
8 5-3 3/2/2014 Y387 1st
8 5-3 3/3/2014 G032 1st
8 5-3 3/3/2014 Y166461 1st
8 5-3 3/3/2014 Y402 1st
8 S-3 3/4/2014 G03 2nd
8 5-3 3/4/2014 G3731 1st
8 S-3 3/4/2014 R1396 1st
8 5-3 3/4/2014 Y29092 1st
8 S-3 3/5/2014 G309 1st
8 5-3 3/5/2014 Y29902 1st
8 S-3 3/5/2014 Y3311 1st
8 S-3 3/5/2014 Y8A20 1st
8 S-3 3/6/2014 R2451 2nd
8 S-3 3/6/2014 Y163391 1st
8 S-3 3/9/2014 Y2014 2nd
8 S-3 3/12/2014 R215 1st
8 S-3 3/15/2014 Y16629 3rd
8 S-3 3/15/2014 Y2014 2nd
8 S-3 3/16/2014 R26861 2nd
8 S-3 3/16/2014 Y2062 2nd
8 S-3 3/16/2014 Y3619 1st
8 S-3 3/17/2014 Y20060 2nd
8 S-3 3/18/2014 Y3630 2nd
8 S-3 3/18/2014 Y80842 2nd
103
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
8 S-3 3/27/2014 R616 2nd
8 S-3 3/27/2014 Y411 2nd
8 S-3 3/30/2014 R616 1st
S3 4/6/2014 S16 1st
S3 4/6/2014 1122 1st
S3 4/6/2014 12SS 1st
S3 4/6/2014 8104 1st
S3 4/6/2014 9203 1st
S3 4/7/2014 7490 1st
S3 4/8/2014 173 1st
S3 4/8/2014 1241 1st
S3 4/8/2014 S416 1st
S3 4/12/2014 1203 2nd
S3 4/12/2014 2487 1st
S3 4/12/2014 2637 1st
S3 4/16/2014 1219 2nd
S3 4/18/2014 711 1st
S3 4/18/2014 1000 1st
S3 4/18/2014 1636 1st
S3 4/18/2014 k23 1st
3 S-X 4/18/2014 2431 1st
* Received multivitamin supplement
Table 8 depicts all S-X treatments given regardless of whether any additional
medications
were administered for Ranches 3, S, and 8.
Table 8: All S-X treatments
Treatment
Ranch S-X Date Calf
Additional Medication
number
8 S-1 S/4/2013 Y122 1st
8 S-1 S/4/2013 Y306B 1st
8 5-1 S/6/2013 Y3S0a 1st
8 5-1 S/IS/2013 Y163 1st Noromycin LA, Toxi
Ban, Nas
8 5-1 S/IS/2013 Y169 1st Noromycin LA
8 5-1 S/IS/2013 Y33 S 1 1st Noromycin LA
8 5-1 S/18/2013 R22326 1st Noromycin LA
8 5-1 5/18/2013 Y169 1st Noromycin LA
8 5-1 S/18/2013 Y3351 1st Noromycin LA
8 5-1 S/29/2013 Y2886 1st Noromycin LA,
Toxi Ban
8 5-1 10/21/2013 Y311 1st Excede Sec
8 5-1 10/23/2013 R287 1st Noromycin LA Sec
8 5-1 10/25/2013 R325 1st Noromycin LA Sec
104
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
8 S-1 10/25/2013 Y238 1st Noromycin LA Sec
8 S-3 2/23/2014 G309 1st Noromycin LA Sec, Toxi
Ban, sulpha
8 S-3 2/23/2014 Y124981 1st Noromycin LA Sec, Toxi Ban,
sulpha
8 S-3 2/23/2014 Y14146 1st Noromycin LA Sec,
Toxi Ban, sulpha
8 5-3 2/23/2014 Y17739 1st Noromycin LA Sec,
Toxi Ban, sulpha
8 S-3 2/23/2014 Y36192 1st Noromycin LA Sec,
Toxi Ban, sulpha
8 S-3 2/23/2014 Y3742 1st Noromycin LA Sec, Toxi
Ban, sulpha
8 S-3 2/23/2014 Y405 1st Noromycin LA Sec, Toxi
Ban, sulpha
8 S-3 2/23/2014 Y420 1st Noromycin LA Sec, Toxi
Ban, sulpha
8 S-3 2/24/2014 Y3742 1st
8 S-3 2/27/2014 Y26262 1st Multivitamin
8 S-3 2/27/2014 Y321 1st Multivitamin
8 S-3 2/27/2014 Y336 1st Noromycin LA,
multivitamin
8 S-3 2/27/2014 Y383 1st multivitamin
8 S-3 2/27/2014 Y422 1st
8 S-3 3/2/2014 R18361 1st
8 S-3 3/2/2014 Y3730 1st
8 S-3 3/2/2014 Y387 1st
8 S-3 3/3/2014 G032 1st
8 S-3 3/3/2014 Y166461 2nd
8 S-3 3/3/2014 Y1883S2 1st Noromycin LA, Toxi
Ban, multivitamin
8 S-3 3/3/2014 Y402 1st
8 S-3 3/4/2014 G03 1st Noromycin LA, Toxi Ban,
multivitamin
8 S-3 3/4/2014 G03 2nd
8 S-3 3/4/2014 G3731 1st
8 S-3 3/4/2014 R1396 1st
8 S-3 3/4/2014 Y29092 1st
8 S-3 3/4/2014 Y389 1st Noromycin LA, Toxi Ban
8 S-3 3/5/2014 G309 1st
8 S-3 3/5/2014 Y29902 1st
8 S-3 3/5/2014 Y3311 1st
8 S-3 3/5/2014 Y3779 1st Toxi Ban
8 S-3 3/5/2014 Y8A20 1st
8 S-3 3/6/2014 GOS61 1st Toxi Ban
8 S-3 3/6/2014 G3731 1st Noromycin LA, Toxi Ban
8 S-3 3/6/2014 R1396 1st Noromycin LA, Toxi Ban
8 S-3 3/6/2014 R2451 1st Noromycin LA, Toxi Ban
8 5-3 3/6/2014 R2451 2nd
8 5-3 3/6/2014 R2456 1st Toxi Ban
8 S-3 3/6/2014 Y163391 1st
8 S-3 3/6/2014 Y2025 1 1st Toxi Ban
8 S-3 3/6/2014 Y3859 1st Noromycin LA, Toxi Ban
8 S-3 3/6/2014 Y408 1st Toxi Ban
105
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
8 S-3 3/7/2014 G03 1st Noromycin LA Sec
8 S-3 3/7/2014 G522 1st Noromycin LA Sec
8 S-3 3/7/2014 R22519 1st Noromycin LA Sec
8 S-3 3/7/2014 Y16131 1st Noromycin LA Sec
8 S-3 3/7/2014 Y1951 1st Noromycin LA Sec
8 S-3 3/7/2014 Y29961 1st Noromycin LA Sec
8 S-3 3/7/2014 Y29962 1st Noromycin LA Sec
8 S-3 3/7/2014 Y3779 1st Noromycin LA Sec
8 S-3 3/8/2014 R2451 1st Noromycin LA Sec
8 S-3 3/8/2014 Y28869 1st Noromycin LA Sec
8 S-3 3/8/2014 Y29962 1st Excede 3cc
8 S-3 3/9/2014 G235 1st Noromycin LA Sec
8 S-3 3/9/2014 R139S 1 1st Noromycin LA Sec
8 S-3 3/9/2014 Y163391 1st Noromycin LA Sec
8 S-3 3/9/2014 Y1954 1st Excede 3cc
8 S-3 3/9/2014 Y2014 2nd
8 S-3 3/9/2014 Y2014 1st Noromycin LA Sec
8 S-3 3/9/2014 Y2220 1st Noromycin LA Sec
8 S-3 3/9/2014 Y3016 1st Noromycin LA Sec
8 S-3 3/9/2014 Y3042 1st Noromycin LA Sec
8 S-3 3/9/2014 Y3562 1st Noromycin LA Sec
8 S-3 3/10/2014 Y166461 1st Toxi Ban
8 S-3 3/10/2014 Y19S41 1st Noromycin LA Sec
8 S-3 3/10/2014 Y2366 1st Noromycin LA Sec
8 S-3 3/10/2014 Y28392 1st Toxi Ban
8 S-3 3/10/2014 Y2985 1st Noromycin LA
8 S-3 3/10/2014 Y3630 1st Noromycin LA
8 S-3 3/10/2014 Y365 1st Noromycin LA
8 S-3 3/10/2014 Y401 1st Noromycin LA Sec
8 S-3 3/11/2014 R2391 1st Noromycin LA
8 S-3 3/11/2014 Y2014 1st Noromycin LA Sec
8 S-3 3/11/2014 Y2162 1st Excede 3cc
8 S-3 3/11/2014 Y2985 1st Noromycin LA Sec
8 S-3 3/11/2014 Y2985 1st Noromycin LA Sec
8 S-3 3/11/2014 Y3042 1st Excede 3cc
8 S-3 3/12/2014 R215 1st
8 S-3 3/12/2014 Y19349 1st Noromycin LA Sec
8 S-3 3/12/2014 Y2116 1st Excede
8 S-3 3/12/2014 Y2366 1st Excede Sec
8 S-3 3/12/2014 Y2985 1st Excede
8 S-3 3/12/2014 Y29962 1st Noromycin LA Sec
8 S-3 3/12/2014 Y3630 1st Excede Sec
8 S-3 3/12/2014 Y646S9 1st Noromycin LA Sec
106
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
8 S-3 3/13/2014 G3731 1st Noromycin LA Sec
8 S-3 3/13/2014 R215 1st Excede Sec, Toxi Ban
8 S-3 3/13/2014 Y16629 1st Noromycin LA Sec
8 S-3 3/13/2014 Y19349 1st Noromycin LA Sec
8 S-3 3/13/2014 Y28392 1st Excede
8 S-3 3/14/2014 Y1106 1st Noromycin LA Sec
8 S-3 3/14/2014 Y16629 1st Excede 3cc
8 S-3 3/14/2014 Y2951 1st Noromycin LA Sec
8 S-3 3/IS/2014 R26861 1st Noromycin LA
8 S-3 3/IS/2014 R2902 1st Noromycin LA Sec
8 S-3 3/IS/2014 Y16629 3rd
8 S-3 3/IS/2014 Y2014 1st Noromycin LA
8 S-3 3/IS/2014 Y2014 2nd
8 S-3 3/IS/2014 Y2366 1st EX
8 S-3 3/IS/2014 Y28392 1st Noromycin LA Sec
8 S-3 3/IS/2014 Y2985 1st Draxxen
8 S-3 3/IS/2014 Y356 1st Noromycin LA
8 S-3 3/IS/2014 Y3619 1st Noromycin LA
8 S-3 3/16/2014 R21441 1st Noromycin LA Sec, Toxi Ban
8 S-3 3/16/2014 R26861 2nd
8 S-3 3/16/2014 Y2062 2nd
8 S-3 3/16/2014 Y2062 1st Noromycin LA Sec
8 S-3 3/16/2014 Y2382 1st Noromycin LA Sec
8 S-3 3/16/2014 Y264 1st Noromycin LA Sec
8 S-3 3/16/2014 Y3619 1st
8 S-3 3/17/2014 G235 1st Noromycin LA Sec
8 S-3 3/17/2014 G3731 1st Noromycin LA Sec
8 S-3 3/17/2014 R139S 1 1st Noromycin LA Sec
8 S-3 3/17/2014 R317 1st Noromycin LA Sec
8 S-3 3/17/2014 Y20060 2nd
8 S-3 3/17/2014 Y20060 1st Noromycin LA Sec
8 S-3 3/17/2014 Y2116 1st Noromycin LA Sec
8 S-3 3/17/2014 Y2382 2nd Noromycin LA Sec
8 S-3 3/17/2014 Y264 1st Noromycin LA Sec
8 S-3 3/17/2014 Y2951 1st Noromycin LA Sec
8 S-3 3/17/2014 Y3630 1st Noromycin LA Sec
8 S-3 3/17/2014 Y80842 1st Noromycin LA Sec
8 S-3 3/18/2014 G34491 1st Noromycin LA Sec
8 S-3 3/18/2014 G4335 1st Noromycin LA Sec
8 S-3 3/18/2014 Y3630 2nd
8 S-3 3/18/2014 Y646S9 1st Noromycin LA Sec
8 S-3 3/18/2014 Y80842 2nd
8 S-3 3/19/2014 R215 1st Noromycin LA Sec
107
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
8 S-3 3/19/2014 R29092 1st Noromycin LA Sec
8 S-3 3/19/2014 Y2382 3rd Noromycin LA Sec
8 S-3 3/19/2014 Y2951 1st Noromycin LA Sec
8 S-3 3/19/2014 Y2985 1st Noromycin LA Sec
8 S-3 3/19/2014 Y3619 1st Noromycin LA Sec
8 S-3 3/19/2014 Y64659 2nd Noromycin LA Sec
8 S-3 3/19/2014 Y80842 3rd Excede 3cc
8 S-3 3/20/2014 Y2951 1st Noromycin LA Sec
8 S-3 3/20/2014 Y411 1st Noromycin LA Sec
8 S-3 3/20/2014 Y80B42 1st Excede 3cc
8 S-3 3/22/2014 R616 1st Noromycin LA Sec
8 S-3 3/22/2014 Y411 3rd Excede 3cc
8 S-3 3/23/2014 R20016 1st Noromycin LA Sec
8 S-3 3/23/2014 R616 2nd Noromycin LA Sec
8 S-3 3/23/2014 Y2382 1st Noromycin LA Sec
8 S-3 3/23/2014 Y2951 1st Noromycin LA Sec
8 S-3 3/24/2014 R1836 1st Noromycin LA Sec
8 S-3 3/24/2014 R29092 1st Noromycin LA Sec
8 S-3 3/24/2014 R616 3rd Noromycin LA Sec
8 S-3 3/24/2014 Y10651 1st Draxxen, Inforce 3
8 S-3 3/24/2014 Y321 1st Draxxen, Inforce 3
8 S-3 3/24/2014 Y3619 1st Noromycin LA Sec
8 S-3 3/24/2014 Y411 1st Noromycin LA Sec
8 S-3 3/2S/2014 R1836 2nd Noromycin LA Sec
8 5-3* 3/2S/2014 R290 1st Draxxen, sulpha
8 S-3 3/2S/2014 R29092 1st Noromycin LA Sec
8 S-3 3/2S/2014 Y298S2 1st Noromycin LA Sec
8 S-3 3/2S/2014 Y3619 2nd Noromycin LA Sec
8 5-3* 3/2S/2014 Y368 1st Draxxen, sulpha
8 5-3* 3/2S/2014 Y3742 1st Draxxen, sulpha
8 5-3* 3/2S/2014 Y3862 1st Draxxen, sulpha
8 5-3* 3/26/2014 G1310 1st Draxxen, sulpha
8 5-3* 3/26/2014 R239 1st Draxxen, sulpha
8 5-3* 3/26/2014 R239 2nd Draxxen, sulpha
8 5-3* 3/26/2014 R3000 1st Draxxen, sulpha
8 5-3* 3/26/2014 R3041 1st Draxxen, sulpha
8 5-3* 3/26/2014 Y1606 1st Draxxen, sulpha
8 5-3* 3/26/2014 Y20142 1st Draxxen, sulpha
8 S-3 3/26/2014 Y259 1st Noromycin LA Sec
8 5-3* 3/26/2014 Y28869 1st Draxxen, sulpha
8 5-3* 3/26/2014 Y29062 1st Draxxen, sulpha
8 5-3* 3/26/2014 Y30162 2nd Draxxen, sulpha
8 5-3* 3/26/2014 Y30162 1st Draxxen, sulpha
108
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
8 S-3* 3/26/2014 Y331 1st Draxxen, sulpha
8 S-3 3/26/2014 Y3619 3rd Noromycin LA Sec
8 S-3 3/27/2014 R1836 1st Noromycin LA Sec
8 S-3 3/27/2014 R616 1st Noromycin LA Sec
8 S-3 3/27/2014 R616 2nd
8 S-3 3/27/2014 R8461 1st Draxxen, sulpha
8 S-3 3/27/2014 Y411 1st Noromycin LA Sec
8 S-3 3/27/2014 Y411 1st
8 5-3* 3/28/2014 Y1361 1st Draxxen, sulpha
8 5-3* 3/28/2014 Y1606 1st Draxxen, sulpha
8 S-3 3/28/2014 Y266962 1st Noromycin LA Sec
8 5-3* 3/29/2014 G1310 1st Draxxen, sulpha
8 5-3* 3/29/2014 R2028 1st Draxxen, sulpha
8 5-3* 3/29/2014 Y16932 1st Draxxen, sulpha
8 5-3* 3/29/2014 Y18835 1st Draxxen, sulpha
8 5-3* 3/29/2014 Y3590 1st Draxxen, sulpha
8 5-3* 3/30/2014 G3060 1st Draxxen, sulpha
8 S-3 3/30/2014 R616 1st
8 5-3* 3/30/2014 Y166461 1st Draxxen, sulpha
8 5-3* 3/30/2014 Y2116 1st Draxxen, sulpha
8 S-3 3/30/2014 Y259 1st Noromycin LA Sec
8 5-3* 3/31/2014 G131 1st Draxxen, sulpha
8 5-3* 3/31/2014 GSOS2 1st Draxxen, sulpha
8 S-3 3/31/2014 G57 1st Noromycin LA Sec
8 S-3 3/31/2014 R3691 1st Noromycin LA Sec
8 S-3 3/31/2014 Y1124 1st Noromycin LA Sec
8 5-3* 3/31/2014 Y119 1st Draxxen, sulpha
8 S-3 3/31/2014 Y26682 1st Noromycin LA Sec
8 5-3* 3/31/2014 Y2839 1st Draxxen, sulpha
8 5-3* 3/31/2014 Y36192 1st Draxxen, sulpha
8 5-3* 3/31/2014 Y365 1st Draxxen, sulpha
8 5-3* 3/31/2014 Y384 1st Draxxen, sulpha
8 S-3 3/31/2014 Y386 1st Noromycin LA Sec
8 S-3 3/31/2014 Y424 1st Noromycin LA Sec
8 5-3* 4/1/2014 B139S 1st Draxxen, sulpha
8 5-3* 4/1/2014 G5052 2nd Draxxen, sulpha
8 S-3 4/1/2014 Y1126 2nd Noromycin LA Sec
8 S-3 4/1/2014 Y2446 1st Noromycin LA Sec
8 S-3 4/1/2014 Y266962 2nd Noromycin LA Sec
8 S-3 4/1/2014 Y298S2 1st Noromycin LA Sec
8 5-3* 4/1/2014 Y3279 1st Draxxen, sulpha
8 5-3* 4/1/2014 Y3412 1st Draxxen, sulpha
8 5-3* 4/1/2014 Y43 1st Draxxen, sulpha
109
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
8 S-3* 4/1/2014 YS92 1st Draxxen, sulpha
8 S-3* 4/2/2014 Y17739 1st Draxxen
8 S-3* 4/2/2014 Y26262 1st Draxxen, sulpha
8 S-3 4/2/2014 Y298S2 2nd Noromycin LA Sec
8 5-3* 4/2/2014 Y399 1st Draxxen, sulpha
8 5-3* 4/3/2014 Y121242 1st Draxxen
8 5-3* 4/3/2014 Y16936 1st Draxxen
8 S-3* 4/3/2014 Y411 1st Draxxen
8 S-3 S/21/2014 G34491 1st Noromycin LA Sec
8 S-3 5/21/2014 R1836 1st Noromycin LA Sec
8 S-3 5/21/2014 R20016 1st Noromycin LA Sec
8 S-3 5/21/2014 R2616 1st Noromycin LA Sec
8 S-3 5/21/2014 R29092 1st Excede 3cc
8 S-3 5/21/2014 Y411 2nd Noromycin LA Sec
8 S-3 5/21/2014 Y5861 1st Noromycin LA Sec
S S3 4/6/2014 8104 1st
S S3 4/6/2014 9203 1st
S S3 4/6/2014 1122 1st
S S3 4/6/2014 S16 1st
S S3 4/6/2014 12SS 1st
S S3 4/7/2014 12SS 2nd Nuflor
S S3 4/7/2014 7490 1st
S S3 4/8/2014 1203 1st Nuflor
S S3 4/8/2014 1241 1st
S S3 4/8/2014 S416 1st
S S3 4/8/2014 173 1st
S S3 4/12/2014 2363 1st Nuflor
S S3 4/12/2014 9203 1st Nuflor
S S3 4/12/2014 1203 2nd
S S3 4/12/2014 2637 1st
S S3 4/12/2014 2487 1st
S S3 4/12/2014 2763 1st Nuflor
S S3 4/14/2014 1219 1st Nuflor
S S3 4/16/2014 1219 2nd
S S3 4/18/2014 1000 1st
S S3 4/18/2014 1636 1st
S S3 4/18/2014 k23 1st
S S3 4/18/2014 711 1st
3 S-X 4/8/2014 2012 1st Drench
3 S-X 4/18/2014 Y273 1st Drench, Baytril
3 S-X 4/18/2014 2431 1st
3 S-X 4/18/2014 Y177 1st Baytril
3 S-X 4/22/2014 Y82 1st Drench, Baytril
110
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
3 S-X 4/23/2014 Y273 1st Suprio
3 S-X 4/24/2014 2811 1st Drench, Nuflor
3 S-X 4/24/2014 wi 1st Drench, Nuflor, sulpha
3 S-X 4/24/2014 1100 1st Baytril
3 S-X 4/25/2014 841 1st Drench
3 S-X 4/25/2014 longhorn 1st Drench
3 S-X 4/25/2014 452 1st Drench, Nuflor
*indicates S-X treatment through nasal passages (2cc)
Example 12
Animal mastitis treatment
The problem of mastitis in the mammary glands in animals is typically caused
by
infections brought about by E. coli or Staphyloccous aureus and other
bacterial pathogens. The
teat becomes inflamed and eventually the condition can spread to all other
sectors of the
mammary gland. Milk production ceases. If untreated, the animal can die. Most
antibiotic
treatments are expensive and ineffective. In the past three months, a yew lamb
and two dairy cows
suffering with mastitis were treated with 15 mL per teat of the mastitis
treatment solution. Figure
25A depicts a teat of a sheep suffering from mastitis. The treated animal was
well developed in
terms of the disease and it did not die but remains healthy. The mammary gland
has ceased
functioning. The S-3 formula was administered via syringe (Figure 25B). Two
cows suffering
with mastitis were in the earlier stages of this disease. Each was treated
with 15 ml per infected
teat and total recovery was noted within 24 hr.
Exemplary formulation and treatment for mastitis of farm animals
Per 90 ml of water:
mg of cremophor or other appropriate surfactant
0.7 ml of propanoic acid and 0.2 ml of isoamyl hexanoates
The formulation was shaken well and administered to a cow up to 15 ml per teat
with a
syringe. The cremophor acts to bring the ingredients of the S-3 formulation
into solution.
Example 13
M/C testing of 5-3 and 5-4 formulations
111
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
MIC Protocol for testing S-3 and S-4
Turbid bacterial cultures grown in the appropriate nutrient broth medium were
adjusted to
OD6so = 0.4 and subsequently diluted 1:100 in broth, representing a
concentration of 1x106
CFU/ml. 50 111 of this culture were added to each well except the negative
control, in which 50 111
broth was added. The final amount of bacteria in each well was 5x106 CFU.
20 111 stock B-23 antibiotic solution was added to 480 111 broth. 250 111 of
this solution was
diluted 1:2. This was repeated twice to form four progressively diluted
antibiotic solutions.
Dilutions are such that final concentrations of the antibiotic in the
appropriate wells were equal
to 1%, 0.5%, 0.25%, and 0.125% ofthe stockB-23 antibiotic solution.
A 96-well microtiter plate was used. 6 total treatments were plated: 1%, 0.5%,
0.25%,
0.125%, 0.061%, 0.03% and 0% antibiotic with bacterial inoculum; and no
bacterial inoculum.
Each treatment was plated in triplicate.
Broth was added to each well to reach a final volume of 200 111. In wells
without bacterial
inoculum or antibiotic solution, an additional 50 111 broth was added.
MIC plates were incubated at appropriate growth conditions to the time points
recorded
on result tables. End points were chosen when the positive control well was
turbid.
The MIC point was taken as the lowest concentration at which no growth was
evident.
Results
The MICs were as follows for the following organisms:
Bacillus subtilis: 0.06125% Vibrio
cholerae: 0.06125% Pseudomonas
aeruginosa: 0.125%
Salmonella enterica serovar Typhimurium: 0.06125%
Escherichia coli: 0.125%
Methicillin-resistant Staphylococcus aureus: 0.06125%
For other MIC tests -Potato dextrose broth was used instead of nutrient broth
and the
tests were done in the same manner. The results were:
Erwinia amylovora: 0.0612%
Lactobacillus sp.: 0.0625%
112
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Erwinia carotovora: 0.125%
The results demonstrate that the S-3 and S-4 are useful for the treatment of
diseases in
plants, animals and humans caused by microorganisms. These diseases include
plant diseases
caused by Erwinia and the problem in grain fermentation to produce ethanol
caused by
Lactobacillus spp. biofilms produced by Pseudomonas. Additional diseases
include food
ailments caused by Salmonella, E. coli and general major diseases caused by
MRS A.
Example 14
Raspberry treatments
The results described herein demonstrate that the S-X technology is useful for
the
preservation of fruit and vegetables during shipment and storage. The S-3
formula was mixed to
form two formulations: 1 ml of S-3 per 10 g of bentonite (the 1:10 mixture); 1
ml of S-3 to 20 g
bentonite (the 1:20 mixture) or other carrier. 1 gram of the mixture was
placed in a small plastic
cup in the presence of store purchased raspberries. The materials were placed
in a small clear
plastic box, which was sealed and held at room temperature for 1 week,
followed by examination
for the presence of contaminating fungi. The results demonstrate that the
normal flora of the fruit
quickly brings about its decay after 1 week at room temperature (Figure 26A).
However, use of
the 1:10 mixture resulted in no decay (Figure 26B). However, the 1:20 mixture
did not perform
quite as well as the 1:10 mixture, as at least 1 berry showed decay.
Nonetheless, the 1:20 mixture
was useful for preventing decay in the berries, and the treated berries were
edible. A similar
experiment was conducted with store purchased Thompson delicious grapes and
the results were
similar, wherein the control grapes were observed to show decay, while the
treated grapes were
not decayed. The grapes were also edible, as 4 people ate them and provided an
evaluation of their
acceptability.
Example 15
Treatment of food poisoning and/or stomach flu in humans using S-X
The symptoms and conditions of food poisoning and/or stomach flu in humans re
similar
to those occurring in animals suffering with scours. For example, possible
symptoms include:
abdominal cramps, diarrhea (may be bloody), fever and chills, headache,
nausea, vomiting, and
weakness (may be serious). Most people simply suffer through the experience
(12-48 hr) by
113
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
doing their best to rest, and drink replacement fluids and minerals being lost
through diarrhea
and vomiting. It appears that no product is available that provides instant
relief
However, in ten volunteers suffering with one or more of these symptoms, at
least 10-15
ml of a 1 A) S-3 formula was taken orally at the onset of symptoms or within
a few hours of the
appearance of symptoms. In all cases, the patients described feeling better
within one to two
hours after treatment. Fever, stomach pain, diarrhea and vomiting all ceased,
and the patients
fully recovered. All patients were adults, white and represented both male and
female classes.
One patient, however reported that there was no difference noted in the
stomach condition after
taking a 10 ml dose of a 1 A) S-3 formula. Although not wishing to be bound
by any particular
theory, it is suspected that the patient was experiencing a viral induced
stomach infection that
would not have responded to S-X treatment. Nevertheless, the fact that 90% of
the people treated
having such an immediate and complete recovery, combined with all of the
animal studies on
scouring, supports the hypothesis that the S-3 is useful for treating humans
suffering from
stomach flu and stomach poisoning caused by bacteria. This hypothesis is
further supported by
the impressive MIC values of S-3 against E coli and S. aureus, which are two
known causal
agents of food poisoning in people (Example 13).
Example 16
Mastitis in dairy cattle and the S-X technology
Treatment:
A formula containing 2% of the S-3 formulation in the presence of 5 mg of
cremophor (a
non- ionic solubilizer) in pure water is thoroughly mixed and is used as the
treatment agent.
Eight dairy cattle suffering with preclinical to sub-clinical mastitis were
treated with 12 ml of the
formula per teat. In seven cases the treatment was repeated during the course
of one day. In all
cases the animals were fully recovered the following day. Although not wishing
to be bound by
any particular theory, the recovery of the animals is likely due to the fact
that the common
bacterial causes of mastitis, such as E. coli and S. aureus, are organisms
that are extremely
sensitive to the S-X formulations described herein (see Example 13.)
Example 17
S-3 Detergent Testing
114
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407
PCT/US2019/053604
Several detergents that were obtained through sample orders were tested with
the S-3
solution for effectiveness on surfaces that are notoriously ridden with a
variety of pathogens.
These surfaces included a laboratory floor, and the women's bathroom floor,
toilet bowl, and
door handle. For the floor testing, about 5 ml of each of the detergent
solutions (with 1 ml of S-3
per 100 ml of deionized water) was poured on different sections of the floor
and wiped dry with
a paper towel. When this section of the floor was dried then it was wiped with
a Kimwipe and
this was then wiped across the surface of a potato dextrose broth petri plate.
For the toilet bowl
testing, a paper towel was wet with the detergent solutions and a section of
the surface was
wiped. Kimwipes were used again once the surface dried and further streaked
across a potato
dextrose broth plate. The procedure for the door handle was the same as that
for the sink except
only one of the detergents was tested along with a control. The results are
depicted in Tables 9
and 10 below.
Table 9: Laboratory floor results
Experiment 1 Experiment 2
Amount of detergent Number of Colonies Number of Colonies
Control 22 23
Sucragel CF 1 milliliter 1 0
Chemoxide CAW 2 milliliter 1 2
BioSoft D40 0.5 milliliter 0 3
Lathanol LAL 1 gram 2 1
BioTerge AS-40 1 milliliter 1 2
Nacconol 90G 1 gram 1 4
Potassium cocoate 2 milliliter 1 1
Table 9 shows the number ofbactenal or fungal colomes that grew on potato
dextrose broth
plates that were streaked from samples wiped with the various detergents or
with just the
Kimwipe as a control after 48 hours. One milliliter of S-3 was used per 100
milliliters of
deionized water.
Table 10: Detergent Testing in Women's Bathroom
Amount of Floor Colonies Toilet Bowl Door Handle
detergent Colonies
Colonies
Control 12 6 2
Sucragel CF 1 milliliter 1 0 0
Chemoxide CAW 2 milliliter 0 1
BioSoft D40 0.5 milliliter 0 0
Lathanol LAL 1 gram 2 16
BioTerge AS-40 1 milliliter 4 21
Potassium cocoate 1 gram 0 4
115
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
Nacconol 90G I 2 milliliter 1 I 0
Table 10 shows the results from women's bathroom testing on a variety of
surfaces (floor, toilet
bowl, and door handle), and the number of bacterial or fungal colonies swiped
from the surfaces
with a Kimwipe that grew after 48 hours on a potato dextrose broth plate.
Example 18
Verticillium Experiment
Thirty pea seeds were inoculated with Verticillium sp. after being placed on a
petri dish
growing the fungus. The seeds were rolled around liberally and then samples of
the fungus were
scraped up and placed with the pea seeds in a petri dish that was sealed with
parafilm and left for
three days. After the three days had passed, potato dextrose agar plates with
sterilized caps
placed in their centers were either filled with 50 microliters of S-3, 20
microliters of S-3, or left
empty as a control. Ten pea seeds from the inoculated group were placed in
each of the three
petri dishes containing potato dextrose agar, and filled or unfilled caps. The
peas were left for
two days and then checked for fungal growth and germination. The results of
the experiment are
depicted in Table 11.
Table 11: Verticillium Inoculated Pea seeds
Treatment Percent with Fungal Growth
Control 100
20 microliters S-3 0
50 microliters S-3 0
The percent of pea seeds inoculated with Verticillium sp. that germinated and
showed fungal
growth after 48 hours in the control (no S-3), with 20 microliters S-3, and
with 50 microliters 5-
3.
Example 19
Camelina Experiment
Camelina seeds known to be contaminated with various fungal and bacterial
pathogens
were taken and placed with S3 to see if fungal and bacterial growth could be
halted. Several
potato dextrose broth plates were obtained along with caps for S-3 placement.
About forty seeds
were placed on one of the plates and an empty, sterilized cap was placed in
the center as the
control group. This plate was parafilmed and left for two days to determine
germination and
fungal and bacterial growth. Over one hundred seeds were placed on another
petri dish with a
116
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
sterilized cap filled with 50 microliters of S-3. These seeds were left to sit
with the S-3 in a
tightly parafilmed dish for the following hourly intervals, at which point
twenty to thirty seeds
were taken out and plated individually on a dish: 1 hours, 2 hours, 4 hours, 8
hours, 16 hours, 24
hours, and 48 hours. For each of the intervals, the plates were left for 48
hours and then checked
for germination and pathogen growth.
Table 12: Camelina Seeds Germination and Pathogen Growth
Seeds Per Plate Percent Germinated Percent with
Pathogen
Growth
Control 39 100 56
50 microliters S-3:
1 Hour 29 97 45
2Hour 25 96 40
4Hour 22 100 9
Table 12 shows the number of infected camelina seeds' percent germination and
percent with
pathogen growth that were either plated with no S-3 (control), or plated with
50 microliters of S-
3 at hourly intervals. All samples were recorded 48 hours after being put on
potato dextrose
broth plates.
FURTHER DEVELOPMENTS
The combination of acid(s) with esters discussed above, including without
limitation
specifically the various combinations of propanoic acid and/or isobutyric acid
combined with isoamyl
hexanoates, provide unexpected degrees of antibacterial activity. In
particular, five specific exemplary
formulations, designated as 5-1 to S-5, or generally as S-X, demonstrated
varying degrees of efficacy
for various purposes and/or in various products. We refer to these various
formulations, including but
not limited to the 5-1 to 5-5 formulations, generally as "Sx" formulations or
as embodying the "Sx
technology".
The Sx technology involves a combination of particular small molecular weight
organic acid or
acids and a more complex ester or mixture of esters that, combined,
demonstrate impressive
antimicrobial activities. Also, because the ingredients are produced from
natural sources they have the
possibility to be prepared and registered as "organic" for that ever large and
expanding market.
The initial uses of the Sx technology are for the treatment of scours in
cattle and other animals.
Products including the Sx technology are also now found to be useful in myriad
other ways, for use in
methods and products designed to control a wide range of microbes that may be
present in various
human endeavors, or otherwise relate to various human and animal activities
and health.
Many of these uses are applicable to humans, livestock, companion pets,
various other
117
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
mammals, birds, and fish, as well as pre-post harvest for vegetables, fruit,
and crops, and other food,
and feed. Such uses include antifungal, antibacterial, antiprotozoal, and
antiparasitic effect, including
for treatment or prevention of pathogenic and wound infections, used as
antiseptic or sterilization
methods including pre- and/or post-operative wounds, cuts, abrasions, etc.
Treatments and preventions
include for diarrhea; lung infections; chronic conditions of the GI tract or
bowel; vaginal infections;
reproductive tract infections; ear, eye, nasal, and oral infections; finger or
toe fungal infections;
pimples; canker sores; .
Formulations can include any form typically used for treatments, including
without limitation
creams, rinses, oils, scrubs, sprays, ointments, shampoos, gels, plasters,
liquids, dips, salve, ear rinse,
powders, eyewash, mouthwash, gas, etc.
Pathogens to be treated include without limitation E. coli, salmonella, Staph
aureus, Listeria,
Clostridium, cryptosporidium, giardia, worms, strongyles, etc. Worms that may
be treated include, for
example, the following:
- Small Redworms (Cyathostomin spp.)
- Roundworms (Parascaris equorum)
- Pinworms (Oxyuris equi)
- Threadworms (Strongyloides westeri)
- Tapeworms (Anoplocephala spp.)
- Lungworms (Dictyocaulus amfieldi)
- Bots (Gastrophilus)
Human and Related Uses
The presently discussed antimicrobial compositions may be used on human in
place of
commonly used antibiotics. As has been previously discussed, the present
antimicrobial composition
provides the benefits of commonly used antibiotics without the negative such
as bacterial resistance.
Mouth wash
Mouths of humans have many pockets and crevasses between the teeth and gums
which may
trap food particles and act as breed ground for harmful microbes. The damp
nature of the mouth in
conjunction with the constant expose to food may result in an overgrowth of
the harmful microbes. As
a result, the microbe may cause gum infections, plaque buildup, dental caries,
and a multitude of other
problems.
The present antimicrobial composition may be provided in a mouth rinse to
combat the harmful
microbes in the mouth of a human. The rinse may be a liquid containing the
present microbial
composition as well as a flavoring such as artificial mint or fruit. In some
embodiments, the mouth
wash product may be formulated for dentists to administer in a professional
environment. Alternatively,
118
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
the mouth wash product may be formulated as an over the counter, consumer
rinse which may be
administer similar to presently known mouthwashes. In some embodiments, the
rinse may include a
base liquid such as water, one or more of the presently discussed
antimicrobial compositions, and a
flavoring composition.
Antibacterial Wound Treatment
One or more of the present antimicrobial composition may be provided in a
cream, serum, or
other topical formulation for application to wounds, sores, or other injuries
to the skin or mucus
membranes of a human. The cream may be an emulsion including a viscus base
material, the present
antimicrobial composition, additional medication composition such as numbing
agents, and other
biologically active substance such as vitamins, minerals, and proteins. In
some embodiments the cream
may be used to treat drug resistant bacterial strains such as S. aureus which
are not responding to
common antibacterial treatments. The present antimicrobial composition may be
applied to bone or
other tissue within the body to break bacterial biofilms that may have
developed for preventing or
treating sepsis.
Fungal Infection
The present antimicrobial compositions may be used as an antifungal treatment.
Nails, feet, and
the crotch area are the areas of the human body most susceptible to fungal
growth. These areas are also
typically sensitive and respond poorly to heavily medicated ointments. An
ointment containing a
concentrated amount of the present antimicrobial composition may be provided
to treat these area with
less irritation.
The present antimicrobial composition may be used to treat infection caused by
Candida
albicans. AIDS patients frequently experience fungal infections caused by this
strain of fungus which
may be combatted using treatments containing the present antimicrobial
composition. In addition, the
female uterus is also susceptible to infections caused by Candida albicans
what may be treated using
the present antimicrobial composition.
It is within the scope of the present disclosure to provide the present
antimicrobial composition
in sprays, gels, pads, liquids, and bandages. Additionally, the composition
may be used on implants.
For examples, the coating on a durable implant may include the composition or
a biodegradable
implant may have the present composition dispersed throughout. The present
antimicrobial composition
may be provided in form for treating, the nose, mouth, eyes, ears, and/or
rectum of a human.
In addition to use on the human body, the present antimicrobial composition
may be used to
provide an antimicrobial environment around the human body. Accordingly, the
present antimicrobial
formulation may be incorporated into cleaning products not designed for
application to humans. For
example, the present composition may be used to treat human waste in hospitals
and homes. Bedding
119
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
which may have been in contact with human waste may be cleaned using a
cleaning product containing
the present antimicrobial composition. The waste may also be treated with the
present antimicrobial
composition to assist in prevent microbial contamination of the surrounding
area.
Animal Uses
Mastitis
Mastitis is a major problem in dairy cattle caused by Salmonella sp. and other
bacterial
pathogens. Since Sx formulations are effective against these organisms, an
effective treatment is to
apply a buffered saline Sx solution to the affected utter segments. This has
been successful, for
example, in a dairy operation in Idaho. Alternatively, a uterine flush and/or
a teat dip treatment could
also be applied to infected dairy cattle, or even as a prophylactic measure on
a regular basis. Many uses
are also applicable to sheep and goats.
Skin and foot and other infections
Treatment of such infectiosn includes, for example, use of Sx formulations to
treat foot rot, rain
rot, hairy wart, and various bacterial and other fungal infections of the
skin, hoof, ears, mouth and other
body parts. This may be accomplished, for example, by developing an Sx saline
solution designed to
serve as an original clean wound application, followed by, or in the
alternative using, an Sx product
applied as a spray solution on a daily or other regular basis, to maintain an
appropriate environment and
treat or avoid such infections.
Litter and waste treatments
As noted above, the Sx technology is useful for treating bedding and waste
sites, including
without limitation for cat litter or cat litter containers. Of course, the
same basic formulations may also
be used for human waste control and other human and animal environments.
Animal feed applications
Especially in view of the recent FDA mandate for the removal of standard
antibiotics from
animal feeds, there is a need for a viable replacement of antibiotic products.
It had been presumed that a
standard animal diet, if it contained one or more antibiotics, would preclude
infectious microbes from
causing disease and may allow the animals to grow at a better than average
rate. The problems of such
practices have meant that there has been a tremendous flux of drug resistant
disease-causing microbes
in our environment, leading to a massive number of drug resistant bacterial
infections in the human and
animal populations that are not easily treatable, resulting in thousands of
unexpected deaths.
120
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
The Sx technology and formulations may be applied directly to animal feed, be
it pelleted or
other form such as crumbles, and including without limitation for dairy and
beef cattle, as well as fowl
and other animals, such as pets, or farm, zoo, or other wildlife animals. The
problem of development of
resistant microbes does not arise with the Sx formulations - no Sx formulation
resistant microbe has
ever been observed. Indeed, the administration of Sx formulations to calves,
for example, results in
healthier animals that more rapidly have weight gain and less evidence of
disease. Such Sx products
may be formulated in many ways such as, for example, with a carrier such as
zeolite, or as small
dissolvable beads, or a top dressing in the feed tray. Many alternatives are
readily available to deliver
the Sx formulations successfully.
The treatment of animal feeds to avoid spoilage is another major application
of this Sx
technology. This is because the Sx formulations are so potent to almost all of
the major decay-causing
fungal organisms, such as Fusarium, Aspergillus etc. The Sx formulations could
be applied, for
example, in a gas phase to stored animal feeds to control contaminating fungi
and other microbes.
Alternatively, the Sx formulation may be included in the feed to preclude
decay-causing organisms
from causing spoilage.
Food Preparation, Storage and Preservation
Because the Sx formula is so effective in controlling bacterial and fungal
growth and because it
is typically edible in dilute solutions ¨ it has applications in many aspects
of human food use as shown
below, including as preventive, treatment, or preservative:
- Treatment of animal carcasses to prevent E. coli and Salmonella
infestations. This could be
done as a spray or other formulation, including without limitation for
poultry, cattle, pigs,
goats, sheep, and horses;
- Treatment of industrial surfaces, floors, walls, ceilings, drains in
places handling and
packing food (both plant and animal based products) with an Sx formulation for
the control
of unwanted bacterial and fungal microorganisms;
- Treatment of home drain boards, bathroom surfaces, and other places that
may house
unwanted microbes including drains, floors etc. This would require special
formulation of
Sx to provide an appropriate product odor, color etc.;
- Treatment of soil or other growth media needed for the production of food
products such as
fruits, vegetables, mushrooms. The Sx formulation would serve as a
decontaminant of
unwanted microbes including pathogens;
- Treatment of fruits, vegetables, and grains after harvest to preclude the
development of
121
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
decay causing microbes. This has wide application including the use of an Sx
formulation
in large grain bins, and in ship holds carrying immense loads of international
wheat and
other grains being shipped. The Sx formulation could be applied, for example,
as a gas that
would kill unwanted pathogens and pests; and
- Treatment of implements and equipment used in food preparation in order
to decontaminate
these items.
Industrial Applications
There are a large number of problems and difficulties encountered with
unwanted bacterial and
fungal growth appearing in and on industrial machinery. Some of these include
unwanted bacterial
growth in lubricating oils in heavy machinery. Also bacterial contamination of
water in cooling towers
has resulted in human deaths from Legionnaires Disease, which is a bacteria-
caused disease. In
addition, there are many bacterial problems associated with fouled surfaces in
naval operations. Sx
formulations are useful to help solve or remedy these problems.
Biofilms and their effects need to be controlled in human health
and virtually all aspects of human endeavor
Microorganisms universally attach to surfaces and produce extracellular
polysaccharides,
resulting in the formation of a biofilm. Biofilms pose a serious problem for
public health because of the
increased resistance of biofilm-associated organism.s to antimicrobial agents
and the potential for these
organism.s to cause infections in patients with indwelling medical devices. An
appreciation of the role
of biofilms in infection should enhance the clinical decision-making process.
Many biofilms as also
associated with problems with biofouling on industrial surfaces. Many aspects
of -biofilms are
associated with problems encountered by the US Navy and its operations. Sx
formulations are effective
against bacteria that can produce biofil.ms, such as Pseudomonas.
Other Applications
Sx technology has application to the control of protozoan parasites as well as
viruses.
Variations of Sx formulations have anti-helminth and anti-insect properties.
ADDITIONAL POSSIBLE PRODUCTS AND TREATMENTS
- Anti-fungals & anti-bacterials
- Treating or preventing rain rot / scald
122
SUBSTITUTE SHEET (RULE 26)
CA 03117821 2021-03-19
WO 2020/069407 PCT/US2019/053604
- foot rot
- scratches
- ear infection (yeast & fungus) ¨ in
livestock, or pets
- genital wash
- wound care
- minor and severe lacerations
- abrasions
- dermatitis
- anti-diarrheal
- equine electrolyte
- treatment for Flee, Tick, and other
Ectoparasites
- Wormer & Endoparasite
- Bio-security Products
- Human Health
- Oral Electrolyte
- Feed Additive
- Dog & Cat Anti-diarhheal
The disclosures of each and every patent, patent application, and publication
cited herein
are hereby incorporated herein by reference in their entirety.
While this invention has been disclosed with reference to specific
embodiments, it is
apparent that other embodiments and variations of this invention may be
devised by others
skilled in the art without departing from the true spirit and scope of the
invention. The appended
claims are intended to be construed to include all such embodiments and
equivalent variations.
123
SUBSTITUTE SHEET (RULE 26)
